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Neisseria meningitidis is a major cause of meningitis epidemics in sub-Saharan 
Africa. A promising broadly-protective vaccine approach is outer membrane particle-
based vaccine comprising GMMA (Generalised Modules for Membrane Antigens). 
To better understand vaccine potential and immune responses induced by GMMA, we 
(i) typed outer membrane vaccine antigens fHbp, NadA, NHBA and PorA in African 
serogroup A, W and X isolates, (ii) produced GMMA from recombinant strains 
expressing fHbp variant 1 or NadA-3, and (iii) generated and characterised 
monoclonal antibodies (mAb) against GMMA. 
 
Characterisation of 94 isolates showed limited variability of fHbp, NadA and PorA 
over time and geographical region. Mice immunised with GMMA developed cross-
reactive bactericidal antibody responses against diverse serogroup A, W and X 
isolates that targeted fHbp, NadA and other unidentified antigens. We obtained 33 
hybridoma clones producing GMMA-binding mAbs. Four mAbs of immunoglobulin 
subclasses IgG1, IgG2a/b and IgG3 bound NadA and four IgG1 mAbs bound fHbp. 
The other 25 mAbs recognised seven other antigens. In bactericidal assays all anti-
NadA mAbs killed the vaccine serogroup A strain. Five mAbs against unknown 
antigens also showed bactericidal activity against another A isolate. Conclusively, the 
results provide support for developing a GMMA-based vaccine with broad coverage 
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1.1 Meningococcal meningitis  
Meningitis is an inflammation of the membrane surrounding the human brain and 
spinal cord, also known as the meninges. The inflammation is usually caused by 
fungal, protozoan, viral or bacterial infection, of which bacterial infection causes the 
most severe life-threatening symptoms (1). Medical records that document bacterial 
meningitis date back to the early 1800s (2). In the United States, Europe and most 
developed countries, Streptococcus pneumoniae, Haemophilus influenzae type b 
(Hib), Neisseria meningitidis, Group B Streptococcus (GBS) and Listeria 
monocytogenes are the most common causes of bacterial meningitis, while in Africa 
S. pneumoniae, N. meningitidis and Hib are the leading causative agents (3). The first 
outbreaks of N. meningitidis were reported in Geneva, Switzerland and New Bedford, 
Massachusetts U.S. in 1805 and 1806, respectively (4). Description of the intracellular 
oval N. meningitidis in a sample of cerebrospinal fluid (CSF) was firstly made by 
Marchiafava and Celli in 1884, and Anton Weichselbaum isolated the meningococcus 
in 1887 distinguishing it from pneumococci. N. meningitidis is a Gram-negative β-
proteobacterium of the family Neisseriaceae that colonise the epithelia of the 
nasopharynx of humans. The anaerobic diplococcus is a strictly human pathogen 
(1,5). Since the initial clinical descriptions, meningococci represent a major global 
public health problem whereby approximately 135,000 are killed yearly due to 
invasive disease (6). Morbidity includes limb loss, cognitive dysfunction, visual 







1.2 Clinical presentations 
The severity of infection associated with N. meningitidis is the rapid onset and 
progression from first symptoms to severe disease (7). This depends on the amount of 
viable bacteria that have reached the blood stream. The incubation period of 
meningococcal disease is usually 3 to 4 days.!During low degree of bacteraemia, 
bacteria are cleared and patients present with febrile flu-like symptoms. When 
bacteria are not cleared, overt disease develop at the start of the bacteraemia phase 
with initial symptoms of fever, vomiting, drowsiness, stiff neck and severe muscle 
pain (8). Occasionally, patients develop meningitis associated with acute 
inflammation of the meninges (Figure 1.1). Inflammation develops when a higher 
concentration of bacteria is present in the CSF than in the plasma. This leads to a 
large compartmentalised inflammatory response in the subarachnoid space with an 
increase in concentrations of cytokines tumour necrosis factor (TNF-α) and 
interleukins (IL-1β, IL-6, IL-8 and IL-10), different chemokines and other mediators 
(2). Patients can also develop fulminant meningococcal septicaemia, which is 
characterised by high levels of bacteria in the blood circulation. Large bacterial 
growth causes a destructive intravascular inflammatory response leading to 
circulatory collapse. Such vascular complications can cause loss of limbs and other 
symptoms including impaired adrenal, renal, pulmonary functions and disseminated 
intravascular coagulation with thrombotic lesions in the skin, limbs and occasionally 
the lungs. (9). Some of these patients may develop transient meningococcaemia with 
fever and a non-specific rash. On rare occasions, chronic meningococcaemia can 
develop that lasts from weeks to months with intermittent symptoms such as fever. 
However, ~30% of patients may also present without distinct signs of meningitis or 
fulminant septicaemia, but instead have persistent hypotension. Patients are classified 
!
$!
in four groups based on the sequence of events and prognosis: (i) patients with 
bacteraemia and no shock, (ii) bacteraemia and shock, (iii) shock and meningitis, and 




Figure 1.1. Clinical manifestations due to infection by Neisseria meningitidis. 
The most common clinical presentation due to invasive meningococcal disease is meningitis and 
bacteraemia. Bacteraemia can occur without meningitis in 5-20% of invasive infections. Other less 
common presentations are pneumonia (6%), arthritis (2%), otitis media (1%) and epiglottitis (0.3%). 
Figure adapted and altered from Center for Disease Control and Prevention (10).  
 
In industrialised countries, more than 60% that get invasive meningococcal disease 
develop meningitis without shock, while in developing countries the proportion is 
higher. Mortality due to meningitis ranges from 8%-12.5% in developed countries and 
is roughly half in developing countries. In epidemic situations, there is a general 
clinical pattern of meningococcal disease. However, for reasons not fully understood, 
the number of patients that present with specific clinical features vary from outbreak 




The first initial signs of meningitis are based on the recognition of symptoms of stiff 
neck, fever, rash and altered mental status. However, diagnosis based on identification 
of clinical presentations is a challenge as symptoms are variable, not specific or might 
not be present. Therefore, in conjunction with clinical symptoms, gold-standard 
detection and confirmation of infection by meningococci is done by blood and CSF 
culture. CSF is taken by lumbar puncture, and an initial sign of inflammation is a 
raised opening pressure. Culturing of CSF and blood are done on chocolate or blood 
agar (11). Colonies of N. meningitidis on blood agar appear grey, smooth, convex, 
glistening and with a defined edge while colonies on chocolate agar are large, 
colourless and opaque. Following characterisation of the colonies, non-culture 
methods such as Gram staining, Kovac’s oxidase test and carbohydrate utilisation 
testing (both positive) are recommended to confirm morphological identity of 
cultures. CSF samples are further analysed for indicators such as presence of bacteria, 
polymorphonuclear pleocytosis, decreased glucose content and raised protein levels 
(11,12). However, culture-based tests take 48-72 hours to complete and are not very 
sensitive (40-80%), especially if prior antibiotic therapy is initiated (8). Alternative 
diagnostic methods such as antigen detection using latex agglutination assays and 
polymerase chain reaction (PCR) has become an increasingly used form of diagnosis 
for meningococcal meningitis. Latex agglutination tests provides quick results in less 
than 15 minutes, and the test uses serum containing bacterial antibodies or 
commercial antisera against the capsular polysaccharide. However, this test has a 
variable sensitivity between 22-93% (12). Polymerase chain reaction (PCR) can be 
performed on CSF, blood and serum samples with an overall sensitivity of 88% for all 
serogroups (13). In the United Kingdom, patients are often diagnosed by PCR without 
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culture. Improved antigen and nucleic acid detection systems has also allowed for the 
enhanced accuracy of epidemiological studies, disease surveillance control measures 
and rapid augmentation of course of treatment for each patient (14).  
 
1.4 Treatment 
Successful treatment depends on the speed and severity of clinical deterioration of the 
patient and the speed of diagnosis. The type of treatment given is based on the clinical 
manifestations; however, prompt start of antibiotic therapy is pivotal after obtaining 
blood and CSF (15). Before the 1920s meningococcal disease was fatal in up to 70-
90% of cases (9). With the discovery of sulphonamides and other antimicrobial 
agents, case fatality rate of systemic meningococcal disease has decreased to about 
10%. Resistance to sulphonamides prompted the switch to penicillin or 
chloramphenicol in the 1950s and 1960s. β-lactam antibiotics such as benzylpenicillin 
are, when used early, effective in stopping the proliferation of N. meningitidis in the 
CSF by killing the bacteria within 3-4 hours after intravenous treatment. 
Chloramphenicol is bactericidal for N. meningitidis as it can penetrate the blood brain 
barrier more effectively than β-lactam antibiotics (9). However, resistance to these 
antibiotics have also been reported, and patients infected with penicillin-resistant 
strains are given third-generation cephalosporin derivatives such as ceftriaxone (8). 
Antibiotics can also be given as a preventative measure whereby contacts of cases can 
be given ceftriaxone, azithromycin and quinolones to aid control of localised 




Depending on the clinical manifestations there are additional forms of treatment. 
Although controversial due to lack of good clinical trials, transfusions have been used 
for treating sepsis, especially in neonates (8,16). The transfusions reduce the TNF in 
plasma and replenish immunomodulatig compounds such as anticoagulant factors 
protein C and protein S. Patients with sepsis are given infusion of protein C, which is 
important for regulating blood clotting, to restore the plasma concentration. If adrenal 
haemorrhage develops, low doses of steroids is given to maintain adrenal functions 
(9). Despite the availability of effective antibiotics and intensive care, due to the high 
morbidity and mortality, 7-15% of individuals who develop meningococcal 
meningitis and about 40% that develop sepsis die (17). A step towards reduction of 
mortality is the development and improved detection, classification and typing 
systems for enhanced disease surveillance.  
 
 
1.5 Classification and typing 
Characterisation of the invasive strain is important for informed public health 
responses, epidemiologic monitoring, vaccine development and the management and 
control of meningococcal disease (18). The first routine classification and typing 
systems were immunological based using monoclonal antibody (mAb) panels that 
identified variants in the capsule (serogroup), outer membrane proteins (OMP; 
serotype [Porin A (PorA)] and serosubtype [PorB]) and lipooligosaccharide 
(immunotype [LOS]) (9). However, limitations including reproducibility between labs 
and incomplete coverage as a result of recombination and phase variability, which are 
common in N. meningitidis, have resulted in an increase of non-typable isolates by 
these means. Genetic applications to classification and typing such as multilocus 
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sequence typing (MLST) and multilocus enzyme eletrophoresis (MLEE), which 
determines sequence or electrophoretic types (ST, ET), and sequencing of OMP PorB, 
PorA and FetA have increased the understanding of epidemiology of meningococcal 
disease (19).    
 
Invasive and non-invasive meningococcal strains express a surface polysaccharide 
capsule of several types. The capsule is a major virulence factor and plays a crucial 
role that aids transmission and colonisation, protects the bacterium from desiccation, 
phagocytic killing, opsonisation and complement-mediated bactericidal killing (20). 
The capsule forms the basis of classification into specific serogroups (1). N. 
meningitidis can be divided into 13 serogroups based on the chemical composition of 
the bacterial capsular polysaccharide designated A, B, C, H, I, K, L, M, X, Y, Z, 29E 
and W (21,22). The vast majority of invasive disease is caused by serogroups A, B, C, 
X, Y and W (>90%) (23). The capsular polysaccharide can be either a homopolymer 
or a heteropolymer consisting of monosaccharide, disaccharide, or trisaccharide 
repeating units (24). The capsular genes are clustered within a single chromosomal 
locus, cps, divided into six regions A-D, D’ and E. Genes in region A encode for 
biosynthesis and polymerisation enzymes of the polysaccharide. Genes in region B 
and C are responsible for translocation of the polysaccharide from the cytoplasm to 
the cell surface, respectively (24). Region D is involved in lipooligosaccharide (LOS) 
synthesis, genes in region D’ are methyltransferases and region E function is 
unknown (23). Region A of serogroups B, C, W and Y harbour the conserved genes 
cssA-C responsible for synthesis of sialic acid in the form of CMP-NANA (24). In the 
same region, genes synD-G encode for a serogroup-specific polysialyltransferase 
involved in capsule polymerisation, which determines the functional and nucleotide 
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specificity for the 4 serogroups and also forms the basis of serogroup–specific PCR 
for diagnosis (24). In contrast, serogroup A contains repeating units of (α1-6)-linked 
N-acetyl-mannosamine-1-phosphate encoded by mynA-D, and serogroup X expresses 
(α1-4)-linked N-acetyl-D-glucosamine-1-phosphate (Table 1.1) (25).  
 
Table 1.1. Meningococcal serogroups that commonly cause disease and their capsular structure 
and operon composition. Adapted and modified from Hill et al. (2010) (26).  
Serogroup Capsule structure Operon 
A 







Sialic acid capsule. 
 





Sialic acid capsule. 
 























During the last 20 years, numerous methods have been developed for epidemiological 
studies of meningococci and for the identification of infectious strains that cause 
disease, which are central to epidemiological surveillance. Among these methods, 
MLEE and MLST are considered as ‘gold standards’ (19). MLEE is a powerful 
technique to distinguish various meningococcal clones, which involves 
characterisation of the alleles of 10-20 housekeeping genes indirectly by the 
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electrophoretic mobility of the enzymes (20). High levels of discrimination are 
achieved by analysing many loci, and the unique combination of alleles is called 
electrophoretic type (ET) (27). This technique has been used for the identification of 
clusters of closely related strains (clonal complexes (CC)) that are particular liable to 
cause disease, so called hyper-virulent lineages, because it uses variation that is 
accumulating very slowly in the population (28). However, the problem with MLEE 
is that the results are difficult to compare between different laboratories (29). Instead, 
during the last 10 years, MLEE has been replaced by MLST. MLST characterises the 
alleles of 7 housekeeping genes (abcZ, adk, aroE, fumC, gdh, pdhC, pgm) by 
nucleotide sequencing of 450-500bp from PCR fragments of the genes (28). The 
unique combination of alleles is termed sequence type (ST), and nucleotide sequence 
data of the different alleles is found on the MLST website 
(http://pubmlst.org/neisseria). MLST has also been employed to determine the CC of 
invasive and carried meningococci for enhanced analysis of clonal diversification and 
the identification of currently circulating hyper-virulent lineages. STs are grouped 
together into CC or ST complex based on their similarity to a central allelic profile or 
genotype. A number given heuristically identifies the ancestral genotype or CC. 
Different STs that are identical or share at least four loci with the ancestral genotype 
are grouped into that CC (30). This information is important for both national and 
international management of meningococcal disease and for studies on population 
biology and evolution (27). Despite the high diversity of the meningococcal 
population, only a few CCs are associated with invasive disease. For example, ST-11 
complex is predominantly associated with serogroup C and W and has caused disease 
in Europe, Australia, the U.S., Canada and Africa. However, MLST does not provide 
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fine discrimination of clonal groups compared to typing utilising antigenic diversity 
of OMP on the cell envelope (29).  
 
Classical characterisation of N. meningitidis OMPs is based on serological methods. 
All meningococci express either class 2 or 3 OMPs, and most also express class 1. 
PorA is termed as class 1 OMP while class 2 and 3 have been named PorB (PorB2 
and PorB3). PorA is assigned a prefix “P1” followed by numbers, separated by 
commas that correspond to the subtype designation. PorA has 8 surface exposed loops 
(loops I-VIII), and loops I and IV being the most variable (31). A panel of mAbs used 
for serosubtyping react with the peptide epitopes located in the two variable regions 
VR1 and VR2 that confer the subtype, for example P1.20,9. The variable regions are 
highly immunogenic and elicit bactericidal antibodies in humans; therefore, 
serosubtyping has been used to identify PorA epitopes for establishing outer 
membrane vesicle (OMV) vaccine composition (32). However, it has been established 
that serological analysis of PorA using a panel of mAbs is not comprehensive. An 
increasing number of isolates become non-serosubtypable due to PorA not being 
expressed or the lack of recognition of the mAb to a variant. Therefore, the mAbs 
scheme has been replaced by nucleotide sequencing that allows for a more detailed 
analysis. The VR families and variants are now assigned based on amino acid 
sequence relationship rather than reactivity with specific mAbs (31,33).  
 
The lipopolysaccharide of N. meningitidis is a major virulence factor that induces 
production of pro-inflammatory mediators, which can lead to septic shock. Since 
meningococcal lipopolysaccharide lack the repeating O-antigen units it is referred to 
as LOS. The LOS is comprised of three short oligosaccharides termed α, β and γ 
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chains that are used to divide N. meningitidis into 13 immunotypes (L1-L13) based on 
specific antibody reactions (34). The biosynthesis of the LOS chains is performed by 
glycoacyltransferases encoded by three genetic loci lgt-1, 2 and 3, and both 
commensal and pathogenic strains share a common lgt gene pool whereby horizontal 
gene transfer contributes to the genetic diversity of this locus. Nowadays, like with 
PorA serosubtyping, serological immunotyping has been replaced by nucleotide 
sequencing. However, genotypic characterisation by nucleotide sequencing has 
become less suitable for modern epidemiologic purposes as typing schemes usually 
involve variation of a few genes, which in all likelihood are under selection pressure. 
In the future, whole genome sequencing will provide a measure of comparing the 
overall relatedness of the chromosomal genome to obtain a more comprehensive 
understanding of meningococcal pathogenicity.  
 
1.6    Epidemiology and pathogenesis 
The epidemiology of N. meningitidis varies both geographically and temporally for 
unclear reasons (Figure 1.2). The worldwide annual case incidence is estimated to be 
around 1.2 million with 135000 deaths and a case fatality rate of at least 10% (6). 
However, the incidence of meningococcal disease in industrialised countries have 
predominantly lower annual rates of approximately 0.5-1.1/100000 of population per 
year while countries in the “meningitis belt” of sub-Saharan Africa have high rates 
between 10-100/100000 (endemic) and up to 1000/100000 during epidemics (6). The 
rate of meningococcal disease is also age dependent, and in general the highest peak 
of disease incidence is seen in children under 2 years of age and a second peak in 
young adolescents and adults between ages 14-25 (35). Although 98% of cases occur 
sporadically, there are several genetic, environmental and behavioural risk factors that 
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increase the risk of contracting N. meningitidis (9). For example, in the sub-Saharan 
Africa, complement protein 6 (C6) deficiency and the dry weather are important 
contributing factors (1,36).  
 
1.6.1 Africa 
Although incidence of meningococcal disease is difficult to estimate due to variations 
in surveillance, high incidence countries mostly include countries of the sub-Saharan 
African meningitis belt. These 25 countries, extending from Senegal in West Africa to 
Ethiopia in the East, experience superimposed frequent endemics that constitute a 
major public health problem. The epidemics involve, by WHO definition, >100 cases/ 
100000 population, and occurs every 8-10 years and can last for several years. Mostly 
children less than 5 years of age are affected (37). This pattern of epidemics was 
firstly described in 1963 by Lapeyssonnie who defined the African ‘meningitis belt’. 
Although the rates of disease vary geographically, the rates also depend on the spread 
of new strains, vaccination status of the population and environmental factors (6). For 
example, epidemics usually coincide with the dry season, whereby it is thought that 
the low humidity and dust-wind blowing from the Sahara affect the mucosa causing 
damage and produces irritant coughs that aids transmission. Cases can also occur in 
clusters and localised outbreaks throughout the year. Outbreaks involve three or more 
confirmed primary cases over a period of less than or equal to 3 months with a 
primary attack rate of more than or equal to 10 cases per 100000 population (10). In 
sub-Saharan Africa, serogroup A was most associated with seasonal hyperendemic 
and epidemic meningitis prior to 2010 (22). The ST5 clone was the first pandemic 
wave and predominated until 1999. However, in 1995 a new closely related clone, 
ST-7, emerged in Algeria and has since caused major epidemics and replaced ST5 
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(38). Since 2003, a major increase in disease rates due to a new clone ST-2859, 
particularly in Burkina Faso, has been detected (39). Historically serogroup W was 
responsible for a small subset of meningococcal infections globally; however, the ST-
11 complex/ET-37 complex that emerged in 2000 during the Hajj pilgrimage in Saudi 
Arabia is now causing sporadic disease and epidemics. This complex is commonly 
associated with serogroup C capsule, thus suggesting there could have been a capsular 
switch from serogroup C to W. In 2002, the ST-11 clone was responsible for an 
epidemic in Burkina Faso with about 13,000 cases (40). In May 2012, an outbreak of 
serogroup W in Burkina Faso contributed to a total of 553 deaths (41). Although 
outbreaks of serogroup X are not of the same magnitude as serogroup A and W, 
incidence of meningitis due to X has been on the increase. In 2006, from January to 
June, an outbreak with over 550 cases infected with serogroup X ST-181 occurred in 
the south-western region of Niger including Niamey with 27.5 cases per 100,000 
population and an incidence of 74.6 cases per 100,000 children between ages of 5-9 
years. Delrieu et al. (2011) showed an increase in incidence of serogroup X from 
2009 to 2010 (4% to 35% of all confirmed cases) in Burkina Faso (42). The authors 
describe an epidemic involving serogroup X in northern and central regions of 
Burkina Faso during 2010, which occurred with a seasonal incidence previously only 
reported in the meningitis belt for W and A. Serogroup X disease has also been 
reported in Togo accounting for 86% of 92 cases in the Kara Region, and in Ghana 
and western Kenya. There have also been occasional outbreaks of serogroup C (38). 
 
1.6.2 United States  
In comparison to Africa, since the end of Second World War until recently incidence 
rates in the U.S. fluctuated between 0.5 and 1.5 cases/ 100,000 population/ year. 
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Surveillance data from 1999-2008 show that the highest rates of meningococcal 
disease were in children <4 years (~2/100,000) mainly due to serogroup B and 
adolescents between 15-19 years (~1/100,000) being caused by serogroup C, Y and 
W. Most outbreaks of serogroup C detected in colleges and schools have been caused 
by the ST-11 complex/ET-37 complex (9,25). Although there are prominent 
fluctuations in the meningococcal serogroup distribution, currently serogroup B 
contributes to 23% of the cases, 31% serogroup C, 35% serogroup Y and 11% 
serogroup W.  
 
1.6.3 Europe 
Serogroup A was the most common cause of invasive disease in Europe before the 
First and Second World Wars. However, for reasons not fully understood, since 
1970’s it has ceased to be the primary cause. The vast majority of cases were then 
caused by serogroup C with an overall incidence of 1.01/100,000, but with higher 
rates in the UK, the Netherlands, the republic of Ireland and Norway. Since the late 
1990s/early 2000s, these countries experienced outbreaks due to the hypervirulent 
serogroup C clone of ST-11 complex/ET-37 complex. The growing burden of disease 
prompted the introduction of the meningococcal serogroup C conjugate vaccine in the 
UK in 1999, which was successful in reducing burden. Ireland and Spain followed 
this example in 2000, the Netherlands in 2002, Belgium 2002, Iceland 2002, Portugal 
2006, Greece 2006, and Germany in 2006 (43). Currently, serogroup B ST-41/44 
complex is the most important cause of disease, responsible for about 50% of cases 
(44). The age distribution of cases varies across countries, however, children under 1 
year of age and young adolescents at universities are mostly affected. Disease can 






Figure 1.2. Worldwide distribution and prevalence of the major serogroups of Neisseria 
meningitidis.  
The sub-Saharan African meningitis belt is marked with dotted lines. Adapted from Stephens et al. 
(2007) (9).  
 
1.7 Meningococcal colonisation and carriage 
The natural reservoir of N. meningitidis is the human nasopharyngeal mucosa, and 
colonisation of the nasopharynx is the first step in the establishment of a human 
carrier state and invasive disease (37). The period of carriage until progression to 
invasive disease is variable. It can be transient or intermittent and can last for many 
months and can change in populations over time (23). However, carriage isolates are 
very diverse in terms of ST and often non-capsulated (50%) (29). Most individuals 
are colonised with only one strain. Due to the diversity of carriage isolates, rates of 
carriage are correlated with colonisation with hyper-invasive clones. Rates of carriage 
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in Europe are low at an early age, increase during adolescence, peak at 20-24 (10-
35%) and decrease in older age groups to <10% (29). While rates of carriage in Africa 
are lower ranging from 3-30% affecting mostly young children in the age group 1-4 
years (22). Carriage can be an immunising process allowing for the systemic 
production of antibodies in response to capsular and non-capsular antigens. Prolonged 
colonisation does not equate to protection from subsequent colonisation or invasion. 
(38). Most individuals colonised asymptomatically in non-epidemic situations carry 
strains that may be capsulated or non-capsulated, whereas during epidemic situations, 
the carriage strains are often capsulated (26).  
 
The establishment of colonisation and carriage state starts with transmission of the 
bacteria through respiratory droplets and secretions; however, the required inoculum 
size is unknown (1). Adhesion to the mucosal surfaces is essential to withstand 
mechanical forces during nasopharyngeal colonisation when bacteria are exposed to 
mucus flow, and this is promoted by various adhesins. Common adhesins in N. 
meningitidis are Type IV pili (PilC, PilQ) Opa, Opc, LOS and NadA. Their receptors 
on the epithelial cells include CD46, CEACAM1, vitronectin and β1-integrins. 
Meningococcal type IV pili (T4P) initiate the initial adherence to non-ciliated 
epithelial cells through the receptor CD46 by major PilE and PilX proteins. The pili 
play an important role in maintaining adherence to the endothelial cells under high 
flow conditions that poses shear stress on the meningococci. For stronger intimate 
cellular interactions required for stable colonisation, other adhesins such as Opa and 
Opc are involved. Although, the capsule is essential for protecting the bacteria from 
environmental and host immune factors, capsulated bacteria can only adhere using the 
pili as the capsule shields other adhesins preventing intimate attachment (26). Phase 
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variation of the capsule, whereby the bacteria can switch capsule production on/off is 
beneficial following initial attachment. When capsulate meningococci initially adhere 
to epithelial cells, a two-component regulatory system PhoP-PhoQ can be activated 
that leads to the loss or down-regulation of the capsule (45). Non-capsulated 
meningococci can easily engage intimately with cells through Opa and Opc, which 
promote barrier penetration. Opc is a 10-stranded β-barrel protein that binds host 
extracellular matrix proteins, and Opa is an eight-stranded β-barrel protein that binds 
CEACAMs (carcinoembryonic antigen cell adhesion molecules) (1,45). Following 
Opc engagement, a number of signalling events result in the recruitment of factors 
that account for the formation of epithelial cell pseudopodia that engulf and 
internalises the bacterium (1). The meningococci also proliferate on the surface of the 
epithelial cells forming small microcolonies at the site of attachment (45). Biofilm 
formation is essential since the bacteria are shielded against the host immune system 
through a matrix consisting of lipids, DNA and polysaccharides (46).  
 
1.8 Cell invasion and invasive disease 
Compared to carriage isolates, invasive strains are from a limited number of 
hypervirulent lineages (29). As N. meningitidis is an obligate human pathogen, there 
is no ‘real’ animal model for meningococcal cell invasion. The hypotheses of 
pathogenesis come from studying post mortem samples and/or biopsies of skin 
lesions. However, pathology is initiated when the meningococcus crosses the mucosal 
barrier where it reaches the bloodstream, survives, replicates and disseminates into 
various tissues and eventually crosses the blood brain barrier (BBB) into the central 
nervous system (CNS) and cause meningitis (47) (46). The BBB is a specialised 
structural component that separates the blood from the brain and spinal cord and 
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protects the CNS from bacteria that have reached the bloodstream through endothelial 
cells (46,48). Although, the entry of the meningococcus into the CSF is still unclear, 
there are four possible strategies that the bacterium can use to cross the BBB. 
Following survival in the bloodstream due to various virulence factors, the blood-
borne bacterium can adhere and proliferate in both peripheral and brain blood 
microvessels (vascular colonisation). Subsequently, the endothelial cells can 
internalise a small number of bacteria that can then further transcytose (26). The 
meningococci are able to survive in a membraneous vacuole and translocate through 
the endothelial layer within 18-40 hours. The survival of the bacteria is determined by 
factors such as IgA1 protease, which prevents phagosomal maturation and the up-
regulation of expression of capsule. Its ability to replicate intracellularly is facilitated 
through the acquisition of iron through specialised transport systems such as 
transferrin binding protein (TbpAB) (1). Secondly, as with adhesion to non-ciliated 
epithelial cells, adherence to vascular endothelial cells is mediated by T4P and the 
receptor CD147 (47). Following attachment, the intimate interaction can cause 
signalling events that lead to disruption of the intercellular junctions enabling 
paracellular passage. The third route involves endothelial damage by LOS-mediated 
cytopathic effects. LOS induces inflammation of the endothelial cells of the 
vasculature, the release of IL-6 and TNF-α and activation of the complement and 
coagulation cascades that leads to capillary leakage and necrosis facilitating 
meningococcal penetration through the endothelia into the peripheral cavity. The last 
possible route involves leukocyte-facilitated transport by infected phagocytes (Figure 
1.3) (49). All of these options are not exclusive, however, suggestive from in vitro 





Figure 1.3. Transmigration and formation of cortical plaque by Neisseria meningitidis.  
The meningococci use Type IV pili to interact and adhere to brain microvascular endothelial cells with 
CD147 as receptor. Following initial adhesion, the pili recruits and activates the "2-adrenoceptor, 
which leads to the organisation of specific cytoplasmic molecular complexes referred to as cortical 
plaques. Local production of PI4,5P2 mediates cortical plaque formation through the accumulation of 
ezrin and ezrin binding receptor such as ICAM-1 and CD44 and the accumulation of "-arrestins and "-
arrestin-binding molecules such as Src, p120-catenin and VE-cadherin. This results in formation of 
microvilli like protrusions that function to protect the bacterial colonies from blood flow and the 
opening of the cell-cell junctions, which allows transmigration through the endothelium. Adapted from 
Coreuil et al. (2012) (46).  
 
1.9 N. meningitidis and the complement system 
The complement system is a major constituent of the immune system and an 
important element of innate immunity, especially against Gram–negative bacteria. It 
is composed of about 35 plasma proteins and membrane bound molecules that are 
mostly produced in the liver, but also from epithelial cells that are active at mucosal 
surfaces in the nasopharynx (50). The complement system is initiated by the classical 
pathway (CP, initiated by antigen-antibody interactions) or lectin pathway (LP, 
binding of mannose-binding lectin (MBL) to microbial carbohydrates) and amplified 
by the alternative pathway (AP), which involves a series of proteolytic steps (Figure 
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1.4) (51). Engagement of complement protein 1 (C1) complex, which consist of C1q, 
C1r and C1s, activates the CP by either binding directly to bacteria or to clustered 
antibody (IgG and IgM) complexes on the surface of bacteria. Upon engagement of 
C1q, the C1s and C1r proteases become activated and cleave C4 and C2 to yield 
C4b2a or C3 convertase. C3 convertase cleaves C3 to form C3a and C3b. C3b is an 
effector protein that covalently binds to the surface of a pathogen resulting in 
phagocytosis, accentuation of inflammatory responses, chemotaxis and lysis through 
the insertion of the membrane attack complex (MAC) into the bacterial outer 
membrane (50). Similarly, LP is initiated upon binding to MBL on the surface of 
bacteria that result in cleavage of C4 and C2 by the MBL-associated serin protease-2 
(MASP-2) to generate C3 convertase. Moreover, C3b can interact with factor B and 
form C3bBb (C3 convertase of AP), and its activity is stabilised by properdin (36). 
The convertases formed from CP, LP and AP activation are able to cleave C5 into 
C5a and C5b that initiates the assembly of the MAC leading to clearance of the 
bacteria (51). Clearance of N. meningitidis through MAC is especially important, 
which is highlighted by patients who suffer from complement deficiencies such as 





Figure 1.4. The three complement pathways.  
The series of proteolytic cleavages all lead to the formation of C3 convertase. Increased cleavage of C3 
also contributes to the assembly of C5 convertase that allows for the formation of the MAC that consist 
of C5b-C9. Polymerisation of C9 takes place inside the bacterial membrane forming a pore that triggers 
lysis. Arrows indicate activation and T-shapes indicate inhibition. 
 
 
1.10 Complement deficiencies: genetics of host 
susceptibility to meningococcal infection 
The discovery of individuals with complement deficiencies has contributed to the 
understanding of the importance of the complement system in host defence against N. 
meningitidis. Complement deficiency can be either inherited or acquired. Inherited 
deficiencies are rare and occur in about 0.03% of the general population, which also 
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depends on the complement protein and the ethnicity of the population. For example, 
hereditary deficiency of C9 in the Japanese population is more common (0.1%) than 
C7 deficiency (0.005%). Acquired deficiencies are more common and are usually 
associated with inadequate production, increased consumption and excretion of 
complement components due to autoimmune disorders (14). For example, about half 
of patients with systemic lupus erythematosus are deficient in C3 and C4 due to 
immune complex formation that activates and consumes complement, thus 
predisposing them to meningococcal disease (52). 
 
Individuals that hereditary lack terminal components of MAC, especially C6, suffer 
from marked susceptibility of meningococcal infection (53). Due to the inability to 
form MAC and cause lysis of bacteria, these patients with a late complement 
component deficiency (LCCD) have a 1,000-10,000-fold higher risk of 
meningococcal disease and also susceptible to infection by N. gonorrhoeae. However, 
they are not at greater risk of contracting other Gram-negative infections. The 
increased risk of developing disease affects anyone who has the deficiency, although 
it is more common for adolescents and young adults due to their increased exposure 
(14,38). Interestingly, reduced serum lytic activity in LCCD patients results in the 
lower release of LOS limiting pro-inflammatory cytokine release (TNF-α, IL-6, IL-1) 
and chemokines, thus endotoxic shock (14). The course of infection in LCCD patients 
is therefore more benign than immunocompetent individuals (51). In contrast, 
individuals lacking other complement components such as properdin may be more 
severe as they are not able to clear bacteria by opsonophagocytosis and lysis, and 
therefore have a poorer prognosis than MAC deficient persons (51). Properdin 
deficiency is the most common genetic defect of the AP, which is inherited in an X-
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linked manner (14,53). Another common hereditary complement deficiency in the 
Caucasian population is MBL polymorphism (5-10%). Polymorphism has been 
associated with predisposition to numerous of infections such as N. meningitidis (53). 
Moreover, factor H (fH) is a soluble negative regulator present in the serum and on 
mucosal surfaces. fH limits the amplification of complement activation of AP by 
functioning as a co-factor for factor I that mediates the cleavage of C3b to iC3b. It is 
also able to dissociate C3bBb. Polymorphism of the promoter of the fH gene can 
result in an increased production of fH (52). This results in the increased risk of 
developing invasive meningococcal disease as meningococci can use fH as a 
mechanism to subvert complement activation.  
 
 
1.11 Bacterial factors important for the avoidance of 
complement-mediated lysis 
There are two main factors that N. meningitidis uses to avoid complement-mediated 
lysis: capsule and LOS (51). Invasive hypervirulent strains recovered from the 
bloodstream of patients encompass a capsule. The capsule contains sialic acid (except 
serogroup A) that on the surface of endothelial cells inhibits complement activation 
(50). This is by preventing the insertion of MAC, however, the exact mechanism is 
not fully understood. A study has shown that the capsule of serogroups B, C, W and Y 
that contain N-acetyl neuraminic acid activates the AP and serves as a site for C3 
fragment deposition distally from the bacterial membrane (54). Moreover, N. 
meningitidis is able to shed outer membrane vesicles (OMV), which can also initiate 
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complement activation in the blood remotely, redirecting the immune system away 
from the meningococci.  
 
N. meningitidis is able to express 13 different LOS types; however, only limited 
subsets are predominantly disease-causing isolates. LOS plays a role in both 
adherence of the bacterium and activation of the innate immune system. The LOS of 
meningococcus has an α and β-chain extending from the oligosaccharide core. The 
lacto-N-neotetraose (LNT) moiety of the α-chain is identical to a human blood group 
antigen, thus it can avoid the immune system by expressing host structures (52). 
Invasive strains of L3,7,9 immunotype express the LNT epitope, and can be further 
modified by sialylation increasing serum resistance.  
 
A known feature of N. meningitidis is that it can recruit negative complement 
regulators to the bacterial surface to promote survival in vivo. Negative regulators of 
complement obstruct excessive complement activation. C4 binding protein (C4bp) 
and fH are two examples. C4bp is a soluble negative regulator that dissociates C3 
convertase of CP and LP, and is also a co-factor for Factor I-mediated C4b to C4c and 
C4d cleavage (14). On the meningococcus, PorA binds C4bp and strains lacking PorA 
are more sensitive to serum. The factor H binding protein (fHbp) on the 
meningococcal surface is able to bind circulating fH in the blood to the bacterial 






1.12 Correlation with protection 
To support licensure of meningococcal vaccines, safety and efficacy studies 
demonstrating that serum bactericidal antibodies are elicited against the vaccine 
antigens that activate complement-mediated bacteriolysis forms such basis (2,32). 
Serum bactericidal assay (SBA) is the “gold-standard” measurement of such 
protection. The principle of the assay was established by Goldschneider in 1969 
where serological studies in military recruits during a serogroup C epidemic 
determined that a protective serum SBA titre was conferred at ≥1:4 using human 
complement as an exogenous source (55). This is currently accepted as a surrogate of 
vaccine induced protection (36). This applies in particular during evaluation of new 
antigens and their ability to elicit antibodies that are bactericidal.  
 
1.13 Prevention of meningococcal disease: Vaccine 
1.13.1 Polysaccharide vaccines 
Meningitis and septicaemia caused by N. meningitidis can be treated with antibiotics; 
however, invasive disease by the meningococcus is feared for its rapid progression 
and propensity to cause illness. Early diagnosis is pivotal for successful treatment, but 
it is rarely achieved, therefore, emphasis has been placed on prevention through 
vaccination (44). Antibiotics are effective, but in the context of recurrent epidemics in 
the meningitis belt, high disease burden and fragile health care systems, sustained 
protection is essential (55). The first effective meningococcal vaccine was developed 
in 1972 in response to meningitis epidemics in military recruits in the U.S. after it was 
demonstrated by Gotschlich, Goldschneider and Artenstain that extracts of 
polysaccharide was immunogenic (55). At that time, the polysaccharide was 
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unconjugated, and such vaccines do not invoke T-cell help. This is because 
polysaccharides are T-cell-independent antigens, and the antigen is not internalised, 
processed and presented on major histocompatability class II molecules (MCHII) on 
B cells (56,57)(57-59). Consequently, CD4+ T helper cells are not recruited, which 
results in a weak proliferation of B cells to produce IgM and IgG2, preventing 
development of memory B cells in adults (3,4,55,59). Un-conjugated polysaccharide 
vaccine only induce short-lived protection, and antibody concentrations wane rapidly 
(4,57). The highest meningococcal disease burden is seen in infants and young 
children (5,55). Consequently, one of the most important limitation with 
polysaccharide vaccines is that children under 2 years of age cannot use these 
vaccines due to poor responses to T-cell independent antigens in the absence of T-cell 
help (Figure 1.5) (60,61). Further limitations with such vaccines include 
hyporesponsiveness if given in repeated doses as primary B cells with affinity to the 
polysaccharide are depleted (2,14,43). The un-conjugated vaccines are also 
ineffective against carriage with only a short-term effect due to lack of anamnestic 






Figure 1.5. Immune responses to polysaccharide and conjugate polysaccharide vaccines.  
Panel A: Polysaccharides are T-cell independent antigens, and they can only cross-link B-cell receptors 
(BCR). Without recruitment of T-helper cells, cross-linking only drives the production of 
immunoglobulin (IgG) of subclass M and G2, and depletes the memory B cell pool since new memory 
cells are not augmented. Panel B: Polysaccharide conjugated to a carrier protein allows for the 
induction of memory B cells and IgG1 and IgG3 antibody production. The polysaccharide cross-links 
the BCR while the carrier proteins gets internalised, processed and presented on major 
histocompatability class II molecules (MHC class II), which recruited T-helper cells recognise through 
T-cell receptor (TCR). CD40-CD40 ligand binding is also initiated along with CD80-CD28 that 
promotes T-cell help for the production of plasma cells and memory B cells. Adapted from Pollard et 
al. (2009) (61).   
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1.13.2 Conjugated polysaccharide vaccines 
Conjugation of the polysaccharide to a protein carrier that stimulates T-cells such as 
diphtheria or tetanus toxoid was a major breakthrough in polysaccharide vaccine 
development in the 1980s. The United Kingdom was the first country to introduce a 
serogroup C conjugate polysaccharide vaccine (MCC) in 1999 as part of routine 
scheduled infant immunisation with a catch up campaign for children and adolescents 
up to 18 years of age (4). Conjugation allows for the carrier protein to be internalised 
and processed by the polysaccharide specific B cell with the peptide situated on BCR 
(61). The fragmented carrier protein is subsequently presented on MHCII receptors, 
which results in T-cell help for the production of plasma cells and memory B cells 
(Figure 1.5) (59). They also provide robust immunity in young children and infants, 
and the responses have a longer duration of protection than un-conjugated vaccines. 
Anamnestic responses to further doses is effective against asymptomatic carriage in 
the nasopharynx, which results in reduced transmission and herd immunity (3). 
Therefore, they can be used in a population-scale intervention (1,43). Currently 














Table 1.2. Conjugate vaccines against Neisseria meningitidis.  
Adapted from Cohn and Harrison (2013) (63).  




Menveo™ Novartis vaccines A, C, Y, W 2-55 years 
Diphtheria cross-
reactive material 197 
(CRM197) 
Menactra™ Sanofi Pasteur A, C, Y, W 9 months-55 years Diphtheria toxoid 
Meningitec™ Wyeth vaccines C >2 months CRM197 
Menjugate® Novartis vaccines C >2 months CRM197 
Neis-Vac-C™ Baxter Bioscience C >2 months Tetanus toxoid (TT) 
MenAfriVac™ 
Serum Institute of 
India 
A 1-29 years TT 
MenHibrix® GlaxoSmithKline C, Ya 6 weeks-18 months TT 
aIncludes serotype b Haemophilus influenzae polysaccharide. 
 
In 2010, the meningococcal serogroup A polysaccharide glycoconjugate vaccine 
(PsA-TT) MenAfriVac™ was introduced in three countries in sub-Saharan Africa to 
prevent invasive meningococcal disease caused by N. meningitidis serogroup A as 
part of a collaborative partnership (Meningitis Vaccine Project) (63). The low-cost 
conjugate vaccine was first introduced in Burkina Faso, and all individuals of age 1-
29 were immunised to ensure maximum effectiveness. Since the roll-out of the 
vaccine, 94% coverage has been achieved. Extensive surveillance and carriage studies 
have shown that, although carriage rates were low during epidemics before vaccine 
introduction, serogroup A can potentially be eliminated. The incidence of meningitis 
fell by 99.8% in the first year, and there was no case of serogroup A disease among 
the vaccinated individuals. Moreover, 1 year after the campaign, no asymptomatic 
carriage was detected in individuals sampled and tested (63). However, 1 year after 
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vaccine implementation, rates of serogroup W and X disease are increasingly 
contributing to the burden of disease. With the high costs of conjugate polysaccharide 
vaccines, an affordable vaccine that provides broad protection in sub-Saharan Africa 
against all serogroups causing disease is needed (65).  
 
 
1.14 Vaccines against meningococcus serogroup B 
1.14.1 Detergent extracted outer membrane vesicles (dOMV) 
Effective conjugated polysaccharide vaccines against serogroups A, C, Y and W are 
available, but no capsular vaccine exists against serogroup B meningococcus (66). Its 
polysaccharide is an α(2-8) linked polysialic acid that is chemically identical to the 
human neural glycoproteins polysialic acids such as neural-cell adhesion molecule 
(NCAM-1) (5,50). Besides poor immunogenicity of the polysaccharide there is also a 
safety concern because it could elicit autoantibodies (45). In the absence of an 
immunogenic polysaccharide vaccine, attempts have been made to develop protein- 
based vaccines (68). One such strategy is the use of dOMV vaccines from whole 
bacteria. Treatment with the detergent deoxycholate increases the yield of OMV 
release, but also decreases endotoxin activity by removing LOS. The dOMVs contain 
4-5 major OMPs such as PorA, and various other periplasmic and cytoplasmic 
proteins (5). dOMV vaccines are safe for use in humans (4,67,69). For example, a 
dOMV vaccine (MeNZB) was licensed in New Zealand against serogroup B in 2004 
when incidence rates had reached 17.4 cases per 100,000 people, and used to control 
regional and national outbreaks (5,44,69). However, serum bactericidal antibodies 
produced against dOMV vaccines are directed primarily against immunodominant 
PorA, which is highly variable in terms of sequence and expression (4,66,68). The 
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prevalence of certain variants of PorA also changes over time and across geographical 
regions. To achieve a broad coverage of above 75% of isolates in a country, as many 
as 9 different serosubtypes of PorA could be necessary (44). Therefore, detergent 
extracted dOMV is best suited for curtailing epidemic outbreaks caused by a specific 
predominant strain with conserved PorA rather than in a population-scale intervention 
(5,14,70).  
 
1.14.2 Protein-based vaccine 
The design of a protein-based vaccine is complicated because of the genetic and 
antigenic variability exhibited by N. meningitidis, and its propensity for horizontal 
gene transfer. Until recently, no broadly protective vaccine against endemic serogroup 
B was available, although it accounts for more than 50% of meningococcal cases in 
some industrialised countries (44,63). In an attempt to identify protein antigens 
against serogroup B, reverse vaccinology approaches have been used. (5). Reverse 
vaccinology is a genome-based approach where vaccine candidates are identified by 
in silico analysis of a pathogen’s genome for potential surface exposed antigens or 
secreted proteins that could be accessible to antibodies (50,71). The search predicted 
around 600 novel antigens, which were expressed in Escherichia coli and used to 
immunise mice. Analysis of the sera identified 29 surface-located proteins that 
elicited bactericidal antibodies (2,63). Of these, the most promising candidate 
antigens identified included fHbp, previously known as lipoprotein 2086 (LP2086) or 
genome derived neisserial antigen 1870 (GNA1870), Neisserial heparin binding 
antigen (NHBA) formerly known as GNA2132 and Neisserial adhesin A (NadA; 
GNA1994) (66). NadA mediates bacterial cell-adhesion and invasion, and it is 
classified into five main alleles 1-5 (72,73). The lipoprotein NHBA binds heparin 
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through arginine-rich regions known to increases serum resistance (30). It is also 
present in all strains tested to-date and induces bactericidal antibodies if enough 
protein is expressed on the outer membrane. fHbp is a surface-exposed lipoprotein 
that binds human complement fH on the bacterial cell surface (71,74,75). The gene is 
present in most invasive meningococcal isolates independent of serogroup, and can be 
divided into three main variants (v.1, 2 or 3) (61). Together these antigens, and a 
dOMV with a PorA P1.7-2,4 from a New Zealand serogroup B strain, are formulated 






Figure 1.6. Components of the 4CMenB vaccine (Bexsero®). 
The vaccine contains four major meningococcal serogroup B components. Two are recombinant fusion 
proteins: GNA2091 fused with fHbp and NHBA fused with GNA1030, and recombinant NadA. The 
dOMV with PorA serosubtype P1.7-2,4 was derived from a serogroup B strain-specific outbreak in 








1.14.3 Native Outer Membrane Vesicles (NOMV) 
The dOMV are safe for use in humans, but dOMVs induces antibody responses 
mainly directed to the antigenically variable PorA, limiting its utility (76). Extraction 
of such vesicles requires the use of detergent that in the process removes desirable 
antigens that may elicit broader bactericidal antibody responses. Compared to 
dOMVs, NOMVs are vesicles spontaneously and naturally released from Gram-
negative bacteria. Hydrophobic OMPs are retained as there is no detergent involved in 
the processing, and the antigens are presented on the membrane in their native 
conformation (76–78). In these vesicles, endotoxicity is reduced by preparing 
NOMVs from recombinant strains with a deleted lpxL1 or lpxL2 genes. These encode 
for acyltransferases in the LOS biosynthesis pathway, and the mutants have a penta- 
or tetra-acylated LOS, respectively, instead of wild-type hexa-acylated LOS (76). The 
mutant forms of LOS are less effective at being recognised by Toll-like receptor 4 
(TLR-4) and stimulate the receptor (50). Consequently, the release of pro-
inflammatory cytokines by human peripheral blood mononuclear cells is reduced by 
100-1000-fold, similar to the level of dOMV vaccines licensed for use in humans (8, 
41).  
 
Previous studies have shown that NOMV vaccines with over-expressed fHbp induce 
broad cross-reactive bactericidal antibodies against a panel of serogroup B strains and 
diverse African strains (76,78,79). Koeberling et al. (2008) prepared a NOMV 
vaccine from a serogroup B recombinant strain H44/76 with deleted lpxL1 with over-
expressed fHbp 10-fold higher than wild-type expression levels (80). In mice, the 
vaccine elicited broader bactericidal antibody responses against genetically diverse 
serogroup B meningococcal isolates with heterologous PorA compared to NOMV 
!
34!
without over-expressed fHbp or recombinant fHbp. Likewise, Pajon et al. (2011) 
showed that the same NOMV as described above induced broadly cross-reactive 
antibodies that were bactericidal against genetically diverse serogroup A, W and X 
strains from various countries of the African meningitis belt (79). The recombinant 
vaccine proteins, however, only elicited anti-fHbp antibodies that killed strains that 
matched the sequence variant of the recombinant vaccines and not to strains with 
mismatched fHbp variants. The results suggests that using a vaccine that presents 
antigens in their native membrane environment is of advantage as they elicit a 
different antibody repertoire with better and broader bactericidal activity. The greater 
bactericidal activity could also be attributable to different IgG subclass responses 
generated or that the NOMV itself act as an adjuvant augmenting immune responses.  
 
 
1.15 New vaccine strategies  
1.15.1 Generalised Modules for Membrane Antigens (GMMA) 
In recent years, new vaccine strategies have been employed to expand vaccine 
protection. One such strategy is GMMA. To have genetically increased release of 
vesicles, one such method is the deletion of gna33. GMMAs are derived from a 
recombinant strain that has been modified through deletion of the gna33. There are 
proteins that connect the outer membrane and peptidoglycan together. Disruption of 
this linkage by deletion of the gna33 gene alters the membrane structure and 
consequently increasing the budding and vesicle release (81). The final product is an 
OMV devoid of inner membrane and cytosolic constituents (82). Compared to 
NOMV, which are naturally released by Gram-negative bacteria in low amounts, 
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GMMA provide a large-scale source of membrane material for reduced and cost-
effective vaccine production platform. Moreover, compared to dOMVs, GMMA are 
not detergent treated and beneficial detergent soluble antigens such as fHbp are 
maintained, enriched and presented in their proper structural state and membrane 
environment (31,68).  
 
The recent study by Koeberling et al. (2014) prepared a GMMA vaccine from a strain 
engineered to over-express fHbp of variant 1 (65). In general, antiserum against fHbp 
v.1 may be bactericidal against N. meningitidis strains expressing fHbp v.1 but has 
limited cross-reactivity against strains expressing fHbp v.2 or v.3 and vice versa 
(84,85). Previously, Pajon et al. (2011) showed that serogroup W from Africa were 
conserved in terms of PorA VR P1.5,2 (79). The authors also confirmed that most 
serogroup A and X isolates have an fHbp of variant 1. Using this information, the 
serogroup W GMMA produced by Koeberling et al. (2014) with over expressed fHbp 
v.1 was shown to elicit bactericidal antibody response against genetically diverse and 
invasive heterologous serogroup A, W and X isolates from Africa expressing fHbp 
v.1 or v.2 respectively (76,79). This illustrates the potential of GMMA as a broadly 
protective vaccine against African strains potentially suitable and safe for use in 
humans and potentially affordable (86,87). Unlike conjugate polysaccharide vaccines, 
the recombinant strains for GMMA production can be engineered to include more 
than one immunogenic OMP potentially expanding vaccine protection against 
serogroups that may emerge in the meningitis belt in the future. Moreover, vaccines 
need to have two basic elements that consist of an antigen that will trigger an immune 
response and an adjuvant to ensure such response is robust. GMMA are potent 
immunstimulators of the humoral immune response both as a vaccine and adjuvant 
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due to its immunogenic properties, whereby production of protective bactericidal 
antibodies is facilitated (82).   
 
 
Although, GMMA are an attractive vaccine platform, the exact antigenic content of 
such vesicles are unknown. Research has combined proteomic analyses, functional 
genomics and structural vaccinology, to elucidate the envelope components and 
hopefully identify new target antigens as the probe to exploit the OMV-concept to 
formulate cross-protective vesicle vaccines. A strategy for that aim, which has not 
been previously employed, is the use of GMMA as a tool to generate mAbs to 
specific and unknown antigens on the surface membrane. Analysis of the properties of 
antigen specific mAbs and their potential bactericidal responses could aid determining 
the fine specificity of the humoral immune responses elicited by GMMA. Moreover, 
generation of mAbs to unknown antigens that may be bactericidal could also aid 











1.16 Thesis objectives 
There were three main goals of the thesis. Firstly, we set out to molecularly 
characterise African serogroup A, W and X isolates. Secondly, to obtain a proof-of-
concept in mice for GMMA meningococcal candidate vaccines, we engineered 
GMMA expressing fHbp v.1 and GMMA expressing NadA. Thirdly, to understand 
the antigenic specificities and immune responses elicited against GMMA, mAbs were 
produced against antigens presented on GMMA. 
In short the aim of the thesis were as follows: 
1. Molecular characterisation of a panel of epidemic meningococcal serogroup 
A, W and X isolates.  
a. Molecular typing of selected genes fHbp, porA, nhbA and nadA to 
determine their genetic variability.  
b. Analysis of fHbp and NadA protein expression levels in serogroup A, 
W and X isolates. 
2. Investigate and characterise the breadth of immune responses elicited by the 
prototype GMMA-based meningococcal vaccines expressing either fHbp or 
NadA against genetically diverse N. meningitidis serogroups A, W and X 
isolates.  
a. Evaluation of IgG antibody responses against NadA by ELISA.  
b. Evaluation of serum bactericidal activity of sera from mice immunised 
with GMMA over-expressing fHbp or NadA against a subset of 
genetically diverse serogroup A, W and X isolates.  
3. To help understand the humoral immune responses elicited, mAbs against 




a. Screening of anti-GMMA antibodies by ELISA and Western blot using 
GMMA and recombinant protein. 
b. IgG isotyping. 
c. Evaluation of mAb binding on surface of bacteria by Western blotting, 
immunofluorescence (IFA) and flow cytometry. 
d. Evaluation of the bactericidal activity of mAbs by serum bactericidal 
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The hallmark of invasive meningococcaemia is rapid progression of disease. 
Therefore, focus has been situated on developing vaccines to prevent disease. The 
development of conjugated vaccines against the known virulence factor associated 
with invasive disease, polysaccharide capsule, provides long-term protection in 
children and adults (1,2). Existing quadrivalent A, C, W and Y polysaccharide-protein 
conjugate vaccines are potentially effective at all ages, but the cost of such vaccines 
deems them unlikely to be affordable for mass distribution in the meningitis belt. 
Developing an affordable broadly cross-protective vaccine against serogroups causing 
disease in sub-Saharan Africa has been a major challenge (2).  
 
Generalised modules for membrane antigens (GMMA) is a new affordable protein-
based approach towards developing a broadly-protective meningococcal vaccine for 
Africa. A first step towards facilitating the developing of a comprehensive GMMA 
vaccine effective against a broad range of serogroups is the selection of a vaccine 
target/antigen, which requires knowledge of the molecular epidemiology of N. 
meningitidis. Molecular characterisation of subcapsular structures that are important 
for mucosal colonisation, spread and crossing of the blood-brain barrier can inform 
what antigen can possibly achieve broad coverage by serum bactericidal antibodies.  
 
 
2.1.1 Our vaccine strategy 
The GMMA vaccines are outer membrane blebs produced from recombinant strains 
that have deleted gna33, and lpxL1 genes. As discussed in Chapter 1, deletion of 
gna33 increases vesicle release by the mutant strain, thus enhancing vaccine 
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production (3). LpxL1 codes for a late functioning acyltransferase, and deletion results 
in penta-acylated lipid A with decreased endotoxic activity compared to wild type 
hexa-acylated lipid A (4). Therefore, these mutations make GMMA a potential 
vaccine platform.   
 
NOMV from isogenic mutants with up-regulated expression of fHbp have been 
shown to provide broad protection against African meningococcal isolates from 
different serogroups (5). Other OMPs that have been shown to elicit bactericidal 
antibodies include NadA, NHBA and PorA (6–8). To help determine the potential 
coverage of these antigens in a GMMA-based vaccine for Africa, we investigated 
their genetic diversity in two sets of serogroup A, W and X carriage and disease 
isolates from various countries of the sub-Saharan Africa collected between 1995 and 
2011. Focusing on isolates collected over a period of years from both a defined and 
wide geographic region provides the opportunity to monitor the dynamics and 
antigenic diversity over time. Here, we also focused on over-expressing fHbp variant 
1 in GMMA, and characterising the immune responses elicited.  
 
2.1.2 Factor H binding protein (fHbp) 
New vaccine strategies have focused on protein-based vaccines, and the search for 
proteins was to find a vaccine against serogroup B that elicits serum bactericidal 
antibodies. The most promising candidate antigen is fHbp previously referred to as 
GNA1870 and LP2086, identified by two different groups, Novartis and Pfizer, 
respectively (9,10). FHbp is a 27 kilodalton (kDa) surface-exposed lipoprotein that 
divided in two subfamilies (subfamily A and B) according to the Pfizer classification 
system or three variant groups, variant 1 (v.1), v.2 and v.3, based on amino acid 
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sequence identity and antibody cross-reactivity (Novartis classification) (9,10). It has 
also been divided into at least nine modular groups based on the combination of five 
variable α and β fHbp segments (1,11). Variant 1 corresponds to subfamily B while 
variants 2 and 3 correspond to subfamily A (12) (Table 2.1). The variants are further 
divided into fHbp sub-variants, and each individual sub-variant is given an ID number 
(13). To date, 715 subvariant peptides have been identified (http://pubmlst.org/ 
neisseria/). The gene has been shown to be present in most strains tested to date, and 
only a few isolates lacking fHbp gene have been identified (14). Hitherto, fHbp 
variant and subtype in African meningococcal isolates were shown to be relatively 
conserved (5).  
 
Table 2.1. Nomenclature of fHbp according to the classification by Pfizer and Novartis. 
Pfizer subfamily classification of fHbp was firstly performed by Fletcher et al. (2004) (15), variant 
designation was by Masignani et al. (2003) (16) and modular architecture was assigned and Beernink 
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One function of fHbp is to bind human complement fH on the bacterial cell surface 
(18–21). This rapidly sequesters fH and down-regulates complement activation of the 
alternative pathway through the decay of C3 convertase C3bBb, enhancing the ability 
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of the bacterium to escape complement-mediated bacteriolysis in human serum or 
blood (11,22–24). A second function of serum anti-fHbp antibodies is that they can 
activate both classical and alternative pathway by blocking binding of fH and induce 
bactericidal activity; however this function is not necessary for complement 
activation. It has been shown that antiserum against fHbp v.1 (subfamily B) may be 
bactericidal against N. meningitidis strains expressing fHbp v.1 but has limited cross-
reactivity against strains expressing fHbp v.2 or v.3 (subfamily A) and vice versa 
(2,5,25). Previously, a study showed that a mixture of two NOMVs with over-
expressed fHbp v.1 and v.2 elicit bactericidal antibody response against genetically 
diverse and invasive serogroup A, W and X isolates from Africa expressing fHbp v.1 
or v.2 respectively. This illustrates the potential of fHbp in a native OMVs as a 
broadly protective vaccine against African strains (26,27).  
 
Expression level of fHbp is naturally variable, and in most wild-type strains 
expression is low (10). Oriente et al. (2010) showed that fHbp expression is under 
control of two promoters: a monocistronic at the promoter of fHbp and a bicistronic 
originating from an upstream gene (28). The monocistronic promoter up-regulates 
transcription under oxygen limitations, such as in the blood stream, ensuring 
enhancement of complement resistance. Moreover, Pajon et al. (2011) showed that 
the level of fHbp expression in meningococcal strains determines their susceptibility 
to killing by anti-fHbp antibodies (5). In general, high expressers of fHbp are more 
susceptible to killing by anti-fHbp antibodies than low expressers. Low expressers are 
more resistant to killing because there is not enough correctly spaced fHbp epitopes 
for IgG antibodies to engage C1 complex (7,10,20). The authors proposed that low 
expression of fHbp could be defined as ≤33%, intermediate as 33-100% and high 
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expression as >100% compared to fHbp expressed by the group B reference strains 
H44/76 or 8047, which are naturally high expressers of fHbp ID 1 v.1 and v.2 ID77, 
respectively.  
 
2.1.3 Neisserial adhesin A (NadA) 
NadA is a surface exposed trimeric protein present in most hypervirulent 
meningococcal strains and involved in epithelial cell adhesion and 
colonisation/invasion (29). The gene is well conserved and it clusters into five well-
defined alleles. Alleles 1-3 are highly conserved and show cross-reactivity. A more 
comprehensive introduction to NadA is given in Chapter 3.  
 
2.1.4 Neisserial Heparin Binding Antigen (NHBA) 
NHBA is a surface exposed lipoprotein that binds heparin through arginine-rich 
regions known to increases serum resistance due to the potential interactions of 
heparin with components of the complement pathway such as fH (30). Most 
pathogenic meningococci express NHBA, and there are several variants of NHBA 
that show cross-reactivity (31). Antibody protection is mediated through 
opsonophagocytocis (32). For example, peptide 2 is most common and included in the 
4CMenB vaccine Bexsero® and it is able to induce cross-protective antibodies 
against many variants (33). Currently 278 peptide amino acid sequences have been 






2.2 Project objectives 
The main objective of this study was to characterise a panel of two sets of African 
meningococcal strains based on the OMP fHbp, NadA, PorA and NHBA and protein 
expression level of fHbp. The first set of 50 serogroup A, W and X isolates were 
received from Swiss Tropical and Public Health Institute isolated from Ghana and 
Burkina Faso and Norwegian Institute of Public Health (NIPH). The second set of 44 
serogroup A, W and X isolates were received from NIPH isolated from various 
countries of the meningitis belt.  
 
The second objective of the study was to investigate and obtain a proof of principle as 
to whether over-expression of fHbp v.1 ID1 on GMMA from a serogroup W isolate 
can induce broadly cross-reactive bactericidal antibodies against epidemic serogroup 
A, W and X strains. The GMMA vaccine was prepared from a mutant engineered to 
over-express fHbp v.1 ID1, and with additionally three mutations that will eliminate 
the capsule (Δcps), detoxify the GMMAs (ΔlpxL1) and increase the production of 
vesicles by the bacteria (Δgna33) (3,4,34). The vaccine is expected to provide 
protection against the majority of serogroup A and X isolates mediated by antibodies 
against fHbp v.1.  
 
In short the aims are: 
 
1. Molecular characterisation of a panel of epidemic meningococcal serogroup 
A, W and X isolates.  
a. Molecular typing of fHbp, porA, nhbA and nadA.  
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b. Further analysis of fHbp protein expression levels in serogroup A, W 
and X isolates. 
c. Selection of a representative strain panel including serogroup A, W 
and X isolates that would be suitable to investigate bactericidal activity 
induced by prototype GMMA vaccines. 
 
2. Characterisation of antibody responses elicited by GMMA with over-
expressed fHbp. 
a. Evaluation of serum bactericidal activity of sera made against GMMA 
with over-expressed fHbp variant 1 against a subset of genetically 























2.3 Materials and Methods 
 
2.3.1 N. meningitidis isolates 
The first set of N. meningitidis serogroup A, W and X isolates investigated in this 
study were kindly provided by Gerd Pluschke at the Swiss Tropical and Public Health 
Institute (STPHI) and Dominique Caugant at the Norwegian Institute of Public Health 
(NIPH; 8 serogroup X isolates). Four were of serogroup A (all cases), 31 of serogroup 
W (10 cases, 21 carriers) and 9 of serogroup X (8 cases; 4869 from STPHI). The A 
and W strains that had been collected in the Kassena-Nankana District (KND) of 
Ghana and in the Nouna Health District (NHD) in the Kossi region of Burkina Faso as 
part of a longitudinal study (Table 2.2). Two isolates of serogroup A were isolated in 
Nouna (Burkina Faso) and two in Navrongo (Ghana) between 2002-2007, 9 of 
serogroup X in Mali, Uganda, Kenya, Burkina Faso isolated between 1995-2010, and 
the remaining 31 isolates were of serogroup W isolated in both Ghana (n=23) and 
Burkina Faso (n=8) between 2003-2009. Case strains were isolated from the CSF of 
meningitis patients, and carriage strains were isolated from throat swabs collected in 
the context of longitudinal carriage surveys. Isolation and characterisation of strains 
has been described previously (35–37). Ethical clearance was obtained from the 
relevant institutional review boards and informed consent was obtained from all study 
participants.  
 
The second set of N. meningitidis serogroup A, W and X case isolates investigated in 
this study were kindly provided by Dominique Caugant. The serogroup A (n=13), W 
(n=20) and X (n=11) isolates were collected from various countries of the sub-
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Saharan Africa (Table 2.3). The serogroup A strains were isolated between 2001-
2010, W between 2001-2011 and X between 2006-2010.  
 
All isolates were molecularly characterised with respect to fHbp, porA VRs, nadA and 
nhbA by gene sequencing and gene typing. A subset of 30 isolates from the first set 
and 42 isolates from the second set of meningococcal strains were also analysed for 
their fHbp expression level.  
 
Table 2.2. Characteristics of the first set of serogroup A, W and X isolates used in this study. 
Molecular characterisation was performed on these isolates by PCR amplification and sequencing of 
fHbp, porA, nadA and nhbA.  















2002 1 5 P1.20,9 3 S ND 




2005 1 5 P1.20,9 3 S ND 




2006 1 5 P1.20,9 3 Y ND 




2007 1 5 P1.20,9 3 Y 2859 
W 1485* carrier Ghana 2003 2 23 P1.5,2 3 S 11 
W 1487 carrier Ghana 2003 2 23 P1.5,2 3 S 11 
W 1489 carrier Ghana 2003 2 23 P1.5,2 3 S 11 
W 1491 carrier Ghana 2003 2 23 P1.5,2 3 S 11 
W 1494* carrier Ghana 2003 2 23 P1.5,2 3 S 11 
W 1625* case Ghana 2003 2 23 P1.5,2 3 Y 11 
W 1626 case Ghana 2003 2 23 P1.5,2 3 S 11 
W 1627* case Ghana 2003 2 23 P1.5,2 3 S 11 
W 1628* case Ghana 2003 2 23 P1.5,2 3 S 11 
W 1629 carrier Ghana 2004 2 23 P1.5,2 3 N 11 
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W 1630* carrier Ghana 2004 2 23 P1.5,2 3 S 11 
W 1632 carrier Ghana 2004 2 23 P1.5,2 3 Y 11 
W 1634* carrier Ghana 2004 2 23 P1.5,2 3 Y 11 
W 1636 carrier Ghana 2004 2 23 P1.5,2 3 Y 11 
W 1681* case Ghana 2003 2 23 P1.5,2 3 Y 11 
W 1682* case Ghana 2003 2 23 P1.5,2 3 S 11 
W 1683* case Ghana 2003 2 23 P1.5,2 3 S 11 
W 1846* carrier Ghana 2004 2 23 P1.5,2 3 Y 11 
W 1848 carrier Ghana 2004 2 23 P1.5,2 3 Y 11 
W 1857* carrier Ghana 2004 2 23 P1.5,2 3 Y 11 
W 1888 carrier Ghana 2004 2 23 P1.5,2 3 S 11 
W 1903* case Ghana 2004 2 23 P1.5,2 3 Y 11 
W 1973 carrier Ghana 2004 2 23 P1.5,2 3 Y 11 
W 2039* case Burkina Faso 2008 2 22 P1.5,2 3 Y 11 
W 2252* case Burkina Faso 2008 2 22 P1.5,2 NA S 11 
W 2716 carrier Burkina Faso 2004 2 22 P1.5,2 3 Y 11 
W 2719* carrier Burkina Faso 2004 2 22 P1.5,2 3 Y 11 
W 2841 carrier Burkina Faso 2005 2 22 P1.5,2 NA Y 11 
W 2855 carrier Burkina Faso 2005 2 22 P1.5,2 NA S 11 
W 2882 carrier Burkina Faso 2009 2 22 P1.5,2 NA S 11 
W 2959* carrier Burkina Faso 2009 2 22 P1.5,2 NA Y 11 
X BF07/07a* case 
Burkina 
Faso 2007 1 74 
P1.5-
1,10-1 N S 181 
X Ug13/07a* case Uganda 2007 1 74 
P1.19,
26 N Y 5403 
X BF12/03a* case 
Burkina 
Faso 2003 1 73 
P1.5-










case Burkina Faso 2010 1 74 
P1.5-





case Burkina Faso 2010 1 74 
P1.5-





case Burkina Faso 1997 1 73 
P1.5-







case Uganda 2006 1 74 P1.19,26 N Y 5403 
X 4869* NG Mali 1995 1 12 P1.19,15 N Y NG 
*Isolate used for fHbp protein expression analysis.  
ST= sequence type 
ND= not defined.  
 NA: Inactive nadA due to insertion sequence IS1301.  
Y: PCR positive sample 
 S: NHBA gene with stop codon. 
 N: PCR negative sample 
a Isolates from NIPH 
 
 
Table 2.3. Second set of serogroup A, W and X isolates received from Dominique Caugant at the 
Norwegian Institute of Public Health.  
Molecular characterisation was performed on these isolates by PCR amplification and sequencing of 
fHbp, porA, nadA and nhbA.  










gene fetA ST 
A BF8/01 Burkina Faso 2001 1 5 P1.20,9 3 Y F3-1 7 
A Mk804/03 Ethiopia 2003 1 5 P1.20,9 3 Y F3-1 7 
A BF3/06 Burkina Faso 2006 1 5 P1.20,9 3 Y F3-1 7 
A BF6/06 Burkina Faso 2006 1 5 P1.20,9 3 Y F3-1 2859 
A BuFa20030020 
Burkina 
Faso 2007 1 5 P1.20,9 3 Y F3-1 6035 
A Mali21/07 Mali 2007 1 5 P1.20,9 3 29 F3-1 2859 
A Su14/07 Sudan 2007 1 5 P1.20,9 3 29 F3-1 7 
A MRS2007446 Togo 2007 1 5 P1.20,9 3 29 F3-1 2859 
A MRS2008162 Niger 2008 1 5 P1.20,9 3 Y F3-1 2859 
A Niga16/09 Nigeria 2009 1 5 P1.20,9 3 29 F3-1 7 
A BF1/10 Burkina Faso 2010 1 5 P1.20,9 3 29 F3-1 2859 
A Tch44/10 Chad 2010 1 5 P1.20,9 3 29 F3-1 7 
A Mali21/10 Mali 2010 1 5 P1.20,9 3 2 F3-1 8639 




W BF6/02 Burkina Faso 2002 2 23 P1.5,2 3 Y F1-1 11 
W BF10/02 Burkina Faso 2002 2 23 P1.5,2 3 Y F1-1 11 
W Nigeria 1/03 Nigeria 2003 2 23 
P1.5-
1,2-36 3 120 F1-1 2881 
W MRS2004034 Benin 2004 2 22 
P1.5-
1,2-36 3 120 F5-1 2881 
W Ghana7/04 Ghana 2004 2 23 P1.5,2 3 Y F1-1 11 
W BF2/06 Burkina Faso 2006 2 22 P1.5,2 3 Y F3-1 5779 
W Mali1/06 Mali 2006 2 23 P1.5,2 3 29 F1-1 11 
W Sudan4/06 Sudan 2006 1 9 P1.5,2 3 29 F1-1 11 
W Uganda 11/06* Uganda 2006 3 349 P1.5,2 3 Y F1-1 11 
W Cam2/09 Cameroon 2009 1 9 P1.5,2 3 29 F1-1 11 
W Cam1/09 Cameroon 2009 1 9 P1.5-1,2-36 3 Y F3-1 2881 
W Tch5/09 Chad 2009 1 9 P1.5,2 3 91 F1-1 11 
W Mali10/09 Mali 2009 2 23 P1.5,2 2 Y F1-1 11 
W Niga85/09 Nigeria 2009 1 9 P1.5,2 3 Y F1-1 11 
W BuFa20/10 
Burkina 
Faso 2010 2 23 
P1.5-
1,2-36 3 Y F5-1 8638 
W Nigeria 4/10 Nigeria 2010 1 9 P1.5,2 3 Y F1-1 11 
W BuFa2/11 
Burkina 
Faso 2011 1 9 P1.5,2 3 Y F1-1 11 
W Mali4/11 Mali 2011 1 9 P1.5,2 3 Y F1-1 11 
W MRS2008218 
Burkina 
Faso 2008 2 22 
P1.5-
1,2-36 3 Y F5-1 2881 
X MRS2006078 Niger 2006 1 74 
P1.5-
1,10-1 3 Y F1-31 181 
X MRS2006089 Niger 2006 1 74 
P1.5-
1,10-1 3 Y F1-31 181 
X MRS2006093 Niger 2006 1 74 
P1.5-
1,10-1 3 Y F4-23 181 
X MRS2006087 Niger 2006 1 74 
P1.5-
1,10-1 3 Y F4-23 5789 
X Uganda 14/06* Uganda 2006 1 74 
P1.19,2
6-4 3 Y F3-27 5403 
X MRS2008223 
Burkina 
Faso 2007 1 74 
P1.5-
1,10-1 3 118 F1-31 181 
X Uganda 11/07 Uganda 2007 1 74 
P1.19,2
6 3 Y F3-27 5403 
X MRS2008112 Benin 2008 1 74 
P1.5-
1,10-1 3 Y F1-31 181 
X BuFa9/10 
Burkina 
Faso 2010 1 74 
P1.5-
1,10-1 3 Y F5-69 181 
X BuFa 16/10 
Burkina 
Faso 2010 1 74 
P1.5-
1,10-1 3 118 F1-31 181 
X BuFa 24/10 
Burkina 
Faso 2010 1 74 
P1.5-
1,10-1 3 47 F1-31 181 




Y: PCR positive sample 
*Isolates not used for fHbp protein expression analysis.  
 
2.3.2 Recombinant DNA techniques 
The strains were sub-cultured on GC agar plates (Becton Dickinson, Franklin Lakes, 
NJ, USA) and incubated overnight at 37°C, 5% CO2. A loop-full of cells was re-
suspended in 500µl sterile water and boiled for 10 minutes. The samples were pelleted 
at 17,900xg for 5 minutes in a microcentrifuge (Eppendorf, Hamburg, Germany). 
Genomic DNA was purified using the Invitrogen PureLink Genomic DNA kit 
(Invitrogen, San Diego, California, USA) according to the manufacturer’s 
instructions. The genes fHbp, porA VRs, nadA and nhbA were amplified by PCR from 
all isolates using the primers described in Table 2.4. The final PCR reaction 
contained: 0.5mM deoxynucleotide triphosphates, 5 U/ml Taq DNA polymerase 
(New England BioLabs, Ipswich, USA), 1×Thermopol Reaction buffer (New England 
BioLabs), 1µM primer solution (Sigma-Aldrich, St. Louis, Missouri, USA) and 100ng 
of genomic DNA quantified by NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Wilmington, USA). The PCR was performed using the Applied 
Biosystems GeneAmp PCR System 9700 (Applied Biosystems, Foster city, USA) 
with maximum ramping speeds using conditions described in Table 2.5. PCR 
products were separated by gel electrophoresis using a 0.8% Tris base, acetic acid and 
EDTA (TAE) agarose gel (Sigma-Aldrich), and purified using the PureLink PCR 
Purification Kit (Invitrogen) according to the manufacturer’s instructions. The DNA 










designation 5’-3’ nucleotide sequence Purpose Reference 
fHbp A1 (Fw) GACCTGCCTCATTGAT PCR, sequencing (26) 
 B2 (Rv) CGGTAAATTATCGTGTTCGTACGGC PCR, sequencing (26) 
porA 210 (Fw) ATGCGAAAAAAACTTACCGCCCTC PCR, sequencing (38) 
 H (Rv) CGCATATTTAAAGGCATAG PCR, sequencing This study 
 EI (Fw) CCAGCCAGGCCATTGATCC Sequencing This study 
 103L (Rv) AACGGATACGTCTTGCTC Sequencing (38) 
nadA NadAF (Fw) AACACTTTCCATCCAAAG PCR, sequencing (39) 
 NadAR (Rv) TTACCACTCGTAATTGACG PCR, sequencing (39) 
nhbA Fw GGCGTTCAGACGGCATATTTTTACA PCR, sequencing (40) 
 Rv GGTTTATCAACTGATGCGGACTTGA PCR, sequencing (40) 







Table 2.5. Conditions used for PCR amplification of the genes fHbp, porA, nadA and nhbA. 




94ºC, 4 minutes 
 
35 cycles: 
94ºC, 40 seconds 
58ºC, 40 seconds 
68ºC, 40 seconds 
 
Final extension: 
72°C, 5 minutes 
94ºC, 5 minutes 
 
30 cycles: 
94ºC, 1 minute 
55ºC, 1 minute 
72ºC, 30 seconds 
 
Final extension: 
72°C, 5 minutes 
 
94ºC, 5 minutes 
 
30 cycles: 
94ºC, 1 minute 
55ºC, 1 minute 
72ºC, 1 minute 30 seconds 
 
Final extension: 
72°C, 5 minutes 
94ºC, 4 minutes 
 
35 cycles: 
94ºC, 1 minute 
55ºC, 1 minute 
72ºC, 1 minute 
 
Final extension: 
72°C, 5 minutes 





2.3.3 DNA sequencing 
The primers used for porA VR1 sequencing were 210 and 103L (Table 2.4). We 
designed primers EI and H for sequencing of the VR2 region, by aligning the 
conserved regions upstream and downstream of VR2 using the alignment program 
Clustal W (http://www.ebi.ac.uk/Tools/msa/clustalw2/). PorA sequences from the 
following strains of different serogroups were used for the alignment: MC58 
(GenBank accession number AE002098.2), Z2491 (AL157959.1), 053442 
(CP000381.1), FAM18 (AM421808.1), M6190 (AEQF01000026.1), M13399 
(AEQG01000023.1) and alpha 14 (AM889136.1) using Uniprot . The sequences were 
read at Novartis Vaccines-Cellular Microbiology and Bioinformatics Unit Automated 
DNA Sequencing Facility, Siena, Italy, on an ABI 3730 DNA Analyzer. Sequences 
were analysed using the Simmonics program (version 1.6), MEGA software package 
(version 5) and Chromas (version 2.01).  fHbp ID, porA VR and nhbA alleles were 
identified using the online Neisseria Sequence Typing database 
(http://pubmlst.org/neisseria).  
 
2.3.4 Western blot analysis of fHbp protein amount  
For 30 isolates, labelled with an asterisk in Table 2.2, Western blot analysis of the 
fHbp expression level in whole cell samples was performed as described by Seib et al. 
(2009) (13). The strains were sub-cultured on GC agar plates (Becton Dickinson) and 
incubated overnight at 37°C with 5% CO2. 7ml Mueller-Hinton Broth (MH; Becton, 
Dickinson) supplemented with 0.25% glucose (Sigma-Aldrich) was inoculated with a 
loop full of single colonies to an optical density at 600 nm (OD600) of 0.12-0.16. The 
suspensions were incubated at 37°C with 5% CO2 to an OD600 of 0.6 corresponding to 
approximately 1.8×108 colony forming unit (cfu)/ml (exponential growth phase). The 
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cells from 1ml of culture were collected by centrifugation at 17,900xg for 5 min in a 
microcentrifuge (Eppendorf), re-suspended in 100µl phosphate buffered saline (PBS) 
and heat inactivated in a water bath at 56°C for 1 hour. Protein concentrations of the 
suspensions were determined using Lowry protein assay kit (BioRad Laboratories, 
Hercules, USA) with bovine serum albumin (BSA; Sigma-Aldrich) as a standard. The 
samples were adjusted to 2000µg/ml and 10µl was loaded onto the gel (20µg). The 
fHbp amounts were estimated by SDS-PAGE and Western blotting. Hexa-Histidine 
tagged recombinant fHbp (rHis-fHbp) v.1 and v.2 of 0.05, 0.025, 0.0125 and 0.006 
µg/ml were used as standards. Positive and negative controls were whole cell lysates 
from N. meningitidis group B strain H44/76 and 8047 expressing fHbp v.1 ID1 and 
v.2 ID77, respectively, and isogenic fHbp knock-out mutants (generated by Oliver 
Koeberling). Proteins were transferred to a nitrocellulose membrane using the iBlot 
system (Invitrogen). After blocking overnight in 3% milk powder in 1xPBS (Merck, 
Whitehouse station, NJ, USA) at 4°C, fHbp proteins were detected with 1µg/ml anti-
fHbp mouse monoclonal antibody JAR5 (IgG2b) raised against rHis-fHbp v.1 ID1 
(41) and JAR31 (IgG2b) raised against rHis-fHbp v.3 ID 28, which shows cross-
reactivity against most fHbp v.2 peptides (18). After washing the membrane four 
times for 10 minutes each with 1xPBS+0.1% Tween20 (Sigma-Aldrich), secondary 
antibody horseradish peroxidase-labelled anti-mouse IgG (Invitrogen) in a 1:20000 
dilution was added. After another four washes, the membranes were developed using 
SuperSignal WestPico Chemiluminescent Substrate (ThermoScientific, Waltham, 
Massachusetts, USA) according to manufacturer’s instructions, and the signal was 
detected with Amersham Hyperfilm ECL (GE Healthcare, Little Chalfont, UK). The 
amount of fHbp expressed by each isolate compared to the standard rHis-fHbp was 
determined by densitometric analysis for three biological replicates using the 
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ImageQuant 400 gel documentation system (GE Healthcare). The expression of fHbp 
by the test isolates was reported as percentages of the amount of fHbp expressed by 
bacterial cells compared to the reference strains H44/76 and 8047, known to express 
relatively high amounts of fHbp v.1 and v.2 (5). The levels of fHbp expression by the 
reference strains were considered to be 100%.  
 
2.3.5 Serum bactericidal assay (SBA) using human complement 
Bacteria were sub-cultured on GC agar plate and incubated overnight at 37°C with 
5% CO2 (Table 2.8, see result section 2.4.5). Single colonies were used to inoculate 
7ml of MH broth (Becton, Dickinson) containing 0.25% (w/v) glucose (Sigma-
Aldrich) to an OD600 of 0.12-0.15, and incubated at 37°C with 5% CO2. 1ml of 
culture at an OD600 of 0.6-0.7 (early log-phase) was transferred into warm 6ml MH 
broth supplemented with 0.02 mM cytidine 5′-monophospho-N-acetylneuraminic acid 
(CMP-NANA, Sigma-Aldrich) and 0.25% glucose and grown to an OD600 of 0.6. The 
cultures were transferred into a 50ml Falcon centrifuge tube and Dulbecco’s saline 
phosphate buffer (DPBS, Sigma-Aldrich) containing 0.5mM MgCl2 and 0.9mM 
CaCl2 supplemented with 1% BSA (minimum 96% electrophoresis, Sigma-Aldrich) 
was added to a final volume of 50ml. The cells were pelleted by centrifugation for 10 
minutes at 3500rpm and re-suspended in DPBS+1%BSA to an OD600 of 0.7 
(approximately 2x108 cfu/ml). The suspensions were subsequently diluted 1:25000 in 
DPBS+BSA. The 40µl reaction mixture prepared in 96 well plates (Techno Plastic 
Products (TPP), Trasadigen, Switzerland) contained: 12µl DPBS+BSA, 10µl of 400-
500 cfu bacterial cells, 8µl 20% (v/v) final human complement and 10µl diluted 
mouse sera starting at 1:10 in serial 4 dilutions. The mouse sera were heated at 56°C 
for 30 minutes to remove endogenous complement activity. The source of 
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complement, kindly provided by Novartis NV&D (Marburg, Germany), was serum 
from a donor with no detectable bactericidal activity against the test strains. Five 
control wells contained cells with buffer only or complement without the test sera. 
12µl from the reaction mixture in the wells were plated and the plate was incubated at 
37°C with 5% CO2, for one hour. The bactericidal titre was defined as the reciprocal 
serum dilution that resulted in a 50% decrease of cfu after 60 minutes compared with 
the average number of cells in the control wells at time 0.  
 
 
2.3.6 Mouse immunisation (performed previously) 
We generated GMMA from three serogroup W mutant strains: one main vaccine 
candidate and two controls (Table 2.6). All strains had deleted lpxL1 and gna33 
genes. Over-expression of fHbp in the recombinant serogroup W isolate 1630 with 
deleted lpxL1, capsule, gna33 genes was done using a multicopy plasmid encoding 
fHbp ID1. The aim was to compare subsequent groups: group 1 + 2 to evaluate effect 
of capsule expression on production of anti-fHbp antibodies, groups 1 + 3 to evaluate 
effect of OE fHbp, and groups 1 + 4 to evaluate the efficacy of antibodies elicited 
against GMMA versus rHis-fHbp protein. Five weeks old CD-1 female mice (8 mice 
per group) were obtained from Charles River (Wilmington, MD, U.S.). The mice 
were immunised intraperitoneally (IP) with three doses of vaccine given at days 0, 14 
and 28. The GMMA vaccines were given at 5µg doses based on total protein. Control 
mice were immunised with 5µg rHis-fHbp ID1 purified from Escherichia coli BL21 
or aluminium hydroxide (Alum) only (Table 2.7). All vaccines were absorbed on 
3mg/ml Alum in a 100µl formulation containing 10mM Histidine and 0.9mg/ml 
NaCl. Blood samples were obtained at day 42 (two weeks after the third dose). The 
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animal procedures were performed under protocols approved by Novartis NV&D 
(Siena, Italy) animal care.  
 
Table 2.6. GMMA vaccine strains. 
GMMA vaccine strains were previously generated by Oliver Koeberling.  
Vaccine strain characteristics Designation of vaccine strain and GMMA used for immunisation 
Prototype vaccine candidate 
 
Serogroup W, strain 1630 
Capsule KO, lpxL1 KO, gna33 KO, over-expressed fHbp 
ID1 
Triple KO, OE fHbp 
Control vaccines 
 
Serogroup W, strain 1630 
Capsule expressed, lpxL1 KO, gna33 KO, over-expressed 
fHbp ID 1 
Double KO, OE fHbp 
Serogroup W, strain 1630 























Table 2.7. Groups of animals, dose, route of immunisation and antigens used in the mice 
immunisation trial. 
The isolate used for the production of GMMAs is serogroup W 1630, PorA P1.5,2, OE fHbp v.1 ID1, 
triple KO (ΔlpxL1, Δgna33, Δcapsule). ΔlpxL1 detoxifies the GMMA due to the production of penta- 
instead of hexa-acylated lipid A. Δgna33 increases blebbing or GMMA release from the bacterial cells. 
Δcapsule deletes the capsule of the bacterium rendering it non-invasive. Production of His-rfHbp ID1 
was presviouslt done by Oliver Koeberling. Following reagents were also used in the vaccine 
formulations NaCl (Sigma-Aldrich S9888), Histidine (Sigma-Aldrich H6034), Aluminium hydroxide 
(NV&D Formulation unit). For the production of vaccine candidates and control vaccines, the isolate 




Antigen Adjuvant Dose (µg) Immunisation route 
Volume (µl) 
per animal 
Primary vaccine candidate 
1 (1-8) Triple KO, OE fHbp Alum 5 IP 100 
Control vaccines 
2 (9-16) Double KO, OE fHbp Alum 5 IP 100 
3 (17-24) Triple KO Alum 5 IP 100 
4 (24-32) His-rfHbp ID1 Alum 5 IP 100 
5 (33-40) None Alum NA IP 100 
KO= knock-out, OE= over-expressed, IP= intraperitoneal.  
 
 
2.3.7 Statistical analysis 
Antibody titres were log10 transformed, and SBA titres <10 were assigned the value 
5. Data analysis was carried out using Graphpad Prism version 5.01 software. The 
Mann-Whitney U test was used to evaluate the serum bactericidal antibody responses 
between two vaccine groups. A probability (P) value of <0.05 was considered 








2.4.1 The first set of N. meningitidis isolates from Africa show 
conserved fHbp variant and porA subtypes  
 
From the sequence analysis of the fHbp gene, all serogroup A and W isolates 
expressed fHbp v.1 ID 5 and v.2 ID22 (isolates from Burkina Faso) or 23 (isolates 
from Ghana), respectively, which differ by one amino acid (aa) at position 30 (ID22 
serine; ID23 glycine). The serogroup X isolates that encoded an fHbp v.1 and an ID of 
12 (Mali), 73 (Burkina Faso) or 74  (Burkina Faso, Uganda and Kenya) (Figure 2.1). 
The meningococcal serogroup A and W case and carrier isolates were also conserved 
in terms of porA subtype as serogroup A encoded P1.20,9 and W P1.5,2. Variability 
was observed among serogroup X case and carrier isolates expressing P1.5-1,10-1, 
P1.19,26 and P1.19,15 (n=5, 3 and 1 respectively). Despite the limited number of 
isolates studied, the results show that between Burkina Faso and Ghana, which share a 
common border, there has been conservation of fHbp and PorA antigens among A 
and W isolates over a period between 2002-2009. Although greater variation was seen 
for serogroup X porA subtypes probably due to larger geographical are covered, 
results are consistent with previous studies of isolates from sub-Saharan Africa, which 









Figure 2.1. fHbp, nad,A porA and nhbA gene-typing analysis of first set of meningococcal 
serogroup A, W and X isolates collected between 1995-2010.  
The fHbp variant group is according to classification proposed by Masignani et al. (2003)(26). fHbp 
sequence ID,  nadA, porA VR and nhbA allele was determined by sequence query on 
http://pubmlst.org/neisseria. Each isolate was typed by PCR amplification of each respective gene, 
sequenced and analysed using bioinformatics software Simmonics, Mega 5 and Chromas. NadA + 
!
69!
IS1301: strains with nadA encoding gene-containing insertion sequence IS1301. NHBA-/stop codon: 
strains lacking NHBA encoding gene or having nhbA with stop codon.  
 
 
2.4.2 Most serogroup A and W isolate genomes from the first set of 
meningococcal strains contain nadA and nhbA  
NadA and NHBA are two antigens included in the vaccine Bexsero®, and they induce 
the production of bactericidal antibodies against N. meningitidis serogroup B strains 
(7,8). Among the first set of 50 African A, W and X strains investigated, the nadA 
allele 3 was present in all serogroup A isolates, 26/31 (84%) of serogroup W isolates 
and a truncated allele 1 of 750bp (Accession number: FJ619647) was detected in the 
serogroup X strains (Figure 2.1; Appendix 1). More carrier isolates (77%, 17/22) 
compared with case isolates (52%, 13/25) harboured the gene. Previous reports found 
that nadA is present in about 50% of case isolates (non-African), but is 
underrepresented among carrier isolates (39).  
 
Among the remaining five W isolates (1 case [2252], 4 carriers [2841, 2855, 2882, 
2959]), PCR amplification across the nadA site gave a 2 kb product instead of the 
expected 1 kb product on a DNA gel. Western blotting using whole cell lysate and 
polyclonal mouse anti-rHis-NadA-3 serum indicated that these isolates did not 
express NadA (Figure 2.3, Panel A). In the blots, rHis-NadA-3 has a band at 45kDa 
representing the monomer whereas in whole cells the trimeric form of NadA is seen at 
around 170kDa. Sequencing of this fragment confirmed the presence of the 842-base 
pair (bp) mobile genetic element IS1301 inserted at nucleotide (nt) 470-474 




The nhbA gene was identified in 30/31 (94%) of the serogroup W isolates, all 
serogroup A and X strains. However, nhba sequencing of the PCR positive isolates 
revealed a stop codon at different nucleotide positions for 15 serogroup A (n=2), W 
(n=13) and X (n=3) isolates, which has not been previously reported. Western blotting 
using polyclonal mouse anti-NHBA antibody showed that NHBA protein was not 
expressed in these isolates. The allele of the W strains was identified as 17 using the 
Neisseria typing database on http://pubmlst.org/neisseria/NHBA/. For the serogroup 
A and X strains no definite match was found.  
 
 
2.4.3 Lack of antigenic diversity of outer membrane proteins in the 
second set of serogroup A, W and X case isolates from Africa  
The diversity of OMP fHbp, NadA and NHBA were investigated in a second set of 44 
strains provided by Dominque Caugant at the NIPH. These strains were isolated from 
a wider geographical range in the meningitis belt over a period of 10 years (2001-
2011). Sequence analysis of the fHbp gene showed that 100% of the serogroup A and 
X isolates have a single fHbp peptide belonging to v.1 with an ID of 5 and 74 
respectively. Half of the serogroup W isolates encompassed fHbp v.2 with a peptide 
ID of 22 or 23. The remaining 45% (9/20) of the strains were of fHbp v.1 (ID 9), and 
only one isolate Uganda 11/06 was found to encode fHbp v.3 ID 349. From the 
sequence analysis of the nadA gene, all serogroup A and X isolates harboured allele 3 
and 75% (15/20) of the W isolates (Figure 2.2). The nadA gene in the isolate 
Ug11/07 is a pseudogene since several point mutations are observed in the N-terminal 
domain between aa 5-18 and coiled-coil region between aa 289-300. As observed for 
five isolates of the first strain panel, PCR amplification across the nadA site of these 
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five W isolates also gave a 2 kb product instead of the expected 1 kb product 
(Nigeria1/03, MRS2004034, Cam1/09, BuFa20/10, MRS2008218). Likewise, 
BLAST analysis of this fragment confirmed the presence of the insertion sequence 
IS1301 at nt 400-469 (Δ69nt; Nigeria1/03), 470-474 (insertion site CTAAG; 
MRS2004034, Cam1/09, BuFa20/10) and at nt 472-496 (MRS2008218). Western 
blotting of these isolates revealed a single band between 49-62kDa (Figure 2.3, Panel 
B). 
 
The nhbA gene was identified all of the 44 N. meningitidis isolates. Six of the 
serogroup A isolates could be classified as belonging to subtype 29 and one isolate as 
2. Two isolates of serogroup W encode subtype 120, three subtype 29 and one was of 
subtype 91. Of the serogroup X isolates, two encode subtype 118 and one 47. All 
other strains were non-typable.  
 
The Norwegian Public Health Institute previously analysed porA and fetA genes. All 
A isolates harboured PorA of subtype 20,9 and all serogroup W isolates had a P1.5,2 
or P1. 5-1,2-36 subtype. Among the serogroup X isolates, P1.19,26 and P1.19,26-4 
accounted for 91% of the isolates, and 9% had a subtype of P1.5-1,10-1. Similarly to 
the set first of strains analysed, results from the typing analysis of these 
meningococcal strains isolated from a wider geographical area indicate limited 






Figure 2.2. Typing analysis of the second set of serogroup A, W and X strains isolated from 12 
countries of the sub-Saharan Africa between 2001-2011.  
The fHbp variant group is according to classification proposed by Masignani et al. (2003) (26). Each 
isolate was typed by PCR amplification of each respective gene, sequencing and analysis using 
bioinformatics software Simmonics, Mega 4 and Chromas.  
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Figure 2.3. NadA protein expression in the African serogroup W isolates measured by Western 
blotting.  
Panel A: NadA protein expression in the first set of serogroup W isolates with full-length NadA and 
NadA with insertion sequence IS1301. Isolates were obtained from Gerd Pluschke at STPHI. Panel B: 
NadA protein expression in the second set of serogroup W isolates with full-length NadA and NadA 
with insertion sequence IS1301. Isolates were obtained from Dominique Caugant at NIPH. The strains 
with the mobile genetic element had the transposon inserted at nt 470-474. Cells were grown to same 
optical density and whole cell extracts were prepared as described in Materials and Methods. Presence 
of NadA expression was detected with a polyclonal antiserum raised in mice against recombinant 
NadA allele 3. Positive controls were recombinant NadA-3 expressed and purified as Hexa-Histidine 







2.4.4 Majority of the African isolates studied have intermediate or 
high fHbp expression. 
The level of fHbp expression has been shown to be a factor that can affect 
susceptibility of meningococci to anti-fHbp antibodies. High expressers of fHbp are 
generally more susceptible to killing than low expressers (5). We measured fHbp 
expression in whole cell extracts from 30 isolates by Western blot using monoclonal 
antibodies JAR5 and JAR31 against fHbp v.1 and v.2/3 respectively. Of the serogroup 
A isolates, we selected all strains from Burkina Faso (n=2, 35%) and 11 of 17 strains 
from Ghana (50%) for the fHbp expression analysis. Of the W isolates, we selected 6 
of 17 strains from Burkina Faso (50%) and all strains from Ghana (65%). All 
serogroup X strains isolated from various countries of the meningitis belt were 
selected. The strains were chosen to cover isolates from different years including 
oldest and newest strains. Within the group of strains selected 72% (n=21) were case 
isolates and 28% (n=8) were carrier isolates.  
 
We prepared whole cell extracts of all test strains and the serogroup B reference 
strains and compared fHbp levels with defined amounts of a fHbp v.1 and v.2 protein 
standard by Western blot and densitometry measurement. Expression level of the 
reference serogroup B strain H44/76 and 8047 were set to 100% and levels of 
expression of the test strains were compared with the reference strain. All serogroup 
A isolates (Figure 2.4, Panel A) have intermediate expression of fHbp. Majority of 
the serogroup X isolates (Panel C, n=5, 55%) expressed high amounts of fHbp 
compared with reference strain H44/76. The expression levels among the W isolates 
were variable, ranging from 50-152%, with 41% of the isolates expressing >100% of 
fHbp compared to the reference strain 8047 (Panel B). There was no significant 
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difference in fHbp expression between case and carrier W isolates studied (P=0.74; 















Figure 2.4. Expression of fHbp in the first set of meningococcal serogroup A, W and X isolates 
assessed by Western blot.  
Panel A: serogroup A isolates with fHbp ID 5; Panel B: W isolates with fHbp ID 22 (isolates 2039, 
2252, 2719 and 2959) or 23 (13 isolates); Panel C: serogroup X isolates with fHbp v.1 ID 12 (4869), 73 
(BF12/03, BF02/97) and 74 (6 isolates). Bars represent the mean percentage from 3 biological 
replicates compared with the expression of fHbp of the reference serogroup B strains H44/76 and 8047, 
both high expressers of fHbp variant 1 ID1 and variant 2 ID 77, respectively. Isolates with means 
below 33% were classified as low expressers while isolates with expression above 100% were 
categorized as high expressers. Values between 33-100% were considered as intermediate expression 




For the second set of meningococcal serogroup A, W and X isolates, fHbp expression 
levels in whole cell extracts was measured for 42 isolates by Western blot using 
polyclonal antibody against rHis-fHbp v.1 and v.2/3 respectively (Figure 2.5). Most 
serogroup A and X isolates (Panel A and C respectively) have intermediate 
expression of fHbp. About half of the serogroup X isolates expressed amounts of 
fHbp lower than 50% compared to H44/76 high expresser of v.1 ID1, and two of 
those expressed very low levels of fHbp at around 4%. Two-thirds of the W isolates 
with a fHbp of v.1 expressed low amounts of fHbp (Panel B). On the contrary, 
majority of the W isolates with a fHbp of v.2 or v.3 were found to express 
intermediate levels of fHbp compared to reference strain 8047 (Panel D). The results 
suggest that fHbp protein expression on the bacterial surface is variable among 
strains, serogroup and fHbp variant. Representative blot of fHbp expression analysis 






Figure 2.5. FHbp protein expression in the second set of African serogroup A, W and X isolates 
measured by Western blot.  
Panel A: serogroup A isolates with fHbp v.1 ID 5; Panel B: serogroup W isolates with fHbp v.1 ID 9; 
Panel C: serogroup X isolates with fHbp v.1 ID 74; Panel D: serogroup W isolates with fHbp v.2 ID 22 
or 23, and fHbp v.3 ID 349. Serogroup X Uganda14/06 and serogroup W Uganda11/06 were not 
included in the analysis since the isolates failed to grow. Bars in panel A-C represent mean percentages 
of a set of 2 independent experiments compared with expression of fHbp by the reference group B 
strain H44/76, which is naturally high expresser of fHbp ID 1 v.1. Bars in panel D represent mean 
percentages of a set of 2 independent experiments compared with expression of fHbp by the reference 
group B strain 8047, which is naturally high expressers of fHbp ID 77 of v.2. Bottom dotted line 
represents the low expresser classification threshold. Top dotted line represents the level of fHbp 





Figure 2.6. Representative analysis of fHbp expression in whole cell extracts of serogroup W 
isolates from the first and second set of African meningococcal isolates.  
Panel A: representative fHbp expression data for four serogroup W isolates (1485, 1625, 1629 and 
1630) from the first set of strains; Panel B: fHbp expression data for four serogroup W isolates 
(BF6/06, BF10/02, Nigeria1/03 and MRS2004034) in duplicate from the second set of strains. 
Serogroup B 8047 is the reference strain. rHis-fHbp v.2 were loaded as standard. Whole cell extracts 
were prepared as described in Materials and Methods. fHbp was detected using a monoclonal antibody 
raised against rHis-fHbp v.3 that shows cross-reactivity with fHbp v.2. Positive controls were 












2.4.5 Serum bactericidal responses of antibodies elicited by a 
recombinant serogroup W GMMA vaccine over-expressing fHbp v.1 
The SBA responses of the antiserum of mice immunised with the recombinant 
serogroup W GMMA vaccine over-expressing fHbp v.1 ID1 was assessed against two 
serogroup A isolates and 3 X isolates expressing heterologous PorA and varying 
levels of fHbp v.1 (Table 2.8). We focussed on A and X strain with heterologous 
PorA to asses potential cross-protection because strains with homologous PorA are 
highly susceptible to bactericidal activity of anti-PorA antibodies (5,42).  
 
Table 2.8. Panel of isolates selected for serum bactericidal activity analysis. 
Selection included case isolates with variation in fHbp expression level, different sequence types and 
year of isolation.  















2007 case 1 5 2859 78 
X BF 2/97 
Burkina 
Faso 1997 case 1 73 751 52 
X BF 12/03 
Burkina 
Faso 2003 case 1 73 751 58 
X BF 07/07 
Burkina 
Faso 2007 case 1 74 181 131 
ND= not defined. 
aAverage level of fHbp expression in percentage compared with expression by reference serogroup B 
H44/76.  
 
GMMA from the Triple KO, OE fHbp strain induced antibodies that killed only the 
serogroup A isolate N2602 (geometric mean titre [GMT]=3033), (Figure 2.7, Panel 
A and B). The serogroup A strain N2008 isolated from Ghana resistant to killing 
expressed similar amounts of fHbp (75%) as N2602, which was sensitive to the 
antiserum. Both strains were readily killed by an anti-A capsular monoclonal 
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antibody. The Triple KO, OE fHbp GMMA vaccine was also able to kill all serogroup 
X isolates tested (GMT=11 to 4413) (Figure 2.7, Panel C-E). GMMA produced from 
the W strain that lacked fHbp v.1 over-expression (Triple KO) induced antibodies that 
were only able to kill the A strain N2602 and X isolate BF7/07 (GMT=135 and 14 
respectively), suggesting that majority of the bactericidal antibodies produced are 
directed against fHbp when measured against strains with a heterologous PorA 
compared to that included in the vaccine. Antibodies induced by rHis-fHbp ID1 did 
not elicit a measurable bactericidal antibody responses against the strain tested (Titre 
<10).   
 
The GMMA vaccines were prepared from a mutant with deleted capsule in order to 
attenuate virulence. A second motive of this was to reduce the potential generation of 
serogroup specific anti-capsular antibodies. The effect of the bactericidal antibody 
responses when maintaining the capsule on the GMMA was tested by immunising 
mice with GMMA vaccine prepared from isogenic mutants expressing the capsule 
(Double KO, OE fHbp). The bactericidal activity observed for the Double KO, OE 
fHbp was lower compared to the Triple KO, OE fHbp vaccine against three of the 
five strains tested (N2602, BF12/03, BF07/07 [P=0.0119]; GMT 386, 57 and 481 
respectively). The results suggest that in accordance with our hypothesis deletion of 






















Figure 2.7. Complement-mediated bactericidal activity responses of mice immunised with 
prototype GMMA vaccine Triple KO OE fHbp against African serogroup A and X 
meningococcal strains.  
Panel A: strain N2602 serogroup A isolated from Burkina Faso; Panel B: strain N2008 isolated from 
Ghana; Panel C: serogroup X isolate BF07/07; Panel D: serogroup X isolate BF12/03 isolated from 
Burkina Faso; Panel E: serogroup X isolate BF02/97 isolated from Burkina Faso. Each symbol 
represents reciprocal serum titre of pooled sera from two mice (except alum where four mice were 
pooled to one group) using human complement. The horisontal line represents the geometric mean titre 
(GMT). Error bars indicate the standard error of the mean. GMMA vaccines: Triple KO, OE fHbp: 
capsule, lpxL1 and gna33 KO with over-expressed fHbp ID1, red dots. Double KO, OE fHbp: lpxL1 
and gna33 KO with over-expressed fHbp ID1, blue dots. Triple KO: capsule, lpxL1 and gna33 KO 
without over-expressed fHbp, green dots. rHis-fHbp: recombinant hexa-Histidine tagged fHbp ID1, 















In the meningitis belt of sub-Saharan Africa, epidemic meningitis caused by N. 
meningitidis is a severe public health problem. The stepwise introduction of 
immunisation campaigns with the conjugate polysaccharide vaccine MenAfriVac™ 
against serogroup A is currently used to control the disease caused by this serogroup 
(43). Conjugate vaccines do not only protect against disease but also block 
transmission of carriage strains expressing the same vaccine serogroup. However, 
meningitis caused by non-serogroup A meningococci, particularly W but also X, are 
an ongoing problem. There is also a concern regarding the effect of the lack of a 
stable nasopharyngeal population of apathogenic meningococci due to the neutralising 
immunity conferred by the conjugate vaccines (43). This could render the population 
vulnerable to epidemics caused by other serogroups than just W and X. Moreover, the 
risk of vaccine induced capsule switching to evade killing has been a long standing 
concern. Evidence of capsule switching between serogroups with a 
polysialyltransferase gene (synD) such as W and C have been reported (44,45). The 
emergence of the epidemic serogroup W ST-11 strain from Haji in 2000 originated 
from a serogroup C ST-11 (6). Therefore, an affordable comprehensive vaccine based 
on OMPs that can provide broad protection against all meningococcal serogroups can 
be a potential solution to control disease caused by all serogroups in the meningitis 
belt (46,47). Molecular typing approaches based on DNA sequencing allow the 
dynamics of the variation and diversification of surface-exposed antigens of 
meningococci to be monitored over time. Such approaches are also useful to 
determine whether escape from immune detection by variation of OMPs has occurred. 
Here, we investigated the putative impact and suitability of the OMPs NadA, fHbp, 
NHBA and PorA to be used in a GMMA-based vaccine platform for Africa.  
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We examined the genetic diversity of two sets of 94 meningococcal carriage and 
disease serogroup A, W and X strains. Both sets of strains studied were isolated from 
various countries in the meningitis belt between 1995-2011, and contain conserved 
fHbp, porA and nadA genes, suggesting little antigenic diversification over time. 
Previously, Pajon et al. (2011) performed a molecular characterization of 106 
invasive meningococcal A, W and X isolates from 13 African countries (5). The study 
showed that 100% of the serogroup A isolates isolated in Burkina Faso and Ghana 
express fHbp ID 5 and PorA subtype P1.20,9. Most of the serogroup X isolates was 
shown to have an fHbp of ID 73 or 74. In contrast to our findings 58% of the 
serogroup W were fHbp v.2, while 34% were v.1 and 8% v.3. The isolates from 
Burkina Faso and Ghana expressed fHbp v.1 ID9 or v.2 ID23. Concordant with our 
findings, 98% of W expressed PorA subtype P1.5,2 or a related subtype indicating a 
marked homogeneity of PorA type among African serogroup W isolates. A more 
recent longitudinal study found that a hypervirulent ST-11 serogroup W clone was 
responsible for most meningococcal disease in 2011 and 2012 (48). All the isolates 
had PorA P1.5,2. In accordance with our study, these two previous studies emphasise 
the limited diversification of major OMPs in the meningococcal population in Africa.  
 
NadA has emerged as an important protein for adhesion and invasion, and has been 
shown to elicit bactericidal antibodies (49). Previous studies have shown that nadA is 
present in 50% of non-African clinical isolates and were highly diversified (32,40). 
Wang et al. (2011) detected nadA-1 and 2 in serogroup B isolates from U.S., allele 
2>1>3 in serogroup C and alleles 3>2 in serogroup Y (40). Commanducci et al. 
(2004) showed that European serogroup B isolates tested harboured 1>2>3, serogroup 
C allele 2>3 and serogroup A allele 3 (50). Serogroup A isolates from China were 
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mainly of allele 3 and 4 (51). To summarise, our results with African strains suggest 
firstly that there is little variability of nadA over time and geographic origin (5,43,52). 
Secondly, the remarkable antigenic stability also indicates that natural immunity to 
these OMPs is not a strong driving force for antigenic diversification, making them 
suitable for use as vaccine candidate antigens for use against African strains. Further 
analysis of nadA sequences showed that 10 (11%) serogroup W isolates had the nadA 
gene disrupter by IS1301. Eight of these had the mobile genetic element inserted 
between nt 470-474 and with a stop codon at nt 166. The others had IS1301 inserted 
in nt 400-469 (Δ69nt; Nigeria1/03) and at nt 472-496 (MRS2008218). Previously 
Comanducci et al. (2004) reported such occurrence of interuption of the open reading 
frame (ORF) by the genetic element at the recognition sequence 5’-ACTAG-3’ in 
position 474 and 583 of nadA-3 coordinates (50). Compared to our study, it has been 
described that approximately 30% of meningococcal serogroup B, C and W strains 
carry the IS, and even higher prevalence was found in Y isolates (86.7%) (54,55). 
Nevertheless, Western blotting of the first set of isolates generated no bands while for 
the second set of isolates revealed a single band between 49-62kDa. As these proteins 
lack most of the C-terminal coiled-coil region and anchor we predict that there is 
some transcript produced, which could account for the band visualised, but not 
inserted into the membrane because the protein is devoid of the predicted anchor 
domain (39,56,57). One way to test this could be by flow cytometry staining of live 
cells using a anti-NadA mAb. However, the benefit of IS1301 insertion into nadA is a 
conondrum. The 842-bp mobile genetic element can cause various effects upon 
insertion such as deletions, knockout of gene expression and regulation of 
downstream located genes (55). For example, previous studies have shown that 
insertion of IS1301 into the siaA gene of the capsule biosynthesis locus is associated 
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with phase variation of capsule expression, therefore conferring fitness to the 
meningococci. The exact excision of the transposon allows for reversible on/off 
capsule synthesis, where expression is on during transmission and switched back to 
off during colonisation (58). Possibly antibodies elicited against NadA protein in the 
host population may give selective advantage to strains with no or decreased 
expression levels establishing immune escape variants. Moreover, such insertion is 
reversible upon precise excision and may predispose a strain to transmission or 
colonisation (54,55,59). Since NadA is involved in colonisation/adhesion and 
invasion, the transposon might render these states interchangable creating diversity in 
a bacterial population pre-adapted to environmental changes by providing another 
mechanism of nadA phase variation.  
 
The GMMA approach is based on OMVs that have already been licensed for use in 
humans. However, the GMMA vesicles are not extracted using detergent rather 
produced from recombinant meningococcal strains that are engineered with a deleted 
gna33 gene, which up-regulates vesicle release and retains hydrophobic OMPs like 
fHbp (1,2,60). Studies with isogenic mutants with different expression levels of fHbp 
suggested that low fHbp expression contributes to resistance to anti-fHbp bactericidal 
activity (5). High expressers of fHbp are generally more susceptible to killing by anti-
fHbp antibodies than low expressers. It has been suggested that sparse distribution of 
antigens on the bacterial surface impedes cross-linking of two IgG anti-fHbp 
antibodies to correctly spaced epitopes (61). Consequently, the antibodies cannot 
engage the complement protein C1q by adjacent Fc domains, preventing subsequent 
C4 activation and C4b deposition of the classical complement pathway (27). It has 
been shown that mAbs that bind abundant antigens such as PorA, which is a trimer, 
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are more effective at engaging C1q (62). In the present study, for the first set of 
isolates tested, the serogroup A strains were found to express medium levels of fHbp 
and the W isolates expressed medium to high levels. There was no difference in 
expression between case and carrier isolates indicating that both could be targets of 
vaccine-induced anti-fHbp antibodies. For the second set of isolates we found that 
serogroup A and X isolates varied in fHbp expression with most isolates expressing 
intermediate levels of fHbp. Two-thirds of the W isolates with an fHbp of v.1 
expressed low levels of fHbp. While majority of the W isolates with fHbp v. 2 or 3 
expressed intermediate levels of fHbp. There is a chance that developing a vaccine 
based on one antigen were the level expression of the protein on the surface of 
bacteria is important could select for escape mutants. Consequently, developing a 
vaccine with additional antigens could possibly prevent this.   
 
For the second objective of the study, we tested the bactericidal activity of sera from 
mice immunised with GMMA OE fHbp v.1 against five serogroup A and X isolates 
with varying expression levels of fHbp and with a heterologous PorA compared to the 
vaccine W strain. We generated the main vaccine GMMA from a recombinant 
serogroup W strain engineered with deleted capsular biosynthesis genes, lpxL1 and 
gna33 genes and up-regulation of fHbp v.1 ID1 (Triple KO, OE fHbp). The Triple 
KO OE fHbp vaccine induced bactericidal antibodies in four serogroup A and X 
isolates tested (80%) compared to none for the rHis-fHbp vaccine. This suggests that 
anti-fHbp antibodies induced by GMMA are of greater functional activity than those 
induced by rHis-fHbp. In the case of serogroup X isolates BF02/97 and BF12/03, 
which have similar levels of fHbp expression, higher titre was obtained for BF12/03 
suggesting that fHbp expression level do not always account for resistance/sensitivity 
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to bactericidal activity. BF12/03 could potentially bind fH more strongly than 
BF02/97. Stability of fH-fHbp binding to the meningococcal surface has been shown 
to be a crucial factor for evading complement killing (63). Moreover, other proteins 
such as antigen NspA (Neisserial surface protein A) and PorB2 could also bind fH. 
PorB2 and NspA are another ligands for fH, and could be responsible for enhancing 
meningococcal resistance to complement (13,62).  
 
An additional meningococcal factor important for evasion of complement-mediated 
killing is the capsule. In this study the serogroup A isolate N2008 was resistant to 
killing by the Triple KO, OE fHbp. However, both N2008 and N2602 were sensitive 
to anti-capsular A mAb. One possible reason for this observation could be that N2008 
produces higher amounts of capsule than N2602 of polysaccharide length or of 
different chemistry. Future experiments that could investigate this could involve 
analysis of the amount of capsule expression by flow cytometry, and more in-depth 
analysis of the polysaccharide length and chemistry by Dionex, HPLC-SEC, NMR 
(currently in progress). Moreover, the capsule could act as an antigenic competitor 
interfering and decreasing the immune response to common protein antigens. This is 
also supported by the lower GMT observed for the Double KO, OE fHbp vaccine 
generated from a recombinant strain expressing the capsule against all strains tested 
compared to the Triple KO, OE fHbp without a capsule. The higher amount of 
capsule could also prevent accessibility of the fHbp antigen on the meningococcal 








This study of meningococcal serogroup A, W and X isolates from several African 
countries, together with the findings of other studies, suggests that there is limited 
antigenic variation of meningococcal OMPs that induce bactericidal antibodies. 
Moreover, the presence of the nadA gene in most case and carrier strains isolated 
from African countries suggests that NadA could be a potentially important vaccine 
antigen to be included in a GMMA vaccine for Africa. The GMMA vaccine with 
over-expressed fHbp v.1 generated here provides a proof-of-concept in mice that it 
can elicit antibodies that are bactericidal against majority of the serogroup A and X 
isolates testes with heterologous PorA and homologous fHbp. These findings support 
a strategy of using protein-based vaccines, such as GMMA, to prevent meningococcal 
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2.8 Appendix 1 
 
Example DNA sequences: 
 
fHbp 






























































































































































Bold base pairs and highlighted in grey: PorA variable region (VR) 1 corresponding 
to allele 5. 
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Vaccines against meningococcal serogroup B disease have proven difficult to produce 
because the capsular polysaccharide is similar to human neural antigens. With the 
quest of developing a broadly protective vaccine against serogroup B through the 
identification of OMP using reverse vaccinology, Neisserial Adhesin A (NadA) was 
discovered (NMB1994) (1). Significantly, Wang et al. (2011) showed that in U.S 
serogroup B, C and W strains this antigen is not specific for serogroup B (2,3). 
Results from Chapter 2 indicated that good immunogenicity and cross-protection of 
fHbp in GMMA. The nadA gene was also detected in 89% (84/94) of the African 
meningococcal strains characterised. NadA is able to elicit bactericidal antibodies in 
mice and humans and is included as recombinant protein in a vaccine licensed for use 
in humans (3–5). Therefore, we set out to investigate the immunogenicity induced by 
NadA in GMMA.  
 
 
3.1.1 Overview of NadA 
Neisseria meningitidis colonises the nasopharynx of 10-35% of healthy individuals. 
The first step of the bacterium to cause invasive disease is to colonise the epithelium 
through multistage adhesion cascades followed by invasion of the cell, intracellular 
persistence and transcytosis (6,7). These events are modulated by the interaction of 
virulence factors with host cell receptors. A new type of antigen described as NadA 
has emerged as an important protein involved in epithelial cell adhesion and invasion 
(8). NadA KO mutants of N. meningitidis show a significantly reduced cell adhesion 
and invasion compared to wild-type strains (9). NadA protein has also been shown to 
stimulate monocytes, macrophages and monocyte-derived dendritic cells during 
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infection (10,11). Previous typing studies have shown that approximately 50% of 
clinical isolates and about 5% of carrier strains from healthy individuals harbour the 
gene; however, it is absent in commensal Neisseria species (7,8).  
 
 
3.1.2 Structure and nomenclature 
 
On the basis of structure prediction and analysis of sequence homology, NadA protein 
presents a tripartite structural organisation. The peptide has a N-terminal globular 
domain with a possible leader peptide of 23 amino acids (aa; head domain), an 
intermediate α-helix region that forms coiled-coil structures (coiled-coil stalk) and a 
conserved C-terminal membrane anchor domain (Figure 3.1) (1,11–13). The anchor 
domain has a conserved COOH-terminal membrane anchor, which with its 
amphipatic β-barrel structure and a terminal aromatic aa allows for autotransport of 
the remaining part of the adhesin, insertion into the outer membrane (OM) and 
oligomerisation of the monomer (9). The aa 88-150 of the stalk domain is important 
for adhesion, and aa 90-146 and 183-288 have a propensity to form coiled coils. 
Residues 122-143 contain four leucine residues in the heptad form that forms a 
leucine zipper domain (L-x[6]-L-x[6]-L-x[6]-L) (13). Together with the coiled-coils, 
they are able to mediate oligomerisation of monomers through the association of two 
or more α-helices (1). The 45kDa NadA protein mostly exist in the membrane as a 
trimer (~170kDa), which is stable in SDS-PAGE and following treatment with β-
mercaptoethanol (5,10). The NH2-terminal region has a globular structure that is 
essential for binding to host cell receptor. The aa 24-88 have been shown to be part of 
the region responsible for interaction with the host receptor (9). Due to the structure 
and ability to form oligomers, NadA has been classified as a non-fimbrial adhesin 
related to other adhesin-invasin pathogenicity factors such as UspA2 of Moraxella 
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catarrhalis and YadA of Yersinia, which are part of the family oligomeric coiled-coil 
adhesin (OCA) (8). The 1086-1215bp ORF of nadA shares approximately 32-34% 
identity to yadA and uspA2.  
 
The nadA gene is conserved in N. meningitidis (89.2%), and the independent genetic 
unit consist of a promoter region, coding sequence and a terminator region (13). 
Analysis of the G+C content of the ORF and its upstream region showed that it is 
lower than average (45% against 51.5% of the genome), suggesting acquisition of the 
gene by horizontal gene transfer. The exact origin has not been established, but 
homologous artefacts of the gene has been found in N. cinerea (13). nadA has been 
divided into five defined alleles 1-5 based on the different PCR sizes obtained with 
primers binding externally to the gene (3). Currently, there are 98 distinct gene 
sequences classified into these alleles based on sequence similarity, which then code 
for 43 distinct aa sequences differing in length mostly between and slight variations 
within an allele (http://pubmlst.org/ neisseria/). The aa sequences are then grouped 
into peptide 1-5 subvariants. The nomenclature scheme is as follows: e.g. NadA-1.3, 
which refers to allele 1 and peptide subvariant 3. The three alleles 1-3 share 84-99% 
homology and induce antibodies with cross-bactericidal activity. They are also 
present in most clinical isolates and hyperinvasive isolates belonging to cc ST-8, 11, 
32 and 213 (1,8). In particular, nadA-2 and nadA-3 are very similar with ≥97% shared 
identity, and are associated with ST-8 and ST-11 while nadA-1 is connected with ST-
32. Although, these alleles differ in length, deletions and substitutions in the gene do 
not affect the overall structure of the protein rather the number of turns of the α-helix 
in the stalk domain (15). Allele 1 codes for a protein of 362aa, allele 2 398aa and 
allele 3 405aa. The nadA-4 gene was first described in carriage isolates. The protein is 
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shorter than NadA-1-3 (323aa), but has the same secondary structure and domain 
organisation. nadA-5 was identified through analysis of isolates belonging to the ST-
213 cc associated with serogroup B. The gene is usually switched off due to an 
internal poly(C) tract unique to this variant, however, “on” variants of this gene have 
been found. Antibodies against NadA-4 and NadA-5 peptides show limited cross-
reactivity against each other and to the alleles 1-3 (16). Nevertheless, the recent study 
by Bambini et al. (2014) revised the nomenclature of NadA by taking into account the 
dataset found in http://pubmlst.org/ neisseria/. The phylogenetic analysis grouped 
nucleotide sequences into two clusters (I, II) and 6 NadA variants: group I consist of 
nadA-1-3 and group II of nadA-4-6. The variants of group II were found to share 75-
99% homology, but only 46-50% with group I. The new variant 6 belonged to ST-11 
cc of isolates from Spain; however, the gene was inactivated by frame shift mutations. 
The authors proposed a new nomenclature, and the protein variants are: NadA-1, 
NadA-2/3, NadA-4/5 and NadA-6 grouped into two groups. The high level 
homologous variants were grouped together. A subvariant is followed by a dot e.g. 
NadA-3.2. However, for simplicity the original classification system of NadA 






Figure 3.1. Structure and domain organisation of Nesserial adhesin A (NadA). 
Panel A: Schematic diagram of NadA protein topology. Panel B: nadA domain structure. The N and C 
represent the N- and COOH-termini of the protein. The leucine zipper is indicated by a black box. The 
numbers represent the amino acid number in the peptide sequence. Adapted and modified from 
Comanducci et al. (2002) (1).  
 
3.1.3 Regulation of NadA expression 
To facilitate adaptation of bacterial population in different microenvironments and 
ensure effective colonisation and at the same time avoid the host immune system, the 
meningococcus must undergo frequent and reversible phenotypic changes resulting 
from regulated and stochastic expression of virulence genes. NadA expression is 
phase variable, which means that expression is mediated by high frequency of 
reversible changes (12). Frequency is estimated to be 4.4x10-4 with promoters of low, 
medium and high activity.  
 
The main regulator of NadA expression is Neisserial adhesin regulator (NadR, 
NMB1843), a member of the MarR family of regulators, which in prokaryotes is 
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critical for control of virulence factor production, response to antibiotics and 
catabolism of environmental aromatic compounds (16). It has been shown through 
microarray analysis that NadR is able to co-regulate over 30 genes, however, nadA 
being the strongest repressed (16). NadR binds to the nadA promoter, and other gene 
promoters, and strongly represses the transcription through a looping mechanism that 
sterically hinders RNA polymerase (RNAP) access to the promoter (13,14). More 
specifically, NadR binds the Growth Phase Regulatory region (GPR), which is a distal 
cis-acting region upstream of the promoter region of about -170- -112 nucleotides 
(nt), also called operator I (OpI). Adjacent to the GPR is the low NadR binding 
affinity OpIII spanning the TAAA repeat tract (-85--50) and the high affinity OpII 
overlapping -10 region of the promoter. NadR normally binds OpII site, obstructing 
access of RNAP to the promoter. The transcriptional regulator IHF (integration host 
factor) binds OpIII looping of the DNA allowing NadR to interact with the other 
operators resulting in more efficient repression of nadA promoter. Moreover, the 
aromatic metabolite 4-hydroxyphenylacetic acid (4HPA) of aa tyrosine and 
phenylalanine, present in saliva, has been shown to relieve DNA binding activity of 
NadR increasing NadA expression (18). It does so by stabilising NadR in a 
conformational state preventing effective binding to the nadA operators, thus inducing 
NadA protein expression (16). Fagnocchi et al. (2011) proposed that this metabolite 
can act as a relevant niche signal for meningococci present in the nasopharynx for the 
induction of NadA expression and other co-regulated genes under NadR control 
during exponential growth phase (16,19). Moreover, the authors observed that 4HPA 
added in the growth medium increased the expression of NadA, but not all isolates 
responded in a similar fashion with partial or full NadR de-repression. 4HPA is an 
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inducer or co-repressor while NadR represses all genes in its regulon, and deletion of 
nadR results in a 60-fold transcriptional increase of NadA expression (19).  
 
Moreover, expression is also controlled by variation of the TAAA tetranucleotide 
repeats 130 nt upstream of the core promoter preceded with a second promoter with -
10 and -35 regions, which suggests that nadA is phase variable (1). 4, 9 and 12 repeats 
result in low transcript level and 7, 8 and 10 repeats result in high transcript level. 5, 
6, 11 and 13 repeats and a promoter mutant lacking TAAA give varying intermediate 
levels. The number of repeats is modified during replication through slipped strand 
misspairing. Loss or gain of TAAA repeats affects the differential spacing between 
the Ops, thus the suboptimal or optimal configuration of protein complexes that affect 
the efficiency of NadR repression (12).  
 
Expression of NadA has been shown to exhibit growth-phase dependent behaviour 
with levels maximal in the stationary growth phase of strains tested to date (12). 
Metruccio et al. (2009) deleted the GPR region between -170 and -108, which 
resulted in increased expression during log phase of growth. The authors suggested 
that this region is responsible for repression of expression of nadA promoter in log 
phase probably due to binding of NadR protein.  
!
 
3.1.4 NadA as vaccine antigen 
 
A large part of the serum antibodies in normal individuals with bactericidal activities 
against N. meningitidis is directed against non-capsular antigens (20). In particular, 
children recovering from invasive disease produce specific antibody responses against 
NadA (3,21). Tavano et al. (2009) investigated the activity of NadA expressed in an 
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OMV compared to rNadAΔ351-405 missing the OM anchor sequence (22). On the 
surface of monocytes, rNadAΔ351-405 binds heat-shock protein 90 (hsp90) that recruits 
hsp70 and TLR-4 into a transducing signal complex, which stimulates the production 
of heat shock related cytokines such as IL-1, TNF-α (14). Compared to the 
recombinant protein, NadA presented in a serogroup B OMV had an increased ability 
to present the antigen to macrophages without the induction of shock-related 
cytokines by monocytes (14).  This pro-immune action of wild-type NadA argues for 
the use of NadA in an OMV platform as a vaccine candidate.  
 
Studies have looked into the bactericidal responses elicited by OMV vaccines over-
expressing NadA. Norheim et al. (2012) tested a conventional bivalent MenA and 
MenW OMV vaccine extracted by detergent, which express NadA-3, fHbp v.1 ID5, 
PorA P1.20,9  and NadA-3, fHbp v.2 ID23, P1.5,2, respectively, against strains from 
Burkina Faso and Ethiopia (20). Zollinger et al. (2010), Pinto et al. (2011) and Moran 
et al. (2012) investigated immunogenicity of a trivalent MenB vaccine over-
expressing fHbp v.1,/2, NadA-3 and three PorA variants against serogroup A, B, C, 
Y, W and X strains from Africa, Cuba, Norway and Germany (5,21,23). The vaccine 
groups, which were used to immunise mice and rabbits, induced broadly cross-
reactive bactericidal antibodies against homologous and heterologous strains. 
Antibodies to LOS, PorA and NadA were responsible for most of the bactericidal 
activity seen. The results of these studies highlight the suitability of using an OMV 
approach for expanding vaccine protection. Given that the set of strains in this study 
showed antigenic stability, the usage of specific OMPs as vaccine candidate antigens 




3.2 Project objectives 
There are several attributes to NadA being a good vaccine candidate. Firstly, it is an 
outer membrane antigen and a virulence factor. Secondly, it is present in most 
hypervirulent lineages. Thirdly, alleles 1-3 found in clinical isolates elicit cross-
protective bactericidal antibodies and when presented in OMVs, it has a pro-immune 
action (1). However, the potential of NadA to control outbreaks of disease has not 
been evaluated for African strains.  
 
GMMAs include the gna33 deletion, which offers an alternative way of vesicle 
production, protein expression and presentation compared to the vaccine strategies 
employed by previous studies. The recombinant strains from which GMMA are 
produced can be engineered to include additional mutations to over-express candidate 
vaccine antigens of choice. To attempt to over-express NadA in our GMMA vaccines, 
we aimed to knock-out its regulator nadR instead of growing the recombinant strains 
for GMMA production in medium supplemented with the inducer 4HPA. This is 
because deletion of NadR has been shown to increase NadA transcription by 60-fold, 
while 4HPA differentially induces NadA expression in meningococcal isolates.  
 
For this project, we aimed to characterise the breadth of immune responses elicited by 
a prototype serogroup A and W GMMA vaccine expressing NadA-3 against 
genetically diverse African N. meningitidis serogroup A, W and X isolates from a 
wide geographical range. The strains were characterised based on their NadA 
expression level. These data could then aid selection of a panel of isolates for the 




In short the aims are: 
 
1. Characterisation of African meningococcal serogroup A, W and X isolates.  
a. Analysis of NadA expression level during growth with and without the 
presence of 4HPA in order to investigate the level of increase that 
4HPA could provide in an “in vivo” condition. 
b. Selection of a representative strain panels including serogroup A, W 
and X isolates suitable to investigate bactericidal activity induced by 
the prototype GMMA vaccines. 
 
2. Characterisation of antibody responses elicited by GMMA with deleted NadR. 
a. Evaluate IgG antibody responses against NadA by ELISA.  
b. Evaluation of serum bactericidal activity of sera made against GMMA 
with deleted nadR against a subset of genetically diverse serogroup A, 
















3.3 Materials and Methods 
 
3.3.1 Neisseria meningitidis isolates 
In this study, the second set of clinical N. meningitidis case isolates (A=13, W=20, 
X=11) received from Dominique Caugant at NIPH were used in subsequent analyses 
(Chapter 2, Table 2.3). All isolates were analysed for their NadA expression level by 
Western blot and comparing the levels to known amounts of recombinant Hexa-
Histidine tagged NadA allele 3 (rHis-NadA-3; produced in this study). In proceeding 
experiments for testing the antisera raised against GMMA expressing NadA-3 made 
from a mutant serogroup A and W strain, sets of meningococcal isolates were selected 
based on genetic diversity and different levels of NadA-3 expression.  
 
3.3.2 Western blot analysis of NadA protein amount  
A subset of 37 isolates were analysed for their NadA expression level during growth 
with and without the addition of 4HPA compared to known amounts of rHis-NadA-3 
produced in this study. Five serogroup W isolates that had IS1301 in the nadA gene 
were not included in the analysis. Preparation of the samples without 4HPA was 
performed as described in Chapter 2 section 2.3.4 on page 62. For the preparation of 
cultures grown in the presence of 4HPA, a loop-full of single N. meningitidis colonies 
from overnight GC plate cultures were resuspended in 7ml MH broth at an OD600 of 
0.12-0.16 and grown until mid-log phase (OD600 = 0.6), harvested, and resuspended in 
7ml MH broth + 5mM 4HPA (Invitrogen). The cultures were then incubated for 1 
hour with agitation at 37°C and 5% CO2, harvested and resuspended in 200µl 1xPBS 
and heat inactivated at 56°C for 1 hour. Preparation of Western blot membranes was 
performed as previously described in Chapter 2. 0.0156, 0.031, 0.063, 0.125µg/ml of 
!
117!
rHis-NadA-3 was used as standards for estimating NadA protein amounts expressed 
by all isolates. Positive control used was serogroup A strain N2602 expressing NadA-
3. NadA proteins were detected with a polyclonal serum against Hexa-Histidine 
tagged NadA allele 3 (rHis-NadA-3; NV&D). The serum was diluted 1:5000 in 
1xPBS + 1% milk and incubated for 2 hours at room temperature. After washing the 
membrane four times 10 minutes each with 1xPBS+0.1% Tween20 (Sigma-Aldrich), 
membranes were incubated with secondary antibody horseradish peroxidase-labeled 
goat anti-mouse immunoglobulin G λ1 chain (Southern Biotech, Birmingham, 
Alabama, U.S.A) for 1 hour at a dilution of 1:20000 in 1xPBS+0.1% Tween20. After 
another four washes, membranes were developed using SuperSignal® WestPico 
Chemiluminescent Substrate (Thermofisher Scientific) according to manufacturers’ 
instructions, and developed using Amersham Hyperfilm™ ECL (GE Healthcare). The 
amount of NadA expressed by each isolate compared to the standard rHis-NadA-3 
was determined by ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2012). NadA 
expression by the test isolates was reported as percentages of the amount of NadA 
expressed by bacterial cells compared to the corresponding reference strain N2602 
expressing high amounts of NadA-3. NadA expression of N2602 was considered to be 
100%.  
 
3.3.3 Cloning, expression and purification of recombinant NadA-3 
The nadA sequence (aa 24-350) of allele 3 was amplified by PCR from chromosomal 
DNA of serogroup A strain N2602 (Chapter 2, Table 2.2). The PCR product was 
ligated with pET21+b vector (Invitrogen) digested with restriction enzymes XhoI and 
NdeI (New England BioLabs). The ligation product was transformed in E. coli DH5α 
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(Invitrogen), and the plasmid was purified by QIAprep spin Miniprep kit (Qiagen, 
Venlo, Limburg, Netherlands). The purified plasmid was subsequently transformed in 
E. coli BL21 (DE3, Invitrogen) to express the protein as COOH-terminal Hexa-
Histidine fusion. Protein expression was induced at 30°C by the addition of 1mM 
IPTG (New England BioLabs) at OD600 0.3 and growing the bacteria for additional 3 
hours. The cultures were subsequently pelleted by centrifugation at 1500rpm for 10 
minutes and re-suspended in 60ml Buffer 1 per 1 litre culture (Table 3.1). 0.2mg/ml 
lysozyme (New England BioLabs) was added and incubated on shaker on ice for 30 
minutes. The cell suspension was sonicated on ice with six-30 seconds bursts in 30 
seconds intervals. Cell debris was centrifuged at 10000xg for 30 minutes at 4°C. 
Supernatants were then transferred into 50ml Falcon tubes, 2ml of 50% slurry Ni-
charged Sepharose (GE Healthcare) and equilibrated with Buffer 1. After over-night 
incubation at 4°C on shaker, the tubes were centrifuged at 2000rpm for 5min at 4°C, 
supernatants were discarded and pellet re-suspended in 5ml Buffer 1. The wash step 
was repeated twice and the resin was loaded into a column (Biorad, Hercules CA, 
USA). The column was then washed twice with 5ml Buffer 2, and the recombinant 
protein eluted by adding 3x1ml fractions of Buffer 3. Protein concentration of each 
fraction was measured, and the fractions that contained the protein were pooled and 
dialysed using a slide-A-lyzer® dialysis cassette G2 10000 MWCO (Thermofisher 
Scientific) and 2l 1xPBS overnight at 4°Cunder stirring.   
 
 
Table 3.1. Buffers used to purify recombinant NadA from Escherichia coli. 
All buffers are adjusted to pH8. All chemicals were obtained from Sigma-Aldrich.  
! Buffer 1! Buffer 2! Buffer 3!
NaCl (mM)! 300! 300! 300!
NaH2PO4 (mM)! 50! 50! 50!




3.3.4 Transformation of N. meningitidis  
 
N. meningitidis knock-out strains generated by transformation with plasmids and 
replacement of target gene with antibiotic resistant markers are described in Table 
3.2. A few single bacterial colonies were added to GC plates, and 1µg plasmid was 
mixed with the bacteria and allowed to grow for 6 hours at 37°C with 5% CO2. The 
cells were then plated on GC plates supplemented with respective antibiotics, and 
grown over night (Table 3.3). Single transformants were sub-cultured on GC plates 
supplemented with antibiotics. Correct transformants were confirmed by Western 
blotting and PCR (Table 3.4). 
 
 
Table 3.2. Plasmids used to generate knock-out mutations. 
Each knock out (KO) mutation was generated in ascending order as indicated in the table starting from 
number 1. ΔnadR with pGEM1843 leads to the de-repression of nadA transcription/expression. ΔlpxL1 
with pUC18::lpxl1 detoxifies the GMMA due to the production of penta- instead of hexa-acylated lipid 
A. Δgna33 with pBSUDGNA33 increases blebbing or GMMA release from the bacterial cells. 
Δcapsule with either p_cpsW or p_cpsA deletes the capsule of the bacterium rendering it non-invasive 
(25).  
Number! Plasmid! Gene target! Resistance marker! Reference!
1! pGEM1843! nadR! Chloramphenicol (Cm)! (12)!
2! pBS961! nadA! Kanamycin (Kan)! (12)!
3! p_cpsW! Capsule serogroup W!
Spectinomycin 
(Spec)! This study!
4! p_cpsA! Capsule serogroup A! Spec! This study!
5! pUC18::lplx1! lpxL1! Tetracycline (Tet)! This study!









Table 3.3. Concentration of antibiotics in GC media for growth of Neisseria meningitidis mutants.  









Table 3.4. Primers for construction of plasmids and for confirming knock-out mutants.  
Monoclonal antibodies JW-W1b-IgG2b and JW-A2-IgG2b were also used to confirm capsular W and 
A deletion, respectively (kindly provided by Dan Granoff). The capsular primers contained restriction 




designation 5’-3’ nucleotide sequence Purpose Reference 
nadA NadAF  (Fw) AACACTTTCCATCCAAAG Confirming KO (8) 
 NadAR  (Rv) TTACCACTCGTAATTGACG Confirming KO (8) 
nadR 1843-F (Fw) ATGCCATCCCAATCAAAACATGCG Confirming KO (12) 
 1843-R (Rv) 
CGGCGTATTACGAGTTCAACGCATCC
TCG Confirming KO (12) 
lpxL1 htrBU  (Fw) GGCACGCGTCCGCTGATCAGTATGT Confirming KO (26) 
 htrBL (Rv) GGCACGCGTAAATTGATTTCGCCGATA Confirming KO (26) 
gna33 33FOR (Fw) 
CGCGGATCCCATATGCAAAGAAAGAG
AATCCCAA Confirming KO (24) 
 33REV (Rv) GCTCTGAGGGCGACGACAGGCGG Confirming KO (24) 




pUC18::lplx1 This study 












cpsA This study 













p_cpsW This study 




p_cpsW This study 
Capsule ctrAf_Xma (Fw) 
CCCCCCGGGCAGGAAAGCGCTGCATA
G Confirming KO This study 
 ctrAr_Xba (Rv) 
CGTCTAGAGGTTCAACGGCAAATGTG
C Confirming KO This study 




We generated five serogroup A and three serogroup W mutant strains (Table 3.5). All 
strains had deleted lpxL1 and gna33 genes. Four serogroup A mutants (strains 1, 3-5) 
had deleted capsule biosynthesis genes and two had deleted nadR gene (strains 1 and 
2). We also prepared a serogroup A control strain that had the capsule biosynthesis 
intact (strain 2), and a control strain that had nadR intact (strain 3). Additional control 
strains were generated that lacked nadA (strain 4) or both nadA and nadR (strain 5). 
Serogroup W mutant strains with deleted capsule biosynthesis genes (strains 6-8) 
were also prepared. One mutant strain had nadR deleted (strain 6), one control strain 
had intact nadR (strain 7) and one was generated with deleted nadA (strain 8). The 
order of mutation/transformation of each recombinant strain produced is shown in 
Figure 3.2.  
 
Table 3.5. GMMA vaccine strains. 
Strain NVGH0348 is serogroup A N2602 and NVGH0385 is serogroup W 1630 (see Table 2.2, 











1 A, NVGH0348_001 (LpxL1, cps, NadR, gna33)! 1 5 P1.20,9 3 
MenA NadR KO 
cps-!
2 A, NVGH0348_002 (LpxL1, NadR, gna33)! 1 5 P1.20,9 3 
MenA NadR KO 
cps+!
3 A, NVGH0348_003 (LpxL1, cps, gna33)! 1 5 P1.20,9 3 
MenA WT NadA 
cps-!
4 A, NVGH0348_004 (NadA, LpxL1, cps, gna33)! 1 5 P1.20,9 3 




(NadA, NadR, LpxL1, cps, 
gna33)!
1 5 P1.20,9 3 MenA NadA and NadR KO cps-!
6 W, NVGH0385_001 (LpxL1, cps, NadR, gna33)! 2 23 P1.5,2 3 
MenW NadR KO 
cps-!
7 W, NVGH0385_002 (LpxL1, cps, gna33)! 2 23 P1.5,2 3 
MenW WT NadA 
cps-!
8 W,  NVGH0385_003 (NadA, LpxL1, cps, gna33)! 2 23 P1.5,2 3 







Figure 3.2. Flow diagram of the order of mutations introduced for generating the recombinant 
vaccine strains. 
The order of transformation and mutation introduced in the recombinant serogroup A N2602 strains 
(panel A) and serogroup W 1630 strains (panel B) are indicated by the direction of the arrows in the 
flow chart. For example, for strain 1, deletion of nadR was performed first followed by deletion of 
capsule (cps), lpxL1 and lastly gna33. Mutations cannot be introduced after deletion of gna33 because 
the bacteria cannot subsequently take up DNA. The integrity of join between inner and outer 














3.3.5 GMMA preparation 
 
The vaccine strains were sub-cultured on GC agar plates with antibiotics. 7ml 
Meningitis Chemically Defined Medium I (MCDMI) medium was inoculated to 
OD600 0.15-0.2 and incubated with shaking at 37°C and 5% CO2 until OD600 0.6 was 
reached (Table 3.6). This culture medium was used to inoculate 50ml MCDMI in 
250ml Erlenmeyer flasks (Thermofisher Scientific) and incubated over night at 37°C, 
5% CO2 and 185rpm. Subsequently, the cultures were centrifuged at 3500rpm for 10 
minutes, and supernatant was collected and filtered using a vacuum filter device with 
0.22µm pore size membrane (Millipore, Billerica MA, USA). 100µl of the filtrated 
supernatant was plated on GC agar and the plates were incubated at 37°C, 5% CO2. 
After 48 hours when the plates tested sterile, the culture supernatants were transferred 
into 50ml ultracentrifuge tubes (Beckman, Brea, California, U.S., rotor Ti45) and 
centrifuged at 35000rpm, 2 hours, 4°C to collect the GMMA. Supernatants were 
subsequently discarded, and the membrane pellet was washed once with 1xPBS and 
centrifuged as before, supernatant discarded and the pellet soaked over night and re-
suspended in 500µl 1xPBS. GMMA preparations were sterilised by filtration (0.22µm 
pore sized syringe filter, Millipore) Concentration of the protein content in the 











Table 3.6. Constituents of the growth medium Meningitis Chemically Defined Medium 
(MCDMI). 










MgCl2 x 6H2O! 0.19!






3.3.6 Mouse immunisations 
 
Five weeks old CD-1 female mice (8 mice per group) were obtained from Charles 
River (Wilmington, MD, U.S.). The mice were immunised intraperitoneally with 
three doses of vaccine given at days 0, 14 and 28 (Table 3.7). All GMMA vaccine 
strains were given at 5µg doses based on total protein. Control mice were immunised 
with 5µg rHis-NadA-3 or Alum only. All vaccines were absorbed on 3mg/ml Alum in 
a 100µl formulation containing 10mM Histidine and 0.9mg/ml NaCl. Collection of 
blood was done two weeks after the second dose and two weeks after the third dose. 
Terminal blood samples were obtained at day 42. The animal procedures were 










Table 3.7. Mouse immunisation scheme.  
ACWY conjugate polysaccharide vaccine is conjugated to a diphtheria CRM197, developed by Novartis 
vaccines (NV&D Vaccine Chemistry). NaCl (Sigma-Aldrich S9888), Histidine (Sigma-Aldrich 





Antigen! Adjuvant! Dose (µg)! Immunisation route!
Volume (µl) 
per animal!
Primary vaccine candidates 
1 
(1 - 8)!
MenA NadR KO 
cps-! Alum! 5! IP! 100!
2 
(9 - 16)!
MenW NadR KO 




MenA WT NadA 
cps-! Alum! 5! IP! 100!
4 
(25-32)!
MenW WT NadA 
cps-! Alum! 5! IP! 100!
5 
(33-40)!
MenA NadR KO 
cps+! Alum! 5! IP! 100!
6 
(41-48)!
MenA NadA KO 
cps-! Alum! 5! IP! 100!
7 
(49-56)!
MenW NadA KO 
cps-! Alum! 5! IP! 100!
8 
(57-64)!
MenA NadA and 
NadR KO cps-! Alum! 5! IP! 100!
9 
(65-72)! rHis-NadA-3! Alum! 5! IP! 100!
10 
(73-80)! ACWY conjugate! Alum!
2, MenA PS 
1, MenC PS 




(81-88)! None! Alum! NA! IP! 100!
 
 
We focused on the primary vaccine candidate group 1 and 2 and the control groups to 
evaluate the potential and coverage of our two vaccine candidates. The aim was to 
compare subsequent groups: group 1 + 3 and group 2 + 4 to evaluate effect of nadR 
KO, group 1 and 5 to evaluate effect of capsule expression on production of anti-
NadA antibodies, group 1+ 6 and group 2 + 7 to compare the contribution of NadA 
antigen on antibody responses, group 1 and 8 to see if there are other antigens than 
NadA possibly regulated by NadR that contribute to immunogenicity, group 1 and 9 
to evaluate the efficacy of antibodies elicited against GMMA versus rHis-NadA-3 
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protein, group 1 and 10 to determine the efficacy of the candidate vaccine compared 
to the ACWY conjugate vaccine. 
 
3.3.7 Enzyme-linked immunosorbent assay (ELISA) screening of 
anti-NadA antibody responses  
4HBX (NUNC-IMMUNOPLATE, Penfield, New York, U.S.A) plates were coated 
with 2µg of rHis-NadA-3 over night. Subsequently, the plates were washed with wash 
buffer (1xPBS + 0.1% Tween20 (Sigma-Aldrich)) three times, blocked with blocking 
buffer (1xPBS + 2% milk + 0.5% Tween 20) for 1 hour and then washed again. After 
2 hours of incubation with primary antibody (mouse sera) starting from 1:10 dilution 
in serial 4 dilutions, secondary antibody 230 (goat anti-mouse IgG γ-chain 
horseradish peroxidase-labelled, Sigma-Aldrich) was added for 1 hour at 1:20000 
dilution. The reaction was developed by the addition of P-Nitrophenyl phosphate 
substrate (PNP; Sigma-Aldrich) in PNP substrate buffer at pH9.6 diluted 1:100 (for 1 
litre: 1.4g sodium carbonate, 3.0g sodium bicarbonate, 0.2g magnesium chloride-
hydrate (Sigma-Aldrich)), and read at 405nm after 30-60 minutes of incubation with 
an ELISA reader (Sunrise Tecan). 
 
3.3.8 SBA using baby rabbit complement 
The assay was performed as previously described for SBA using human complement 
in Chapter 2 section 2.3.5 page 63. Isolates used are listed in Table 3.9 (Result 
section 3.4.4). The source of complement was serum from baby rabbit (Cedarlane, 





3.3.9 Statistical analysis 
 
Data analysis was carried out as described in Chapter 2 section 2.3.7 page 67. For the 
Western blot results, multiple group comparison (ANOVA) was utilised to evaluate 






























3.4.1 Majority of the serogroup A, W and X isolates expressed 
intermediate to high levels of NadA protein  
Fagnocchi et al. (2012) previously showed that the small molecule 4HPA is able to 
relieve NadR-mediated repression of NadA expression in meningococcus (16). Unlike 
fHbp, it has not been ascertained whether the level of NadA expression is an 
additional factor for determining the susceptibility of a strain to anti-NadA antibodies. 
To establish this and to understand the effect of 4HPA on the NadA expression in 
vitro, we investigated the expression of NadA with and without the presence of 5mM 
4HPA. We compared the level of NadA protein expression to the vaccine serogroup 
A strain N2602. Most serogroup A and W isolates express intermediate to high levels 
of NadA compared to the reference strain N2602 (Figure 3.3, Panel A and B). 
However, selected X isolates expressed low amounts of NadA (Panel C). When the 
strains were grown in the presence of 4HPA, analysis of the whole cell extracts 
suggested an increased level of NadA expression for 31/37 isolates. Statistical 
analysis using two-way ANOVA showed that this difference was statistically 









Figure 3.3. NadA protein expression in African serogroup A, W and X isolates grown with and 
without the presence of the metabolite 4HPA as measured by Western blotting.  
Panel A: serogroup A isolates; Panel B: serogroup W isolates; Panel C: serogroup X isolates. All 
serogroups were of NadA-3 except for Mali10/09, which expresses NadA-2. Serogroup X isolates 
Uganda14/06 and Ug11/07 were not included in the analysis since the isolates failed to grow. Bars in 
panel A-D represent mean percentages of a set of 2 independent experiments compared with expression 
of NadA by the reference serogroup A vaccine strain N2602. Dotted line represents the level of NadA 
expression by the reference strain. Error bars represent standard errors. Statistical analysis was 
calculated using multiple group comparison [ANOVA]. 
 
 
3.4.2 Quantification of NadA protein amount on GMMA from  
serogroup A and W mutant strains 
To attempt to over-express NadA, we deleted nadR in the serogroup A N2602 and W 
1630 isolates by transforming them with plasmid pGEM1843 that contains flanking 
regions of the nadR gene. NadA protein expressions in the GMMAs were measured 
by Western blotting using polyclonal anti-rHis-NadA-3 antibody (Figure 3.4, Panel 
A). Densitometry indicated that the GMMA produced from the recombinant 
serogroup A and W strains with deleted capsule and nadR (MenA NadR KO cps- and 
MenW NadR KO cps-) have lower NadA amounts than isogenic control strains with 
the capsule expressed (MenA NadR KO cps+, MenW NadR KO cps+) or wild-type 
NadA expression (MenA WT NadA cps-, MenW WT NadA cps-) (Table 3.8). We 
expected that the MenA NadR KO cps- and MenW NadR KO cps- GMMAs would 
contain the highest amount of NadA since nadR was deleted in the respective 
recombinant strains for that purpose. During development of the recombinant vaccine 
strains, Western blotting of whole cell lysates of all serogroup A and W NadR KO 
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mutants were assessed prior to introducing subsequent mutations. The NadR KO 
mutants with capsule expressed the highest amount of NadA compared to the wild-
type strains with capsule (Figure 3.4, Panel B). Plausible explanation for the lack of 
over-expression of NadA in MenA NadR KO and MenW NadR KO could be that the 
introduction of subsequent cps, lpxL1 and gna33 deletions affect the trafficking of 
proteins, membrane environment and stability of the anchoring of the NadA in the 
OM (25). It could be that the NadA protein produced does not get transported out to 
the OM for GMMA formation, but rather stuck in the whole cell biomass.  
 
 
Figure 3.4. Expression of NadA-3 in GMMA and whole cell lysate prepared from serogroup A 
N2602 and serogroup W 1630 recombinant vaccine strains measured by Western blotting. 
Panel A: Expression of NadA in serogroup A N2602 and W 1630 GMMA lysates; Panel B: amount of 
NadA expression in whole cell lysates from serogroup A N2602 and W 1630 mutant strains with nadA 
and nadR knock-out only. The serogroup W GMMA with deleted nadR and expressing the capsule 
(MenW NadR KO cps+) was produced during the generation of vaccine serogroup W GMMAs, but not 
included in the mouse study. This is because the corresponding GMMA made from the serogroup A 
strain N2602 (MenA NadR KO cps+) will evaluate effect of capsule expression on production of anti-
NadA antibodies. The rHis-NadA-3 standard is in µg, and 4µg of GMMA and 10µg of whole cell 





Table 3.8. Quantification of expression of NadA-3 in GMMA vaccines prepared from serogroup 
A and W recombinant strains.  
Each GMMA preparation were from mutants with ΔlpxL1 that detoxifies the GMMA due to the 
production of penta-acylated lipid A, and Δgna33 that increases GMMA release from the bacterial 
cells. Δcapsule (cps-) deletes the capsule, and in two preparations the capsule was retained (cps+). The 
amount of NadA on GMMA was assessed based on total protein concentration of the GMMA 
preparations. Total protein amounts were determined by Lowry protein assay kit (BioRad DC™ 
Protein Assay, BioRad Laboratories, Hercules, California, U.S.), and the GMMA preparations were 
adjusted to the same protein concentration. The primary vaccine candidates are highlighted in blue. 

















NadR KO  
cps+ 
MenW 
NadR KO  
cps- 
% of total 




3.4.3 Antibody responses elicited in mice immunised with GMMA 
We measured anti-NadA IgG antibody responses in serum samples containing sera 
from two mice each by ELISA. GMMA from recombinant serogroup A strains with 
deleted capsule (MenA WT NadA cps-) and deleted nadR but expressing the capsule 
(MenA NadR KO cps+) elicited significantly higher GMT compared to the serogroup 
A GMMA with deleted capsule and nadR genes (MenA NadR KO cps-; Figure 3.5, 
Panel A; GMT= 463410, 463410 and 5120 respectively; P=0.0052). Possibly 
corresponding to the higher amount of NadA in MenA WT NadA cps-. The rHis-
NadA-3 also induced more bactericidal anti-NadA antibodies than MenA NadR KO 
cps- (GMT= 463410 and 40960 respectively; P=0.0147). In contrast, MenW NadR 
KO cps- and MenW WT NadA cps- GMMAs elicited low anti-NadA-3 IgG antibody 
responses (Figure 3.5, Panel B; GMT=160 and 226 respectively). GMMA from both 
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groups without NadA expression induced no measurable anti-NadA antibody 





Figure 3.5. Anti-NadA IgG antibody responses elicited in mice immunised with serogroup A and 
W GMMA vaccines as measured by ELISA. 
Panel A: anti-NadA IgG responses elicited by GMMA from serogroup A isogenic mutants, Panel B: 
anti-NadA IgG responses elicited by GMMA from serogroup W recombinant strains. The ELISA 
plates were coated with 2µg of rHis-NadA-3. For each vaccine group, eight mice were immunised with 
three doses, 2 weeks apart. The serum samples analysed were obtained 2 weeks after the third dose. 
Each symbol represents sera of two mice pooled. Of each vaccine group the line indicates the GMT. 
GMMA used for immunisation: MenA NadR KO cps- and MenW NadR KO cps- (nadR, capsule 
biosynthesis locus, lpxL1 and gna33 KO); MenA WT NadA cps- and MenW WT NadA cps- (capsule, 
lpxL1 and gna33 KO); MenA NadR KO cps+ (nadR, lpxL1 and gna33 KO); MenA NadA KO cps- and 
MenW NadA KO cps- (nadA, capsule, lpxL1 and gna33 KO); rHis-NadA-3: recombinant hexa-
histidine tagged NadA allele 3; Alum: aluminium hydroxide. Statistical analysis between pairs of 





3.4.4 SBA responses of sera from mice immunised with GMMA from 
serogroup A and W mutant strains 
The SBA responses of the antiserum of mice immunised with GMMA from the 
recombinant serogroup A and W strains were assessed against three serogroup A 
isolates, three W and one X isolate expressing low, intermediate and high levels of 
NadA (Table 3.9). 
 
Table 3.9. Panel of isolates selected for serum bactericidal activity analysis. 














A Su14/07 Sudan 2007 1 5 P1.20,9 3 25.9 7 
A BuFa20030020 
Burkin
a Faso 2007 1 5 P1.20,9 3 60.2 6035 
A Mali21/07 Mali 2007 1 5 P1.20,9 3 102.9 2859 
W BF 10/02 
Burkin
a Faso 2002 2 23 P1.5,2 3 30.4 11 
W Ghana 7/04 Ghana 2004 2 23 P1.5,2 3 57.6 11 
W Mali 10/09 Mali 2009 2 23 P1.5,2 2 100.0 11 
X MRS2006087 Niger 2006 1 74 
P1.5-
1,10-1 3 18.6 5789 
 
 
3.4.4.1 Isolates expressing low amounts of NadA 
The MenW NadR KO cps- GMMA from the recombinant serogroup W strain 1630 
(NVGH0385) with PorA P1.5,2 and fHbp v.2 ID23 induced bactericidal antibodies 
that were able to kill the serogroup A isolate Su14/07, expressing heterologous PorA 
P1.20,9 and fHbp v.1 ID5 (GMT=3822) (Figure 3.6, Panel A). Higher titres were 
observed for MenW WT NadA cps- (GMT=26425), which contained slightly higher 
amounts of NadA (3 and 7% respectively). GMMA from the MenW NadA KO cps- 
strain was also able to induced bactericidal antibodies (GMT= 2053) of similar level 
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as MenW NadR KO cps-. The results suggest that majority of the bactericidal 
antibodies induced by the GMMA vaccine are being directed against other OMP than 
NadA, fHbp and PorA. Moreover, rHis-NadA-3 also elicited high titres with equal 
levels to the ACWY vaccine (GMT=85334 and 163840).  
 
The MenA NadR KO cps- and MenA WT NadA cps- GMMA from the recombinant 
serogroup A strain N2602 (NVGH0348) with NadA-3, PorA P1.20,9 and fHbp v.1 
ID5 elicited bactericidal titres that killed the serogroup W isolate BF10/02 expressing 
heterologous PorA P1.5,2, fHbp v.2 ID23 and low amounts of NadA-3 (30%; Figure 
3.6, Panel B; GMT=10328 and 14382 respectively). GMMA from the isogenic 
mutant expressing the capsule MenA NadR KO cps+ induced a lower titre 
(GMT=380, not significant). Possible explanation could be that the capsule masks 
OMP preventing accessibility of the antigens on the meningococcal surface to C1q 
complement protein and bactericidal antibodies. Antibodies induced by rHis-NadA-3 
elicited a measurable bactericidal antibody responses against the strain tested 
(GMT=915). Three pools of sera for the control groups MenA NadA and NadR KO 
cps- and MenA NadA KO cps- could kill BF10/02 indicating that other OM than 
NadA, fHbp and PorA, some possibly regulated by NadR, are inducing bactericidal 
antibodies (GMT=3947 and 544 respectively). For reasons not fully understood, 
neither GMMA from the recombinant serogroup A and W strains elicited any 
bactericidal titres against serogroup X strain MRS2006087 expressing NadA-3 and 
heterologous PorA P1.5,10 and fHbp v.1 ID74 (Figure 3.6, Panel C). Possible 
explanations could be the low amount of NadA or other immunogenic antigens on the 






Figure 3.6. Serum bactericidal antibody responses of mice immunised with MenA and MenW 
GMMA against African meningococcal strains expressing low NadA amounts.  
The sera from immunisation with the serogroup A and W vaccine groups were tested against serogroup 
A Su14/07 (panel A), serogroup W BF10/02 (panel B), respectively, and both sets of sera against 
serogroup X MRS2006087 (panel C). The isolates expressed low amounts of NadA (~19-30%). Serum 
bactericidal responses were measured with baby rabbit complement. The serum samples used in the 
analyses were obtained 2 weeks after the third vaccine dose. Each symbol represents a sample of sera 
from two mice pooled, and the line of each vaccine group indicates the GMT. Half open symbols 
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represent the sera from the MenW vaccine groups. Error bars indicate ±95% confidence interval of the 
GMT. GMMA used for immunisation: MenA NadR KO cps- and MenW NadR KO cps- (nadR, 
capsule biosynthesis locus, lpxL1 and gna33 KO); MenA WT NadA cps- and MenW WT NadA cps- 
(capsule, lpxL1 and gna33 KO); MenA NadR KO cps+ (nadR, lpxL1 and gna33 KO); MenA NadA KO 
cps- and MenW NadA KO cps- (nadA, capsule, lpxL1 and gna33 KO); MenA NadA and NadR KO 
cps- (nadA, nadR, capsule biosynthesis locus, lpxL1 and gna33 KO); rHis-NadA-3: recombinant hexa-
histidine tagged NadA allele 3; Alum: aluminium hydroxide. Statistical analysis between pairs of 
groups was performed using Mann–Whitney U test. 
 
 
3.4.4.2 Isolates expressing intermediate amounts of NadA 
 
GMMA from the MenW NadR KO cps- strain induced bactericidal antibodies that 
were able to kill the serogroup A isolate BuFa20030020 with heterologous PorA 
P1.20,9 and fHbp v.1 ID5 (Figure 3.7, Panel A; GMT=4207). Significantly higher 
titres were observed for MenW WT NadA cps- and rHis-NadA-3 (GMT=70336 and 
163840 respectively). The MenW NadA KO vaccine group also induced titres 
(GMT=498), showing that a fraction of bactericidal antibodies were directed against 
other immunogenic OMPs.  
 
GMMA from the MenA NadR KO cps- recombinant strain elicited bactericidal titres 
that killed the serogroup W isolate Ghana7/04 expressing heterologous PorA P1.5,2 
and fHbp v.2 ID23 (Figure 3.7, Panel B; GMT=72843). Significantly higher titres 
were generated for MenA WT NadA cps- and MenA NadR KO cps+ (GMT=6.9x106 
and 4.8x106 respectively). This could be due to higher levels of NadA in both the 
GMMA vaccine strains MenA WT NadA cps- and MenA NadR KO cps+ and the 
strain tested compared to MenA NadR KO cps-. Low but measurable titres were also 
induced by the MenA NadA and NadR KO cps- and MenA NadA KO cps- vaccine 
groups (GMT=24 and 76 respectively) indicating the presence of other immunogenic 
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Figure 3.7. Serum bactericidal antibody responses of mice immunised with MenA and MenW 
GMMA against African meningococcal strains expressing intermediate NadA amounts.  
The sera from immunisation with the serogroup A and W vaccine groups were tested against serogroup 
A BuFa20030020 (panel A) and serogroup W Ghana7/04 (panel B), respectively, expressing 
intermediate amounts of NadA (60 and 58% respectively). Serum bactericidal responses were 
measured with baby rabbit complement (see legend of Figure 3.6). Statistical analysis between pairs of 










3.4.4.3 Isolates expressing high amounts of NadA 
 
The antibody responses elicited following immunisation with GMMA from the 
MenW NadR KO cps- strain did not kill the serogroup A isolate Mali21/07 with 
heterologous PorA P1.20,9 and fHbp v.1 ID5, despite it expressing high levels of 
NadA-3 (103%) (Figure 3.8, Panel A). Only MenW WT NadA cps- and rHis-NadA-
3 elicited measurable bactericidal titres (GMT=13898 and 19837 respectively) 
possibly, differences in fine antigen specificities and capsular amount. 
 
All vaccine groups, except Alum, induced bactericidal antibodies against the high 
NadA-2 expresser Mali10/09 (100%) with heterologous PorA P1.5,2 and fHbp v.2 
ID23 (Figure 3.8, Panel B). Serum from the MenA NadR KO cps- GMMA vaccine 
group was able to kill the strain, and the MenA WT NadA cps- significantly more so 
(GMT=1.3x106 and 1.1x107 respectively). The presence of the capsule on the GMMA 
seemed not to affect the bactericidal antibody activities as similar GMT was obtained 
as for the capsular negative group MenA NadR KO cps- (GMT=1.3x106). Antibody 
responses generated by MenA with deleted NadA+NadR and NadA (GMT=7750 and 
194156 respectively) also killed the isolate. The data are consistent with the 
hypothesis that there are additional antigens on the GMMA that can elicit bactericidal 
antibodies. Antibodies induced by rHis-NadA-3 induced bactericidal antibody 
responses against the strain tested (GMT=1.3x106), which shows that cross-protection 





Figure 3.8. Serum bactericidal antibody responses of mice immunised with serogroup A and W 
GMMA against African meningococcal strains expressing high NadA amounts.  
The sera from immunisation with the MenW and MenA vaccine groups were tested against serogroup 
A Mali 21/07 (panel A) and serogroup W Mali10/09 (panel B), respectively, expressing high amounts 



















Phase variation often results in ON/OFF changes of expression or graduated 
alterations. The mechanism of NadA expression is complex, and the many ways of 
regulation result in different levels of expression (27). Although, results from the 
typing analyses in Chapter 2 suggests that natural and herd immunity is not a strong 
driving force for antigenic variability, it could be so for antigenic expression. 
Selection for the ON phenotype or high expression involves gain of function such as 
adhesion and invasion to epithelial cells, but at the same time it also involves potential 
susceptibility to anti-NadA antibodies (12). While the OFF phenotype or decreased 
protein expression reduces adhesion to epithelial cells, perhaps promoting spread of 
the bacterium, and allowing escape of killing by bactericidal antibodies due to a 
reduction in the concentration of surface-bound antibody and hence reduced 
complement activation (28). The correlation between the level of expression of NadA 
on bacterial OM, and the susceptibility and production of bactericidal antibodies has 
not been established. In this study, majority of the serogroup A and W isolates were 
found to express intermediate to high levels of NadA while the X isolates investigated 
showed low expression of NadA. Although the regulation of gene expression is 
bifunctional, low expressers still have the potential to respond to proper niche signals 
such as 4HPA and express higher levels under certain environmental conditions such 
as during adhesion (19). Here, we saw that when the bacterial cells were grown in the 
presence of 4HPA, the molecule differentially induced a significant increase in NadA 
expression (p<0.001). Fagnocchi et al. (2011) also showed that 4HPA and human 
saliva increased NadA expression. This suggesting that 4HPA could mimic 
physiologically relevant signalling molecules in vivo promoting the bacteria to switch 
to the “ON” phenotype (16). However, at this point it not clear as to how the increase 
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of NadA expression by 4HPA or other niche signals in vivo translates into e.g. 
increased adhesion capability. Further adhesion assay experiments on Chang cells is 
warranted (9).  
 
GMMA is a new vaccine strategy recently employed for the development of a broadly 
protective vaccine against disease causing serogroups in Africa (29). This vaccine 
strategy involves the deletion of the gna33 gene, which differentiates GMMA from 
NOMV vaccines. During normal bacterial cell growth, osmotic stability is maintained 
by a network of glycan strands linked with peptides (peptidoglycans) (30). The 
protein Genome Derived Neisseria antigen 33 (GNA33) was identified through 
reverse vaccinology screening of serogroup B genome. GNA33 is a membrane-bound 
lipoprotein with murine hydrosylase activity that is present in all Neisseria species 
(31–33). In this study, gna33 gene was knocked-out to increase membrane blebbing 
for efficient vaccine production. Adu-Bobie et al. (2004) have previously shown that 
deleting the gene not only increases vesicle release through physiological dissociation 
of the membrane, but also affects cell separation, membrane assembly and 
architecture (24). Quantification of NadA on GMMA from serogroup A and W 
isogenic mutant strains showed that control strains with the capsule expressed (MenA 
NadR KO cps+, MenW NadR KO cps+) or wild-type NadA expression (MenA WT 
NadA cps-, MenW WT NadA cps-) expressed the highest amount of NadA. We 
anticipated that GMMA from the serogroup A and W recombinant strain MenA NadR 
KO cps- and MenW NadR KO cps- would contain the highest amount of NadA since 
nadR was deleted for that purpose. Western blotting of whole cell lysates of nadR KO 
serogroup A and W mutants showed that NadA was over-expressed as a result of 
nadR KO. However, the NadA protein does not seem to have been transported to the 
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OM for GMMA formation. There are several plausible explanations for this. The 
mutations introduced for the generation of the recombinant vaccine strains are not 
neutral and their cumulative effect could affect the trafficking of NadA and other 
proteins to the OM. NadA could be accumulated in inclusion bodies or possibly NadA 
is over-expressed in the “final” strain MenA NadR KO cps-. To determine the 
localisation of NadA in the “final” recombinant strains one could do FACS and 
Western blot analysis of NadA expression in the isogenic mutants. Further electron or 
fluorescence microscopy experiments could be done on cell fractionations of the 
mutant strain MenA NadR KO cps- using an anti-NadA mAb to determine NadA 
protein location. Moreover, deletion of gna33 by itself has been shown to affect the 
membrane architecture. It could be that deleting gna33 and in combination with 
deletion of nadR, capsule and lpxL1 in one strain (e.g. MenA NadR KO cps-) affects 
assembly and insertion of NadA into the OM more profoundly than the isogenic 
strains with fewer mutations (e.g. MenA WT NadA cps-). NadA has to go through the 
transmembrane domain for insertion into the OM, and this could be impeded since the 
integrity of the membrane is impaired. NadA could be in the cytoplasm, and 
microscopy studies with cell fractionation of the different recombinant strains could 
aid prove this hypothesis. Therefore, to perform these experiments it would also be 
beneficial to develop a mAb against native NadA on GMMA. The Western blot 
results of the GMMA lysates showed that the mutant strains with a capsule (MenA 
NadR KO cps+, MenW NadR KO cps+) contained more NadA than the mutants 
without the capsule (MenA NadR KO cps-, MenW NadR KO cps-). It could be that 
the capsule somehow helps to stabilise the NadA trimer in the OM. Further 
investigations are also needed to look into the individual effect of the mutations on 
the membrane composition of the isogenic mutants, and if the cell membrane 
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composition is reflected by the GMMA. The protein composition of GMMA is 
unknown and GMMA may not represent the entire cell membrane composition. A 
more in-depth mass spectrometry analysis such as MALDI-TOF of the GMMA and 
membrane fraction of the mutant strains is necessary.  
  
 The expression of vaccine candidate antigens in a GMMA format allows for their 
representation in the correct orientation and conformation that resembles whole cell 
vaccine, which is naturally presented to the host upon infection. Here, we generated 
GMMA from serogroup A and W recombinant strains with deleted nadR, capsule, 
lpxL1 and gna33. The effectiveness of these vaccine groups were evaluated at 
inducing an antibody response (ELISA) that also showed serum bactericidal activity 
against African meningococcal strains of serogroup A, W and X expressing low, 
intermediate and high levels of the vaccine antigen NadA. The ELISA results showed 
that the MenA WT NadA cps- and MenA NadR KO cps+ GMMA elicited 
significantly higher anti-NadA IgG titres compared to MenA NadR KO cps- and rHis-
NadA-3. While all MenW GMMAs elicited measurable but low anti-NadA antibody 
responses. A similar trend was seen when MenA and MenW vaccine groups were 
assessed based on their ability to kill a low, intermediate and high expressing 
serogroup W and A isolates, respectively. For all strains except serogroup W BF10/02 
MenA WT NadA cps-, MenA NadR KO cps+ and MenW WT NadA cps- GMMA 
elicited the highest bactericidal titres that killed the test strains. The results suggest 
that the higher the NadA expression in the GMMA in combination with other 
immunogenic antigens contribute to an increase in bactericidal responses. The results 
do not, however, indicate whether there is a cut off level of NadA expression on the 
surface of the meningococcus needed to cross-link IgG antibodies and activate the 
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complement cascade. This is because one cannot exclude bactericidal activity against 
other target antigens. Such experiments require an anti-NadA mAb or the rHis-NadA-
3 serum to determine the minimum level of NadA on the surface of meningococcus 
that is necessary to kill the bacteria. Moreover, for reasons not fully understood lack 
of bactericidal antibody responses by MenW NadR KO cps- and a low titre generated 
by MenW WT NadA cps- did not effectively kill the serogroup A strain Mali21/07 
despite it expresses high amounts of NadA-3. Sera from mice immunised with rHis-
NadA-3 killed the isolate. In addition, low titres for the MenW NadR KO cps- were 
elicited when tested against serogroup W isolate Mali21/07, and X isolate was not 
killed by any of the vaccine groups. The results could be due to the difference in 
epitope specificity of the NadA and other immunogenic proteins of isolates 
MRS2006087 and Mali21/07 compared to N2602 and rHis-NadA-3. More functional 
antibodies could have been generated against recombinant NadA than that in GMMA. 
The isolates may also express more capsule preventing accessibility of OMPs on the 
meningococcal surface. The capsule may also be of different chemistry and length. To 
assess this, FACS analysis using mAb against the serogroup A capsule could 
determine if a higher capsule amount is expressed by these isolates. If it the length 
and chemistry is a factor, Dionex, HPLC-SEC and NMR provides a more in-depth 
analysis.  
 
Nonetheless, the fact that sera from the NadA KO cps- GMMA vaccine groups from 
both serogroup A and W recombinant strains killed the test strains highlights the 
advantage of using GMMA as a vaccine strategy. MenA NadA and NadR KO cps-, 
MenW NadA and NadR KO cps-, MenA NadA KO cps- and MenW NadA KO cps-
vaccine groups elicited bactericidal antibodies to antigens other than NadA, fHbp and 
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PorA. The data indicate even strains that express low levels of certain target surface 
antigen, antibodies to other but shared OM antigens along with antibodies to the main 
target bactericidal antigens may provide protection (23). Thereby dependency on a 
single antigen or antigen type is avoided. A second advantage is that there is a 
potential for synergistic function of antibodies to different antigens in cases where 
expression level of a particular antigen is low (20,23,34). To identify such 
immunogenic antigens, one could mine for them by generating mAbs against GMMA. 
The bactericidal mAbs can then be used to immunopresipitate the antigens from 
whole cell lysates and analyse the immunopresipitates by Mass spectrometry.  
 
In this study we also showed that removal of capsule does not significantly enhance 
the level of bactericidal activity induced against strains with heterologous fHbp and 
PorA compared to the isogenic non-encapsulated GMMAs. In Chapter 2, we saw that 
removal can significantly affect antibody responses towards fHbp. Possibly, it could 
be that the capsule is not able to fully mask the NadA trimer on the surface. An 
alternative explanation is that the high amount of NadA on the GMMA from 
serogroup A isogenic mutant expressing the capsule (MenA NadR KO cps+) 
compared to the wild-type GMMAs and GMMAs with deleted nadR and capsule 
biosynthesis locus (MenWT NadA cps-, MenW WT NadA cps-, MenA NadR KO 
cps-, MenW NadR KO cps-) interferes with the capsule being an antigenic competitor 
(29). In principle, one could test this by performing a FACS analysis on the mutant 
strains using anti-NadA mAbs and compare the results with FACS analysis against 
fHbp mutant strains using anti-fHbp mAbs. In combination with SBA analysis of the 
mutant strains using the mAbs, this could also give a clearer indication than using 




Previous studies have shown that serum antibodies produced against recombinant 
proteins have either no or limited bactericidal activity against meningococcal isolates 
expressing the same fHbp variant (29,35,36). This was confirmed in Chapter 2 where 
antibodies induced by rHis-fHbp ID1 did not elicit a measurable bactericidal antibody 
responses against the strain tested. It could be that bactericidal antibodies are induced 
towards conformational epitopes. Compared to the rHis-fHbp antibody responses, 
rHis-NadA-3 induced bactericidal antibodies that killed all strains tested. The results 
suggest that immunogenicity to NadA is less dependent on the three-dimensional 
conformation of the protein than other OMPs such as fHbp. To test this, one could 
map the epitopes on linear rHis-NadA fragments responsible for eliciting bactericidal 
antibodies using bactericidal anti-NadA mAb generated towards NadA expressed in 
GMMA. The results can be compared with the eiptopes mapped on rHis-NadA using 
bactericidal anti-NadA mAbs generated against rHis-NadA-3.  
 
3.6 Conclusion 
To conclude, the GMMA vaccine strategy offers an additional mode of expressing 
vaccine candidate antigens compared to recombinant, dOMV and NOMV approaches. 
Here, we investigated the bactericidal antibody responses elicited by NadA expressed 
in GMMA. The results show that NadA in GMMA provides a broad protection 
against African serogroup A and W isolates expressing low, intermediate and high 
amounts of NadA. Despite some of its current limitations, such a vaccine strategy 
could serve as an alternative or a supplement to the existing conjugate vaccines 
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GENERATION OF MONOCLONAL 
ANTIBODIES AGAINST NADA, FHBP AND 





















The existence of antibodies or immunoglobulins (Ig) in blood were firstly described 
in 1890 by von Behring and Kitasato. In the following years, the classical tautology of 
antibodies or “antikörper” and the substance that induced the production of them 
(antigen) was discriminated. After more than 100 years of investigation into the 
structure and function, the eponymous description of antibodies is their classical 
heterodimeric composition of two heavy and two light chains, which consist of either 
a κ or ι chain. Each chain has a NH2-terminal variable domain and one or more 
COOH-terminal constant domain (1). The chains are held together by disulfide 
bridges between two conserved cysteine residues. Pepsin digestion of IgG has shown 
that the Ig can be split into a Fc fragment and a single dimeric F(ab)2 that can bind 
antigens. Moreover, the Ig can be separated into five isotypes based on the heavy 
chain (IgD, IgG, IgM, IgA, IgE). IgG is the most predominant subclass with longest 
half-life, and investigation into the functional difference of IgG has identified 4 
subclasses with highest levels in serum ranked accordingly IgG1>IgG2>IgG3>IgG4. 
In mice the subclasses are IgG1, IgG2a, IgG2b and IgG3 (1). The Fc portion of each 
of these subclasses affects antibody flexibility (hinge region), and each Ig exhibit 
different functional activity. For N. meningitidis, activation of the complement 
cascade is an important means of clearance of the pathogen through bacteriolysis. 
Human IgG3 and IgG1 and murine IgG2a are the most prominent subclasses that fix 
C1q through binding of constant domain (2). The purpose of antibodies is to bind 
pathogen surface components and promote cell signalling and activation, but also 
bind soluble effector molecules for neutralisation. Antibodies are able to bind almost 
any ligand through the diversity and alteration of the DNA encoding antigen binding 
regions of individual B cells (affinity maturation). This has been exploited for the 
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development of single specific (monoclonal) antibodies that recognise specific targets 
for diagnostic, therapeutic and research purposes.  
 
 
4.1.1 Monoclonal antibody production and their applications 
Monoclonal antibodies (mAb) are specific and homologous antibodies to a particular 
target antigen or epitope produced from a single B cell clone. The first successful 
generation of mAbs in vitro was in 1975 by Kohler and Milstein (3). The spleen of a 
mouse immunised with an antigen was fused with immortal myeloma cancer cell line 
(4). The classical hybridoma method involves cloning the fusion mix into 96 well 
plates and screening of the supernatant for target antigen specific antibodies. Positive 
cell lines are cloned further to generate monoclonal immortalised B cell lines, which 
produce unlimited amounts of antibody that have a specific heavy and light chain 
derived variable regions (Figure 4.1).  
 
To date, mAb can be produced in a variety of expression systems and cell lines, which 
has increased the usability and application of mAbs (5). Development and production 
of mAb now include DNA based recombinant technologies, expression in bacterial 
systems, phage display libraries, chimerisation and humanisation strategies based on 
transgenic mice. This has revolutionised, for example, therapeutic treatment where 
mAbs have been produced for the treatment of cancer and autoimmune diseases (6). 
Moreover, due to their high-specificity and sensitivity of binding antigens, mAb have 
become a well established tool in research for detecting antigens in their native 
conformation, Western blotting or in immune-affinity based assays (3). Recently, the 
utility of mAb has been expanded to proteomic and recombinant protein structure 
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analysis. This application has been employed for the characterisation of vaccine 










Figure 4.1. Hybridoma technology for production of murine monoclonal antibodies. 
A mouse is immunised with a desired antigen. B cells from the spleen of this mouse are fused with 
immortal myeloma cells that have lost the ability to synthesis hypoxanthine-guanine-phosphoribosyl 
transferase (HGPRT), an enzyme that salvages synthesis of nucleic acids. The HAT medium contains 
hypoxanthine, aminopterin and thymidine that is selective for fused hybridoma cells. Un-fused 
myeloma cells cannot grow because they lack HGPRT and cannot replicate DNA, and unfused B cells 
die after a few cell cycles. The fusion mix is plated onto 96 well titre plates, and after 7-10 days 
screened. Positive hybridomas are selected and cloned again into 96 well plates to generate single cell 
derived lines. Positive clones are subsequently selected for expansion and large-scale production of 
monoclonal antibodies.  
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4.1.2 Monoclonal antibodies against Neisseria meningitidis antigens 
 
N. meningitidis is a global pathogen responsible for local to epidemic outbreaks. As 
previously mentioned, mAbs have been used in serological studies to characterise 
meningococcal strains based on their capsule (serogroup), OMP PorB (serotype) and 
PorA (serosubtype). The information gained has been pivotal in monitoring and 
epidemiologic surveillance of disease-causing strains (7). However, serological 
methods have been complicated by the numerous variants of these OMP, which show 
strain-to-strain variation limiting sensitivity and specificity (7). Serological typing has 
been mostly replaced by PCR-based genotyping techniques and recently genomics. 
MAbs are now being primarily prepared against specific vaccine antigens to 
characterise the fine specificity of immune responses towards the protein.    
 
In the case of fHbp, many studies have generated mAbs against the recombinant 
protein to elucidate the specific epitopes involved in generating bactericidal 
antibodies and binding of fH (8–10). Beernink et al. (2008) generated a panel of 
mAbs from mice immunised with recombinant fHbp v.2 and v.3 to determine the 
regions on fHbp in these variant groups that are recognised by bactericidal antibodies, 
and the regions that are involved in binding of fH (8). The authors found that none of 
the mAbs were bactericidal individually, only in combination with each other. This 
was firstly shown by Welsch et al. (2004), and was likely to be due to the sparse 
distribution of fHbp on the surface of the meningococci that prevents cross-linking of 
two IgG anti-fHbp antibodies to correctly spaced epitopes and engagement of 
complement protein C1q (11). However, alignment of fHbp sequences together with 
site-specific mutagenesis of fHbp genes confirmed that residues between aa 174-216 
of fHbp v.2 and v.3 are recognised by bactericidal antibodies. Giuntini et al. (2012) 
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compared two mAbs against fHbp v.1 that share overlapping epitopes in relation to 
their different effects on fH binding and bactericidal activity, as they expected that 
blocking of binding of fH renders the pathogen more susceptible to bacteriolysis (9). 
Yeast display and site-specific mutagenesis showed that binding of antibodies JAR1 
(IgG3) and mAb502 (IgG2a) was eliminated by a single aa substitution, R204A. 
However, only JAR1 inhibited binding of fH to fHbp and had human complement 
dependent bactericidal activity. Although, susceptibility to anti-fHbp antibodies is 
influence by IgG subclass and amount of fHbp expressed by the strain, their data 
illustrates that subtle differences in fine antigenic specificity affects fH binding and 
mAb-induced protection. Studies performed so far have been focused on generating 
mAbs against recombinant fHbp and not against the antigen in its native membrane 
environment.  
 
Far fewer studies have looked at the epitopes of NadA. Tavano et al. (2011) 
developed deletion mutants devoid of sequences distributed in the coiled-coil domain 
and progressively closer to the anchor domain (12). Together with polyclonal 
antibodies (Fab fragments), the mutants were analysed for their ability to form surface 
oligomers on their E.coli model, and their ability to promote bacterial adhesion to 
Chang cells. The authors showed that two critical regions present in the globular head 
domain and intra-chain coiled-coil stalk were responsible for NadA-cell receptor 
binding with Chang cells. Fukusawa et al. (2003) developed a mAb against NadA 
expressed in serogroup B OMV (13). The mAb showed bactericidal activity and 
cross-reactivity to serogroup B and C strains from Brazil. It also recognised 




4.2 Project objectives 
 
Antigens presented on GMMA are in their native conformation, and this is what is 
presented to the host during an infection. As discussed in Chapter 2, recombinant 
fHbp induces limited cross-reactivity against fHbp from different sub-families or 
variant groups compared to fHbp natively presented on NOMV or GMMA. While 
recombinant NadA is able to induce cross-protective antibodies against NadA of 
different peptides similarly to NadA natively presented in GMMA. We set out to 
determine the difference of such immunological responses by generating mAbs 
against antigens on GMMA in their native conformation and membrane environment 
as approaches so far have focused on generating mAbs against recombinant fHbp. 
The specific focus was on developing mAbs targeting vaccine candidate antigens 
fHbp and NadA in GMMA in order to better understand the antigenic specificities of 
fHbp and NadA. We also aimed at investigating the antibody repertoire induced by 
GMMA when given with or without Alum. Three fusions were made, and the first 
two fusions were performed using mice immunised with MenA NadR KO cps- 
(generated in Chapter 3) formulated on Alum. The third fusion was performed using a 
mouse immunised with GMMA Triple KO OE fHbp ID9 R41S absorbed to Alum 
(see Materials and Methods 4.2.1). The expansion and production of mAb against the 
fHbp protein is currently underway. Therefore, the focus of this chapter is on the 




1. Production of monoclonal antibodies against NadA allele 3 and fHbp v.1 ID9 




a. Screening of anti-GMMA antibodies by ELISA and Western blot using 
GMMA and recombinant protein. 
b. IgG isotyping. 
c. Evaluation of mAb binding to bacterial cells by immunofluorescence 
(IFA) and flow cytometry.  
d. Evaluation of the functional bactericidal activity of monoclonal 
antibodies by serum bactericidal assay against serogroup A, W and X 

























4.3 Materials and Methods 
 
4.3.1 Vaccine GMMA groups used for immunisation 
Vaccines used for immunisations were GMMA from a Neisseria meningitidis 
serogroup A ST2859 case strain N2602 (NVGH0348_001), PorA P1.20,9, fHbp v.1 
ID5 expressing NadA-3 (MenA NadR KO cps- [Chapter 3]) and GMMA from 
serogroup W carrier strain 1630 ST11, PorA P1.5,2 over-expressing fHbp v.1 ID9 
(Triple KO OE fHbp [generated by Oliver Koeberling]). The fHbp had the R41S 
mutation, which is a single aa substitution Arg at residue 41 replaced by Ser. This 
results in decreased binding of fH (10). Both strains had deleted capsule biosynthesis 
genes, lpxL1, and gna33. We also deleted the gene encoding for the nadA repressor 
nadR. The third vaccine group received rHis-NadA-3 produced and described in 
Chapter 3 section 3.3.3 on page 117. 
   
4.3.2 Monoclonal antibody production 
Eight weeks old Balb/c female mice (3 mice per group) were obtained from Charles 
River. The mice were immunised intradermally with three doses of vaccine given at 
days 1, 21 and 35 (Table 4.1). Two groups of mice received 5µg of GMMA MenA 
NadR KO either absorbed to Alum or not. The third group was immunised with 5µg 
of Triple KO OE fHbp GMMA. These three groups were used for mAb production. 
Two control groups were immunised with 30µg of recombinant rHis-NadA-3 given 
with CpG or SIGMA adjuvant. Blood samples were obtained prior to the first 
immunisation and 14 days after the third immunisation. Three days prior to cell-
fusion (day 49) a final boost was given intravenously with 5µg pure non-adjuvated 
antigen. Vaccines received by two groups of mice were absorbed on 3mg/ml Alum in 
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a 100µl formulation containing 10mM Histidine and 0.9mg/ml NaCl. Terminal blood 
samples were obtained at the day of fusion (day 49). Vaccines were prepared as 
described in Chapter 3 and sterilised prior to formulation by filtration (0.22µm). 
Sterility of the formulations was confirmed by plating 100µl on GC agar (Becton 
Dickinson) and growing over night at 37°C.  
 
 
Table 4.1. Mouse immunisation scheme for monoclonal antibody production.  
CpG and SIGMA adjuvants were obtained from the Swiss Tropical and Public Health Institute. NaCl 
















Alum 5 100 µl ID (IV)b 
MenA NadR KO cps- + 
NaCl 9 mg/ml 
Histidine 10 mM 
Alum hydroxide (3 mg/ml) 
Fusion 2 
2 





- 5 100 µl ID (IV) 
MenA NadR KO cps- 
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(7 - 9) 
His-














Alum 5 100 µl ID (IV) 
GMMA, Triple KO OE fHbp 
NaCl 9 mg/ml 
Histidine 10 mM 
aluminium hydroxide (3 
mg/ml) 
a 2% squalene oil-in-water emulsion, 0.2% Tween 80, LipidA from Salmonella Minnesota and 0.5mg 
synthetic trehalose dicorynomycolate.   
b Two days before fusion with hybridomas, an Intravenous booster (IV) is given to the mice. All other 
immunisations are performed intradermal (ID). 
 
 
One week before the fusion, PAI myeloma cells (obtained in-house from STPHI) 
were cultivated to approximately 1x108 cells in myeloma cell medium (Table 4.2). 
All cells were combined with the same amount of spleen cells from sacrificed mouse 
(1:1 ratio) in a 50ml falcon tube with the addition of PEG 1500 (Roche, Basel, 
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Switzerland) over 1 minute. After 10 minutes incubation at room temperature the 
fused cells were harvested by centrifugation for 10 minutes 1500 rpm and 
resuspended in 150ml HAT medium. The cells were then distributed in 12x96 well 
plates (Costar) with 100µl of cell suspension in each well, and incubated for 10 days 
before screening for GMMA specific IgG producing hybridomas (positive) by ELISA 
coated with 2µg MenA NadR KO cps- or Triple KO OE fHbp GMMA. After the 
initial screening, positive clones were selected and re-cloned in order to obtain 
individual clones in each well. Re-cloning was done by adding 0.3 cell/well (limiting 
dilution) into 10ml HAT medium each and distributed in 96 well plates. The re-
cloned hybridomas were subsequently screened for single positive clones by ELISA 
coated with 2µg MenA NadR KO cps- or Triple KO OE fHbp. Positive clones were 
transferred into a 24 well plate (Techno Plastic Products (TPP), Trasadigen, 
Switzerland). After screening of the clones in the 24 well plates, positive IgG 
producing clones were selected and transferred to 6 well plates (TPP). Subsequently, 
the clones were screened by Western blotting using 10µg MenA NadR KO cps- and 
Triple KO OE fHbp GMMA. Further testing involved screening of positive 
hybridomas growing in the 6 well plates with ELISA and Western blotting using rHis-
NadA-3 or rHis-fHbp v.1 ID9. The hybridoma cells were isotyped to test if they were 
monoclonal. Positive cell lines were subsequently selected for production and grown 
in HAT medium in 150cm2 vented flasks (TPP). The supernatant of the hybridoma 
cells that contain the mAbs were collected by centrifugation for 10 minutes at 










Table 4.2. Medium for cell cultivation. 
 Myeloma medium HAT medium 










Aldrich) 5.5ml 5.5ml 

















4.2.3 ELISA screening of sera and hybridoma supernatant 
 
Screening and isotyping of sera from mice immunised with MenA NadR KO cps- and 
Triple KO OE fHbp GMMA and mAbs was performed as previously described in 
Chapter 3 section 3.3.7 page 126. 4HBX (NUNC-IMMUNOPLATE) plates were 
coated with 2µg of MenA NadR KO cps- and Triple KO OE fHbp GMMA or 5µg 
rHis-NadA-3 and rHis-fHbp v.1 ID9 overnight. Secondary antibodies used for the 
screening and IgG isotyping are listed in Table 4.3. 
 
Table 4.3. Secondary antibodies for ELISA and for IgG isotyping. 
Antibody Dilution Source 
Goat anti-mouse γ (230) 1:20000 Sigma-Aldrich 
Goat anti-mouse γ1 (2400) 1:3000 Southern Biotech (Birmingham, 
Alabama, U.S.A) 
Goat anti mouse γ2a (209) 1:1000 Southern Biotech 
Goat anti-mouse γ2b (2403) 1:1000 Southern Biotech 
Goat anti-mouse γ3 (208) 1:1000 Southern Biotech 
Goat anti-mouse µ (207a) 1:1000 Southern Biotech 





4.3.4 Monoclonal antibody purification and quantification 
Antibody purification was performed following mAb production using affinity 
chromatography over a 5 ml HiTrap Staphylococcal rProtein A FF (for mouse IgG2 
and IgG3 subclass antibody) or Streptococcal protein G column (IgG1) (GE 
Healthcare). Buffers used for the purifications were prepared as listen in Table 4.4. 
Before purification, the BioRad pump system was washed with 20% 50ml ethanol and 
50ml 1xPBS (not filtered). For purification of IgG1 subclass, the filtered supernatant 
was premixed 1:1 with High salt binding buffer to promote binding of the mAbs to 
the column. The filtered supernatant was subsequently loaded with a flow rate of 
3.5ml/min (amplitude sensitivity 1.0). Subsequently, 1xPBS was used to wash the 
system until the base level of absorption (OD) was reached. Elution buffer of pH 3.5 
was used to elute IgG1 subclass and elution buffer pH 2.7 was used for IgG2 and 
IgG3. The elution-fraction was collected and the pH adjusted to 7.0 with Tris-HCl 
buffer. To remove excess antibody, the column was washed with elution buffer pH 
2.2. The eluted fractions were dialysed using a slide-A-lyzer® dialysis cassette G2 
10000 MWCO (Thermofisher Scientific) and 2L 1xPBS overnight at room 
temperature under stirring. Antibody concentration was measured using Pierce BCA 












Table 4.4. Buffers used for monoclonal antibody purification. 
All buffers were filtered through a sterile filter before purification. The chemicals were purchased from 
Sigma-Aldrich unless stated otherwise.  
High salt 
buffer pH 8.9 
Elution 
buffer pH 2.2 
Elution 
buffer pH 2.7 
Elution 
buffer pH 3.5 
Collection 





Citric acid  3.75g Glycine 
360ml 0.1M 






4.38g NaCl 140ml 0.2M Na2HPO4 
100ml dH20 




4.3.5 Immunofluorescence (IFA) 
Strains were cultured as previously described in Chapter 2 for Western blot analysis 
section 2.3.4 page 62 before diluting the cell suspension 1:100 in 1xPBS+1% BSA 
(Sigma-Aldrich; Table 4.5). 10µl of the cell suspension was added to each well on the 
10 well diagnostic microscope slide (Thermofisher Scientific) and mixed with 30µl 
fixing solution (4% neutral buffered formalin; DiaPath, Martinengo, Italy). After 30 
minutes incubation in a humid chamber at room temperature, the solution was 
removed and washed 5 times with 50µl 1xPBS. Following blocking of the wells with 
50µl 1xPBS+1%BSA for 30 minutes, the blocking solution was removed and 30µl/ 
well of 1mg/ml mAb or sera from mice immunised with MenA NadR KO cps- were 
added and incubated in a humid chamber for 1 hour before washing 5 times with 50µl 
blocking buffer 1xPBS+1%BSA. Subsequently, 30µl of 1:400 diluted secondary 
antibody Alexa Fluor 568 donkey anti-mouse antibody (emission 578⁄603nm;!Sigma-
Aldrich) was added. After 1 hour, the wells were washed 5 times with 50µl 1xPBS, 
and mounting solution (Prolong Gold antifade reagent with DAPI staining, 
Invitrogen) was added to the slides before fitting with a glass slide cover. 
!
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Fluorescence microscopy was performed on a Leica DM-5000B using a X60 oil 
immersion objective lens and documented with a Leica DFC300FX digital camera 
system. Images were processed using the Leica Application Suite.  
 
4.3.6 Flow cytometry 
Strains were cultured as previously described in Chapter 2 for Western blot analysis 
section 2.3.4 page 62 (Table 4.5). 1ml of the culture was diluted with 5ml Dulbecco’s 
phosphate buffered saline (DPBS; Sigma-Aldrich), centrifuged 5 minutes at 5000rpm, 
pellet resuspended in 1ml 4% formalin and incubated for 30 minutes at room 
temperature to inactivate the bacteria. After inactivation, the suspension was 
centrifuged for 5 minutes at 5000rpm and the pellet re-suspended with 5ml 0.5% 
BSA-DPBS (Sigma-Aldrich) and stored at 4°C for 30 minutes. 100µl of the cells were 
incubated with mAb at a concentration of 25mg/ml for 1 hour at room temperature 
before the cells were collected. Subsequently, 100µl of the secondary antibody Alexa 
Fluor 488-conjugated goat anti-mouse heavy and light chain IgGs specificity 
(emission 488/519nm; Invitrogen) at a 1:200 dilution was added for 1 hour at room 
temperature. After collection, the cell pellets were resuspended in 400µl FACS flow 
(Beckton Dickinson (BD)) and surface staining was detected by FACS calibur (BD) 
FL2-H channel and analysed using the software Cell quest pro version 5.2.1 (BD).  
 
To ensure that the experiments were correctly performed, initially unlabelled cells 
were run through the flow cytometer. Following this the FS and SS parameter 
voltages were adjusted to enable appropriate gating of cells so at least 30000 events 
were recorded within the gated region. To ensure consistency of the data, each isolate 
preparation was labelled with secondary antibody alone, to ensure there was no 
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staining of the cells with the dye. The two controls were also used to ensure the 
reading was placed in the first decade for each experiment. The same protocol and 
controls was used for all experiments in this study ensuring intra-experimental 
consistency. The data were plotted in a one-dimensional histogram format.  
 
 
4.3.7 Bactericidal assay  
The assay was performed as previously described for SBA using human complement 
in Chapter 2 section 2.3.5 page 63 and baby rabbit complement in Chapter 3 section 
3.3.8 page 126. Isolates used are listed in Table 4.5. The source of complement was 
human serum from a healthy individual with no detectable bactericidal activity 
against the test strains. The serum was depleted of IgG over a 5 ml HiTrap 
Staphylococcal rProtein G FF column and displaced with equal amounts of 1xPBS, 
and filter sterilised. Antibody depletion was confirmed using Pierce BCA protein 
assay kit (Thermofisher Scientific). Total haemolytic activity before and after 















Table 4.5. Panel of isolates selected for IFA, flow cytometry and serum bactericidal activity 
analysis. 
* Strains used in IFA analysis.  







































2007 1 5 P1.20,9 3 100.0 2859 
W Ghana 7/04 Ghana 2004 2 23 P1.5,2 3 57.6 11 
W Mali 10/09*§ Mali 2009 2 23 P1.5,2 2 100.0 11 
X MRS2008223*§ 
Burkina 
Faso 2007 1 74 
P1.5-





4.4.1 Selecting mice suitable for fusion based on the nature of their 
immune response  
 
In this study, three fusions were performed to generate mAb against natively 
expressed NadA, fHbp and other OMP in GMMA. We also included two control 
groups: rHis-NadA given with CpG or SIGMA adjuvant. These two control groups 
were used to compare the immune responses elicited against recombinant NadA and 
that towards GMMA. The mice were bled 14 days after the third immunisation, and 
the sera were characterised by ELISA and SBA to determine the mouse with the 
highest antibody titres to GMMA (MenA NadR KO cps-, Triple KO OE fHbp) and 
recombinant protein (rHis-NadA-3, rHis-fHbp ID9). We also characterised the sera by 
Western blotting to determine if a band was seen for the corresponding vaccine 
antigens fHbp or NadA. With these tests, we also wanted to understand the effect of 
adjuvant on the immune responses induced to GMMA alone and GMMA formulated 
with Alum in terms of Western blotting profile and titres obtained in an ELISA and 
SBA measurement.  
 
ELISA analysis showed that the MenA NadR KO cps- GMMA preparation not 
absorbed to Alum elicited higher specific antibody titres (not significant) compared to 
the respective Alum absorbed group when the ELISA plate was coated with this 
vaccine (Figure 4.2, Panel B). On the contrary, when the plate was coated with rHis-
NadA-3, the mice immunised with rHis-NadA-3+CpG and rHis-NadA-3+SIGMA 
generated the highest titres most likely due to dosage effect (Figure 4.2, Panel A). 
These two adjuvants are known to induce high antibody titres in mice when measured 
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in an ELISA compared to recombinant proteins absorbed on Alum (14). When anti-
NadA antibody responses were measured, MenA NadR KO cps- GMMA alone 
elicited higher titres (not significant) than MenA NadR KO cps-+Alum (Panel B). 
ELISA analysis of the sera generated from all three mice immunised with Triple KO 
OE fHbp v.1 ID9 absorbed to Alum showed that all of the mice had similar antibody 




Figure 4.2. ELISA analysis of sera from mice immunised with rHis-NadA-3 formulated with 
CpG or SIGMA adjuvant and MenA NadR KO cps- GMMA absorbed to Alum or without.   
ELISA plates were coated with 5µg of rHis-NadA-3 (Panel A) and 2µg of MenA NadR KO cps- 
GMMA (Panel B). Pre-bleed serum was used as negative control and polyclonal rHis-NadA-3 serum 
(NV&D) as positive control. Each symbol represents a mouse serum sample. GMMA used for 
immunisation: MenA NadR KO cps- and MenW NadR KO cps- (nadR, capsule, lpxL1 and gna33 KO); 
recombinant Hexa-Histidine tagged rNadA allele 3. Error bars represent standard error. Statistical 














Figure 4.3. ELISA analysis of sera from mice immunised with Triple KO OE fHbp variant 1 ID9 
R41S GMMA absorbed to Alum.   
ELISA plates were coated with 2µg of Triple KO OE fHbp GMMA (Panel A) or 5µg of rHis-fHbp v.1 
ID9 (Panel B). Each symbol represents one mouse labelled 1, 2 and 3. GMMA used for immunisation: 
Triple KO OE fHbp (capsule, lpxL1 and gna33 KO, over-expressed fHbp variant 1 ID9). Error bars 









To further investigate the Th antibody responses generated by the vaccine groups, IgG 
isotyping was performed on mouse serum. Antibodies of subclass IgG2a were most 
predominant in mice immunised with rHis-NadA-3+CpG (Figure 4.4, Panel A) while 
the vaccine group rHis-NadA-3+SIGMA generated mostly IgG1 subclass antibodies 
(Panel B). This has previously been reported for these adjuvants (16,17). In mice 
immunised with GMMA MenA NadR KO cps-+ Alum, antibodies of IgG2b and IgG1 
subclass were mostly predominant (Panel C), while mice immunised with MenA 





Figure 4.4. IgG isotyping of mouse sera from mice immunised with rHis-NadA-3 formulated with 
CpG and SIGMA adjuvant and MenA NadR KO cps- GMMA formulated with Alum and 
without.  




Western blotting analysis of the individual mouse sera from mice immunised with 
MenA NadR KO cps- formulated with Alum and without generated two different 
immune response profiles in terms of the bands visualised. Strongest bands for the 
MenA NadR KO cps- + Alum group were around 38-62kDa, while for the MenA 
NadR KO cps- alone bands at 170kDa were most prominent. A common band for all 
vaccine groups was observed at around 170kDa that represents oligomeric NadA 
(Figure 4.5). In comparison, Western blot analysis of the sera of mice immunised 
with Triple KO OE fHbp revealed a single strong band at 28kDa both in the blot with 
GMMA (Figure 4.6, Panel A) and the blot with recombinant fHbp (Panel B). This 
band represents fHbp as the polyclonal anti-fHbp antibodies showed a band at this 
size. The mouse number 2 showed the strongest band for the recombinant fHbp blot 
(Panel B). Therefore, this mouse was selected for fusion, which is currently under 
progress. Western blot results show that immune responses elicited by the Triple KO 
OE fHbp GMMA were mostly towards fHbp, while the MenA NadR KO cps- 





Figure 4.5. Western blot analysis of sera from mice immunised with rHis-NadA-3 formulated 
with CpG or SIGMA adjuvant and MenA NadR KO cps- GMMA absorbed to Alum (MenA + 
Alum) or without (MenA).   
The blot was prepared with 5µg of MenA NadR KO cps- GMMA. Each strip 1-13 represent serum 
from individual mice [mouse 1 rHis-NadA-3 + CpG group (strip 1), mouse 2 rHis-NadA-3 + CpG2 
(strip 2), rHis-NadA-3 + CpG3 (3), rHis-NadA-3 + SIGMA1 (4), rHis-NadA-3 + SIGMA2 (5), rHis-
NadA-3 + SIGMA3 (6), MenA NadR KO cps- + Alum1 (7), MenA NadR KO cps- + Alum2 (8), MenA 
NadR KO cps- + Alum3 (9), MenA NadR KO cps- 1 (10), MenA NadR KO cps- 2 (11), MenA NadR 








Figure 4.6. Western blot analysis of sera from mice immunised with Triple KO OE fHbp ID9 
R41S GMMA absorbed to Alum.   
The blots were prepared with 10µg of Triple KO OE fHbp ID9 R41S GMMA and 10µg of rHis-fHbp 
ID9. Each number represents mouse 1, 2 and 3. Lane 4 for panel A, poly-GMMA OE fHbp v.1 was 
added while for panel B poly rHis-fHbp v.1 was added. Sera were diluted 1:100 in 1% milk + 1xPBS. 
Blots were exposed for 5 minutes.  
 
The SBA responses of the antisera of mice immunised with MenA NadR KO cps- and 
rHis-NadA3 was assessed against the serogroup W isolate Ghana7/04 with 
heterologous PorA P1.5,2 and fHbp v.2 ID23, grown with and without the presence of 
4HPA. 4HPA is an aromatic metabolite in the human saliva that relieves NadR 
repression of NadA expression. Using 4HPA in the growth medium simulates in vitro 
the niche signal for meningococci present in the nasopharynx. GMMA from the 
MenA NadR KO cps- recombinant strain induced bactericidal antibodies that were 
able to kill the serogroup W isolate expressing intermediate amounts of NadA 
(geometric mean titre [GMT]=4008) (Figure 4.7, Panel A). Lower titres, but not 
significant, were seen for the MenA NadR KO cps- GMMA group formulated with 
Alum (GMT=391). When 4HPA was added to increase NadA expression from 58% 
to 82%, again the MenA NadR KO cps- GMMA group elicited the highest 
bactericidal titres (GMT=121874) compared to the MenA NadR KO cps-+Alum 
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group (GMT=76528) (Figure 4.7, Panel B). From these results, mouse number two 
of both MenA NadR KO cps- alone and MenA NadR KO cps-+Alum group were 
selected for fusion as they showed highest bactericidal titres in each group (number 8 
and 11 in Figure 4.5).  
 
 
Figure 4.7. Complement-mediated bactericidal activity of sera from mice immunised with rHis-
NadA-3 formulated with CpG or SIGMA adjuvant and MenA NadR KO cps- GMMA absorbed 
to Alum or without.  
Each symbol represents reciprocal serum titre (50% killing of bacteria) of serum from a mouse using 
baby rabbit complement. Panel A: isolate Ghana7/04 grown without 4HPA; Panel B: isolate Ghana7/04 
grown in the presence of 4HPA. The serum samples used in the analysis were obtained 2 weeks after 
the third vaccine dose. The line indicates the GMT of each vaccine group. Error bars indicate ±95% 
confidence interval of the GMT. GMMA used for immunisation: MenA NadR KO cps- (nadR, capsule, 
lpxL1 and gna33 KO); recombinant Hexa-Histidine tagged rNadA allele 3. Statistical analysis was 









4.4.2 Summary of mAbs generated from fusion with NadA and fHbp 
GMMA 
We obtained 25 hybridoma clones producing GMMA-binding mAbs from fusions 1 
and 2 of mice immunised with MenA NadR KO cps- GMMA formulated with Alum 
and without Alum. From fusion 1 and 2, 4 mAbs were specific for NadA and they 
were of the immunoglobulin subclasses IgG1, IgG2a/b and IgG3 (3 from fusion 1). 
The other 21 mAbs were specific for seven other unknown surface exposed antigens 
on GMMA (2 from fusion 1 of IgG1 and IgG2b subclass (Table 4.6 [fusion 1], Table 
4.7 [fusion 2]). These antigens were numbered according to the number of bands seen 
in the Western blot analysis with MenA NadR KO cps- GMMA (Figure 4.8) starting 
from the top (1:NadA) to the last band at 3 kDa (10). From fusion 3 with Triple KO 
OE fHbp ID9 R41S GMMA, we obtained eight hybridoma clones, of which 4 were 
specific for fHbp of IgG subclass IgG1 as determined by ELISA and Western blotting 
(Table 4.8). The other four mAbs of the IgG2a subclass were specific for two other 
GMMA antigens. The results suggest that GMMA alone generates a wider immune 
response and antibody repertoire compared to GMMA formulated on Alum.  
 
 
Table 4.6. Fusion 1 monoclonal antibodies generated from a mouse immunised with MenA NadR 
KO cps- GMMA formulated with Alum.  
Molecular weights are given as approximations from Western blot results. 
Monoclonal antibody Protein number Molecular weight (kDa) IgG isotype 
3B10/F8 1: NadA 170 IgG3 
5A5/F3 1: NadA 170 IgG2b 
11H6/E9 1: NadA 170 IgG1 
1D11/C3 4 45 IgG1 







Table 4.7. Fusion 2 monoclonal antibodies generated from a mouse immunised with MenA NadR 
KO cps- GMMA. 
The vaccine was not formulated with Alum. Molecular weights are given as approximations from 
Western blot results. 
Monoclonal antibody Protein number 
Molecular weight 
(kDa) IgG isotype 
1F12/F6 1: NadA 170 IgG2a 
10F9/H9 2 100 IgG2b 
10A6/B7 3 49 IgG2a 
6H9/F3 4 45 IgG1 
6H9/D6 4 45 IgG1 
6H9/D6 4 45 IgG1 
7F11/F2 4 45 IgG2a 
2C8/F6 5 38 IgG2b 
2F12/A1 5 38 IgG2a 
4G1/D3 5 38 IgG2b 
4H5/F6 5 38 IgG2b 
8D3/D1 5 38 IgG2a 
5H4/G7 5 38 IgG1 
6G9/G10 5 38 IgG3 
4H5/F9 5 38 IgG2b 
10E2/E7 5 38 IgG3 
4G1/A7 8 8 IgG2b 
6H9/C2 8 8 IgG1 
3E7/D7 9 6 IgG2a 
2B9/F4 9 6 IgG2a 





























Figure 4.8. Representative Western blot analysis of monoclonal antibodies generated from fusion 
1 and 2 of splenocytes from mice immunised with MenA NadR KO cps- + Alum and MenA NadR 
KO cps- GMMA, respectively. 
The blots were prepared with 10µg of MenA NadR KO cps-. 1µg/ml mAbs were added to 1% milk + 
1xPBS. Exposure of the blot was for 5 minutes. Each strip 1-17 represents a mAb or serum from 
individual mice [3B10/F8 (strip 1), 5A5/F3 (2), 11H6/E9 (3), 1G10/D6 (4), 1D11/C3 (5), 2C8/F6 (6), 
2F12/A1 (7), 4G1/D3 (8), 4H5/F6 (9), 6H9/F3 (10), 7F11/F2 (11), 8D3/D1 (12), 6H9/D6 (13), 5H4/G7 









Table 4.8. Fusion 3 monoclonal antibodies generated from a mouse immunised with Triple KO 
OE fHbp v.1 ID9 R41S GMMA. 
Monoclonal antibody Protein number 
Molecular weight 
(kDa) IgG isotype 
9F1/A3 1 38 IgG2a 
10D3/H11 1 38 IgG1 
9G5/E5 1 38 IgG2a 
9H4/F3 2: fHbp 28 IgG1 
9H5/H5 2: fHbp 28 IgG1 
9F7/B11 2: fHbp 28 IgG1 
11C6/C2 2: fHbp 28 IgG1 
9A1/A3 3 17 IgG2a 
 
 
4.4.3 Binding specificity of mAbs from fusion 1 and 2 of mice 
immunised with MenA NadR KO cps- GMMA 
From fusion 1, the three anti-NadA mAbs of IgG1, IgG2b and IgG3 subclass showed 
broad reactivity with differences in binding in Western blotting analyses using a panel 
of 44 N. meningitidis serogroup A (n=13), W (n=20) and X (n=11) strains (Table 4.9, 
Figure 4.9). Most isolates were of NadA-3 except the sergroup W isolate Mali 10/09, 
which expresses NadA-2. The isolates exhibited varying NadA expression from low 
to high as determined in Chapter 3 Figure 3.3. The 3B10/F8 mAb of IgG3 subclass 
showed specific binding to two serogroup A and four W isolates while the other two 
anti-NadA mAbs both reacted with 87 % of A strains and 65% of W strains. None of 
the anti NadA mAbs reacted with serogroup X strains that expressed NadA-3. The 
mAbs against protein 4 or 5 only bound to whole cell lysates prepared from the 











Table 4.9. Specificity of monoclonal antibodies generated from fusion 1 from a mouse immunised 
with MenA NadR KO cps- +Alum GMMA. 
Summary of Western blotting results with whole cell lysates. Preparation of whole cell lysates was 











3B10/F8 1: NadA IgG3 2 (13%) 4 (20%) - 
5A5/F3 1: NadA IgG2b 13 (87%) 13 (65%) - 
11H6/E9 1: NadA IgG1 13 (87%) 13 (65%) - 
1D11/C3 4 IgG1 1 (6%) - - 






Figure 4.9. Representative Western blot of mAbs 5A5/F3 and 2B9/F4 generated from fusion 1 
and 2 of mice immunised with MenA NadR KO cps- + Alum and MenA NadR KO cps- GMMA, 
respectively, against African serogroup A, W and X isolates. 
The blots were prepared with 20µg of whole cell lysate per lane. 1µg/ml mAbs were added to 1% milk 
+ 1xPBS. Exposure of the blot was for 5 minutes. Panel A: anti-NadA 5A5/F3 mAb produced from a 
spleen of the mouse immunised with MenA NadR KO cps- + Alum against serogroup W [Ghana 7/04 
(1), BF10/02 (2), Nigeria1/03 (3), Mali 10/09 (4)], X [MRS2006078 (5), MRS2006087 (6), 
Uganda11/07 (7), MRS2008223 (8)] and A [Su14/07 (9), Mali21/07 (10), BF6/06 (11), BuFa20030020 
(12), Mali21/10 (13), N2602 (14)] isolates. Panel B: anti-protein 9 2B9/F4 mAb produced from the 
spleen of a mouse immunised with MenA NadR KO cps- against serogroup A [BF8/01 (1), MK804/03 
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(2), BF3/06 (3), BF6/06 (4), BuFa20030020 (5), Mali21/07 (6), Su14/07 (7), MRS2007446 (8), 
MRS2008162 (9), Niga16/09 (10), BF1/10 (11), Tch44/10 (12), Mali21/10 (13)] isolates.  
 
From fusion 2 the anti-NadA mAb 1F12/F6 of IgG2a subclass showed reactivity only 
against serogroup A strains (Table 4.10). The other mAbs directed against unknown 
antigens also showed binding specificity to serogroup A isolates only. The mAbs 
2F12/A1 (IgG2a, protein 5), 4H5/F9 (IgG2b, protein 5), 4G1/A7 (IgG2b, protein 8) 
and 4H5/D2 (IgG2b, protein 10) did not bind to any whole cell lysates, which could 
suggests that the mAbs are very specific or the target conformational epitopes may 
have been destroyed upon preparation of the lysates with SDS-PAGE. The mAbs 
4G1/A7 and 4H5/D2 did show surface binding by IFA analysis (Figure 4.10, Panel 
B). Future analysis of their binding to live bacteria by flow cytometry was performed 
to confirm the hypothesis (section 4.3.4). Moreover, Western blotting as a technique 
may not be sensitive enough for certain mAbs targeting unknown antigens if the 
















Table 4.10. Specificity of monoclonal antibodies generated from fusion 2 from a mouse 
















1F12/F6 1: NadA IgG2a 11 (73%) - - 
10F9/H9 2 IgG2b 1 (6%) - - 
10A6/B7 3 IgG2a 13 (87%) - - 
6H9/F3 4 IgG1 12 (80%) - - 
6H9/D6 4 IgG1 12 (80%) - - 
7F11/F2 4 IgG2a 13 (87%) - - 
2C8/F6 5 IgG2b 13 (87%) - - 
2F12/A1 5 IgG2a - - - 
4G1/D3 5 IgG2b 13 (87%) - - 
4H5/F6 5 IgG2b 1 (6%) - - 
8D3/D1 5 IgG2a 1 (6%) - - 
5H4/G7 5 IgG1 6 (40%) - - 
6G9/G10 5 IgG3 7 (47%) - - 
4H5/F9 5 IgG2b - - - 
10E2/E7 5 IgG3 13 (87%) - - 
4G1/A7 8 IgG2b - - - 
6H9/C2 8 IgG1 12 (80%) - - 
3E7/D7 9 IgG2a 12 (80%) - - 
2B9/F4 9 IgG2a 10 (67%) - - 
4H5/D2 10 IgG2b - - - 
 
 
4.4.4 Immunofluorescence assay binding of monoclonal antibody to 
panel of African serogroup A, W and X isolates 
To determine whether the mAbs generated from fusion 1 and 2 bind to whole 
bacteria, we analysed their immunofluorescence assay (IFA) binding to a set of 
meningococcal serogroup A (n=1), W (n=2) and X (n=1) strains from Africa. All anti-
NadA mAbs showed surface binding to vaccine serogroup A N2602, expressing 
NadA-3 (Figure 4.10, Panel A) and serogroup W strain Mali10/09 expressing NadA-
2, suggesting that the mAbs are cross-reactive between NadA encoded by these alleles 
(Figure 4.11, Panel A). However, the anti-NadA mAbs did not bind to the serogroup 
X isolate MRS2008223, which expresses NadA-3 (Figure 4.11, Panel B). These 
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results have two possible explanations; firstly MRS2008223 is a low expresser of 
NadA (27%) compared to N2602 and Mali10/09, which are both high expressers 
(both 100%). Therefore, the amount of NadA on the surface of MRS2008223 might 
not be sufficient to generate fluorescence due to the lack of sensitivity of IFA. 
Secondly, the anti-NadA mAbs may be directed to specific epitopes shared by only 
some subtypes of NadA-3 and not present in the serogroup X isolate. The mAbs 
1D11/C3 (IgG1, protein 4), 4H5/F6 (IgG2b, protein 5), 4G1/A7 (IgG2b, protein 8), 
2B9/F4 (IgG2a, protein 9), 4H5/D2 (IgG2b, protein 10) targeting unknown antigens 
also showed surface binding against vaccine serogroup A N2602 strain, highlighting 
that these proteins are surface located and distributed across the bacterial surface 











Figure 4.10. Immunofluorescence staining of formalin fixed serogroup A N2602 bacteria with 
anti-NadA mAbs and mAbs against protein 4, 5, 8, 9 and 10. 
Panel A: binding of anti-NadA mAbs against NadA-3 on sergogoup A isolate N2602 expressing fHbp 
v.1 ID5, PorA P1.20,9; Panel B: binding of mAbs against unknown proteins on N2602. Polyclonal 
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serum used was from mice immunised with MenA NadR KO cps- GMMA. Exposure times were 
identical for all pictures of the same channel. Nuclei were stained with DAPI (blue). Original 




Figure 4.11. Immunofluorescence staining of formalin fixed serogroup W Mali10/09 and X 
MRS2008223 bacteria with anti-NadA mAbs. 
Panel A: binding of anti-NadA mAbs against NadA-3 on sergogoup W isolate Mali10/09 expressing 
NadA-2, fHbp v.2 ID23, PorA P1.5,2; Panel B: binding of mAbs against serogroup W MRS2008223 
expressing NadA-3, fHbp v.1 ID74, PorA P1.5-1,10-1. Exposure times were identical for all pictures of 






4.4.5 Flow cytometric assessment of monoclonal antibody binding to 
African N. meningitidis serogroup A, W and X isolates  
To investigate whether the anti-NadA mAbs generated bind to live bacteria, we 
stained two serogroup A, one W and one X isolates with all mAbs from fusion 1 and 
2 and analysed the population of cells positively or negatively stained by FACS. Anti-
NadA mAbs of subclass 5A5/F3, 11H6/E9 and 1F12/F6 showed better binding to the 
vaccine strain serogroup A N2602 and serogroup W isolate Mali10/09 than 3B10/F8 
(Figure 4.12, Panel A and C). MK804/03 is, like the serogroup X isolate 
MRS2008223, a low expresser of NadA, which may be one reason for decreased 
binding (Panel B). None of the anti-NadA mAbs showed binding to serogroup X 
MRS2008223 (Panel D). Only mAb 1F12/F6 stained the second serogroup A isolate 
tested MK804/03 (Panel B). The results suggest that the ability of the different anti-
NadA mAbs are dependent upon the NadA expression level on the bacterial surface, 





Figure 4.12. Histogram plots of serogroup A, W and X isolates stained with anti-NadA mAbs. 
Alexa Fluor 488 secondary antibody was used to label the cells. Gating was set at 30000 events. 
 
To better understand the properties of protein 4, we stained bacterial cells with 4 
mAbs (3 from fusion 2 [GMMA]) directed against this protein. All mAbs were able to 
bind serogroup A isolates N2602 and MK804/03 (Figure 4.13, Panel A and B). No 
binding was observed for the serogroup W isolate Mali10/09 and serogroup X 
MRS2008223. Further flow cytometry analysis was performed with 10 mAbs (4 from 
fusion 2 [GMMA alone]) directed against protein 5. MAbs 8D3/D1, 4H5/F6, 
1G10/D6 (fusion 1 GMMA+Alum) were able to bind to N2602 and MK804/03 
serogroup A isolates (Figure 4.14, Panel A and B). In comparison, both 5H4/G7 and 
6G9/G10 mAbs from fusion 2 had lower ability to bind both serogroup A isolates. 
Likewise, the anti-protein 5 mAbs 2C8/F6, 2F12/A1, 4G1/D3 and 4H5/G9 bound 
N2602 and MK804 except 10E2/E7 (Figure 4.15, Panel A and B). The mAbs 
directed against protein 2, 3 and 10 were able to bind the serogroup A isolates 
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(Figure 4.16, Panel A and B), and only one mAb 4H5/D2 stained the serogroup W 
cells (Panel C). MAbs against protein 8 bound both serogroup A isolates, and mAb 
4G1/A7 was also able to bind serogroup W Mali10/09 (Figure 17, Panel A-C). 
Overall, only mAbs 4G1/A7, 4H5/D2, 2F12/A1, 2C8/F6, 4H5/G9, 4H5/F6, 8D3/D1, 
2B9/F4, 3E7/D7 directed against unknown surface antigens showed binding to the 
serogroup W isolate. The anti-protein 9 mAb 2B9/F4 was the only mAb that bound all 
isolates (Figure 4.18, Panel A-D). None of the other mAbs tested that were directed 
at non-NadA antigens bound to the serogroup X isolate tested, suggesting that either 
the genetic diversity of these proteins affects cross-reactivity or the expression level 
of them in the X isolate is not sufficient to stain cells to detectable levels by flow 
cytometry.   
 
Figure 4.13. Histogram plots of serogroup A, W and X isolates staining with anti-protein 4 mAbs. 





Figure 4.14. Histogram plots of serogroup A, W and X isolates staining with anti-protein 5 mAbs. 








Figure 4.15. Histogram plots of serogroup A, W and X isolates staining with anti-protein 5 mAbs. 










Figure 4.16. Histogram plots of serogroup A, W and X isolates staining with anti-protein 2, 3 and 
10 mAbs. 






Figure 4.17. Histogram plots of serogroup A, W and X isolates staining with anti-protein 8 mAbs. 








Figure 4.18. Histogram plots of serogroup A, W and X isolates staining with anti-protein 9 mAbs. 













4.4.6 Bactericidal activity of mAbs from fusion 1 and 2 against 
African meningococcal A, W and X isolates   
The SBA responses elicited by the mAbs generated from fusion 1 and 2 were firstly 
assessed against the vaccine serogroup A strain N2602 using baby rabbit complement 
(Figure 4.19). The results showed that out of the 25 mAbs generated, all four anti-
NadA mAbs of IgG1, IgG2a/b and IgG3 subclass were bactericidal against the 
serogroup A isolates N2602 (Panel A). Only mAbs 10A6/B7 targeting protein 3 
(IgG2a), 1D11/C3 and 7F11/F2 specific for protein 4 (IgG1 and IgG2a) and 1G10/D6 
and 2B9/F4 (IgG2b and IgG2a) specific for proteins 5 and 9, respectively, were 
bactericidal against the second serogroup A isolate MK804/03 (Panel B). mAbs 
10/A6/B7, 7F11/F2 and 2B9/F4 also killed the serogroup W isolate Mali10/09 (Panel 
C). None were bactericidal against the X isolate MRS2008223 (Panel D). The 
bactericidal activity of these mAbs was further assessed using human complement 
against the same serogroup A, W and X isolates. Likewise, all the mAbs were able to 
kill the vaccine strain N2602 with human complement as source (Figure 4.20, Panel 
A). Against serogroup A isolate MK804/03, bactericidal titres were again elicited by 
mAbs 10A6/B7, 1D11/C3, F11/F2, 1G10/D6 and 2B9/F4 (Panel B). None of the anti-
NadA mAbs showed bactericidal activity against MK804/03 consistent with results 
each of binding obtained from the IFA and flow cytometry analyses. The low NadA 
expression of the strain may account for the inability of the mAbs to cross-link IgG 
antibodies and activate the complement cascade. Lack of bactericidal activity of all 
mAbs was also seen against the serogroup W Mali10/09 and serogroup X 
MRS2008223 isolates expressing high and low amounts of NadA-2 and 3, 
respectively (Panel B and D respectively). This is despite the fact that the mAbs bind 
to NadA of the serogroup W isolate in Western blotting, flow cytometry and IFA 
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analyses. The results suggest that the ability of the mAbs to trigger serum bactericidal 
activity is specific with regards to the presence of specific epitopes and the expression 
level of NadA. mAbs of murine IgG subclass IgG2a produced the highest bactericidal 
titres in this study compared to the other subclasses. This may have implications for 











Figure 4.19. Bactericidal responses using baby rabbit complement and monoclonal antibodies 
generated from mice immunised with MenA GMMA NadR KO cps- GMMA formulated with 
and without Alum against African meningococcal strains.  
The mAbs generated from fusion of the spleenocytes of mice immunised with with the MenA NadR 
KO cps- GMMA formulated with Alum and without any adjuvant were tested against serogroup A 
vaccine strain N2602 (panel A) expressing high amounts of NadA-3, serogroup A MK804/03 (panel B) 
isolate expressing low amounts of NadA-3, serogroup W Mali10/09 (panel C) expressing high amounts 
of NadA-2 and serogroup X MRS2008223 (panel D) expressing low levels of NadA-3. The 
bactericidal responses were measured using baby rabbit complement as source (see Materials and 
Methods Chapter 3). Each symbol represents a SBA measurement of a mAb. Sera G1 was obtained 
from the final bleed of the mouse used for Fusion 2. The line indicates the geometric mean titre (GMT) 





Figure 4.20. Complement-mediated bactericidal responses of monoclonal antibodies generated 
from fusion 1 and 2 against African meningococcal strains.  
The mAbs generated from fusion of the spleenocytes of mice immunised with the MenA NadR KO 
cps- GMMA formulated with Alum and without any adjuvant were tested against serogroup A vaccine 
strain N2602 (panel A) expressing high amounts of NadA-3, serogroup A MK804/03 (panel B) isolate 
expressing low amounts of NadA-3, serogroup W Mali10/09 (panel C) expressing high amounts of 
NadA-2 and serogroup X MRS2008223 (panel D) expressing low levels of NadA-3. The bactericidal 
responses were measured with human complement. ACWY conjugate polysaccharide vaccine is 
coupled to diphtheria CRM197 and developed by Novartis vaccines (NV&D Vaccine Chemistry). Each 
symbol represents a SBA measurement of a mAb. The line indicates the GMT of each group. Error 





GMMA is a new vaccine platform currently under investigation as approach against 
meningococcal disease in Africa. An in-depth evaluation of the immunological 
responses generated against GMMA and the antigens presented on it have not been 
performed. As an approach to better understand this, we generated mAbs against 
surface exposed antigens from Balb/C mice immunised with MenA NadR KO cps- 
formulated with Alum and without, and GMMA from a group W strain with deleted 
lpxL1, gna33, capsule and over-expressed fHbp ID9 R41S (Triple KO OE fHbp). The 
aim was to generate mAbs against NadA-3, fHbp v.1 ID9 and other antigens on 
GMMA, characterise the fine specificity and activity of NadA and fHbp specific 
antibodies and mine for other immunogenic/immunodominant antigens that elicit 
bactericidal antibodies for future vaccine design. The sera generated from the 
immunisations described above showed different immune profiles when antigen 
specificities were visualised on Western blot loaded with MenA NadR KO cps- and 
Triple KO fHbp GMMA. Analysis of the sera from the MenA and MenW GMMA 
groups formulated with Alum showed that the immune responses were mostly 
targeted towards the main vaccine antigen NadA or fHbp. The MenA NadR KO cps- 
GMMA alone group had a wider spectrum of bands on the Western blot, and elicited 
highest titres in an ELISA when assessed against MenA NadR KO cps- GMMA. 
Similarly, the MenA NadR KO cps- serum was more bactericidal than the sera of 
mice immunised with GMMA group absorbed to Alum. This was also observed when 
the serogroup W isolate was grown in the presence of 4HPA. There could be several 
explanations for this observation. For example, the absorption of GMMA on Alum 
could affect the structure of the GMMA thus leading to the generation of a different 
antibody repertoire compared to GMMA alone. Adjuvants are known to modulate the 
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immune response against antigens by creating a depot effect, targeting immune cells 
or increasing the production of certain cytokines. Although aluminum salts are 
extensively used in vaccine formulations, their mechanism of action and effect on 
GMMA structure and stability has not been explored. Jones et al. (2005) observed, 
based on spectroscopic and differential scanning calorimetry studies, that the structure 
of proteins absorbed to Alum were altered rendering the proteins less thermally stable 
(18). The authors also observed that the absorptive strength and amount of Alum 
affected protein structure. GMMA consists mostly of lipids and outer membrane 
proteins (19). Thus, hypothetically GMMA absorbed to Alum may make the proteins 
on the vesicle surface less accessible to antigen presenting cells or more destabilised 
upon absorption. Chemical changes of the proteins such as deamidation and oxidation 
may also be a possibility. This could in turn explain the different pattern visualised on 
the Western blots. Moreover, GMMA is likely to be used in man in conjunction with 
Alum for safety reasons, as Alum is also an absorbant for free LPS, which with Alum 
is released more slowly. GMMA without Alum could present more LPS to the 
immune system, thus enhancing the immune response, which could be an additional 
explanation for the ELISA and Western blot results.  
 
We generated 25 mAbs from the spleens of mice immunised with MenA NadR KO 
cps- formulated on Alum and without, and Triple KO OE fHbp + Alum. Western 
blotting, IFA and flow cytometry analysis with these mAbs showed limited cross-
reactivity of the anti-NadA mAbs against other meningococcal serogroup A isolates 
than the vaccine A strain N2602. Some cross-reactive binding of the anti-NadA mAbs 
was seen against serogroup W strains, but none against serogroup X strains. The other 
mAbs specific for unknown surface antigens showed a broader reactivity against both 
serogroup A isolates N2602 and MK804/03 isolates. A few mAbs also cross-reacted 
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with the serogroup W isolate Mali/10/09. Only one mAb 2B9/F4 specific for protein 9 
showed staining in the flow cytometry analysis against the serogroup X isolate 
MRS2008223. When human complement was used as a source, the anti-NadA mAbs 
were only bactericidal against the vaccine serogroup A strain N2602, while the other 
5 mAbs showed cross-reactivity against a second A strain MK804/03. The results 
suggest that there is microheterogeneity within the subtypes of NadA. Some mAbs 
bind to specific epitopes, while others bind to epitopes shared across several subtypes 
that may or may not kill the meningococcus. The specificity of bactericidal anti-NadA 
mAbs can be used to map epitopes on the NadA protien and compare these with 
epitopes that elicits bactericidal antibodies on recombinant NadA (20). Such results 
are beneficial in the understanding of the immune responses against GMMA.  
 
Th1/Th2 patterns coexist in the immune response but one often predominates over the 
other, depending on the antigenic stimulation and vaccine formulation. In mice, a Th1 
response is associated with the induction of IgG2a/b and IgG3 antibodies while IgG1 
is associated with a Th2-like response. IgG2a and 2b exhibit strongest binding to Fc 
receptors and are able to activate complement efficiently, while in humans IgG1 and 
IgG3 provide protection (21,22). In this study, the results suggest that GMMA without 
Alum generate mAbs that are more diverse in terms of protein target and IgG 
subclass. IgG isotyping of the serum of the mouse immunised with GMMA without 
Alum and with a mAb antibody repertoire of predominantly IgG2a/b subclass, the 
immune response is suggestive of a Th1 type. We obtained only one mAb against 
NadA while GMMA formulated on Alum seems to direct the immune responses more 
specifically towards NadA skewed towards Th2 with predominantly IgG1 and IgG2b 
subclass. Despite this, the lack of bactericidal activity seen for the mAbs produced 
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against other strains than the vaccine strain N2602 and the second serogroup A strain 
MK804/03 could be related to the epitopes recognised and their specificity, and 
maybe un-related to the adjuvant effect. To obtain a clearer picture of the Th type of 
response that the GMMA elicit, cytokine release in response to GMMA alone and 
GMMA+Alum immunisation could give additional indications (Chapter 5, section 
5.1.2) (23).  
 
Bactericidal activity is dependent on Fc-mediated differences in complement 
activation, amount and density of surface protein on the pathogen and epitope 
specificity of the mAbs. For example, Giuntini et al. (2012) constructed chimeric 
mAbs with three different murine fHbp-specific binding domains paired with human 
IgG1, IgG2 or IgG3 (21). The authors concluded that IgG3 mAbs had bactericidal 
activity >5-fold higher than IgG1 mAbs, and IgG2 mAbs had least activity when 
assessed against serogroup B isolates. However, the bactericidal activity was 
dependent on epitope density where IgG3 anti-fHbp mAbs had greatest activity at low 
epitope density while IgG1 had highest bactericidal activity at high epitope density. 
The IgG3 subclass has an extended hinge region allowing greater flexibility of the Fc 
portion promoting more efficient engagement of C1q during low fHbp density. These 
observations highlight the importance of isotype when comparing the relative 
effectiveness of mAbs in a bactericidal assay, but also the quantity of antigen. The 
ability of a vaccine to elicit protective antibodies regardless of adjuvant effect, is 
therefore likely enhanced if the antibody repertoire is of high avidity (6,19). The 
mAbs produced here may thus be bactericidal if enough antigens are present on the 
pathogen surface. For example, we observed that all anti-NadA mAbs killed the 
serogroup A isolate N2602 expressing high amounts of NadA-3, while the anti-NadA 
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mAbs did not kill the second serogroup A isolate MK804/03 expressing low levels of 
NadA-3. Similarly, flow cytometry showed that the anti-NadA mAbs bound the 
isolate N2602 and only one bound to MK804/03. For low expressing strains the mAbs 
may show synergism if combination of 2 non-bactericidal mAbs bind to non-
overlapping epitopes engage C1q. Welsch et al. (2008) observed that JAR 3 (IgG3) 
mAb and JAR 4 (IgG2a) mAb independently did not elicit SBA against high fHbp 
expressing strains (25). Together the mAbs increased C4b binding and elicited SBA 
titres. The results suggest that the failure of an individual mAb to activate 
complement may not be exclusive to IgG subclass or antigenic specificity. Further 
studies on the C3b deposition activated by the mAbs could elucidate whether the 
mAbs are able to cause killing by opsonophagocytic bactericidal activity via Fc and 
iC3b receptors.  
 
In the case of NadA, Ciabattini et al. (2008) immunized Balb/c mice intranasally with 
recombinant strains (26). Assessment of the local and systemic immune responses 
revealed that immunisation with live bacteria expressing NadA induced a Th1 
response with a dominance of IgG2a. However, unlike the monomeric fHbp, NadA 
exists in an oligomeric state in the cell membrane, and the dependence of antigenic 
density and epitope specificity need to be further assessed.  
 
Unlike the studies using recombinant protein to generate mAbs, our approach reflects 
the overall response against GMMA including antigens that are not over-expressed. 
With respect to over-expressed antigens, native proteins imbedded in their natural 
environment are primarily B cell epitopes presented to the B cell that are exposed on 
the outside of GMMA. mAbs made against antigens on GMMA may thus be 
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primarily directed against epitopes that are present on the surface of live bacteria and 
may, therefore, bind the same epitope during meningococcal infection. In contrast, 
recombinant proteins are usually linear may not have adopted entirely their native 
conformation. Thus, a smaller proportion of mAbs may be generated against 
bactericidal epitopes and may have reduced SBA activity. The generation of mAbs 
against GMMA may prove to be a useful tool to better understand and dissect the 
humoral immune responses towards N. meningitidis.  
 
4.6 Conclusion 
To conclude, the overall results reconfirm that immune response against a vaccine 
depend on multiple factors that influence the immune response. The route of 
immunisation, adjuvant, antigen dose, time and interval between immunisations all 
contribute towards the type of immune response and hence antibody repertoire 
produced (3). We generated 25 mAbs from fusions of spleen of mice immunised with 
MenA NadR KO cps- GMMA. The anti-NadA mAbs were only bactericidal against 
the vaccine strain, while 5 mAbs targeting unknown antigens were also bactericidal 
against a second A strain. Future studies should, however, identify the unknown 
antigens that the mAbs bind from fusion 1 and 2. This will lead to the identification of 
new target antigens that elicit bactericidal antibodies. Expressing them in GMMA as a 
“multi-protein” delivery system may have massive synergistic effects and enhance the 
protective potential of the vaccine strategy. Other potential future investigations could 
involve elucidating the epitopes on the antigens that the mAbs bind, and to test 
whether synergies of antibodies against the same antigen and different target antigens 
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5.1 General discussion  
          
5.1.1 Summary of findings  
In the sub-Saharan Africa, high disease burden of Neisseria meningitidis, especially in 
young children, is a public health problem. Despite the availability of effective 
antibiotics for treatment, mortality is still high due to fragile health care systems, 
affordability and distribution issues. Effective polysaccharide conjugate vaccines are 
available, but they are unlikely to be affordable. Hong et al. (2013) showed that the 
bactericidal antibody responses induced by 4CMenB vaccine Bexsero® suggested 
coverage of serogroup X isolates tested (1). An affordable serogroup A specific 
conjugate polysaccharide vaccine was rolled out in 2010 in several countries of the 
sub-Saharan Africa. However, there is a need for an inexpensive vaccine that covers 
other serogroups that cause disease such as W and X, and those that may potentially 
do so in the future (2,3).  
 
GMMA is a new protein-based approach towards developing a broadly-protective 
meningococcal vaccine for Africa, which we employed here. To be able to obtain a 
proof-of-principle in mice of the effectiveness of such a vaccine for the use in Africa, 
we firstly set out to determine the genetic variability of potential OMP vaccine 
candidate antigens fHbp, NadA, NHBA and PorA of strains isolated from various 
countries in Africa (Chapter 2). Secondly, we generated GMMA from a serogroup A 
and a serogroup W strain. Both strains had deleted capsule biosynthesis genes, lpxL1, 
and gna33. The candidate antigen fHbp of variant 1 was over-expressed in the 
serogroup W strain 1630 by a multicopy plasmid. The gene encoding for the nadA 
repressor nadR was deleted in the serogroup A isolate (N2602) and the W isolate 
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(1630) in order to attempt to increase expression of NadA-3. In the latter two 
GMMAs, fHbp was not over-expressed. The first immunogenicity study evaluated the 
GMMA over-expressing fHbp (Chapter 2). The second mouse immunogenicity study 
evaluated GMMA from the serogroup A and W recombinant strains expressing 
NadA-3 (Chapter 3). Moreover, to obtain additional insights into the immune 
responses towards GMMA, we generated mAbs against fHbp, NadA and other 
proteins natively presented on the GMMA as opposed to traditional methods of mAbs 
developed against processed recombinant proteins (Chapter 4).  
 
Molecular characterisation of 94 meningococcal serogroup A, W and X isolates from 
sub-Saharan Africa isolated between 1995-2011 showed limited antigenic variability 
of fHbp, NadA, PorA and NHBA across the serogroups. The results also suggest that 
natural herd immunity against these protein target antigens does not seem to be a 
strong driving force for allelic replacement. Rather, variation was seen for the 
expression level of the fHbp and NadA antigens, and the isolates analysed expressed 
intermediate to high amounts of NadA and fHbp. From our immunogenicity studies, 
serum from the mice immunised with GMMA from a recombinant strain with over-
expressed fHbp was able to kill 3 out of 4 group A isolates, and one X isolate. The 
ability of the sera to induce bactericidal antibody responses was dependent upon level 
of fHbp expression on the surface of the isolates. Strains expressing low levels of 
fHbp were resistant to killing by anti-fHbp antibodies. Bactericidal antibodies 
generated from serogroup A GMMA with deleted nadR and capsule killed isolates 
expressing low, intermediate and high NadA of serogroup A and W. Serum from mice 
immunised with wild-type serogroup W GMMA without capsule induced bactericidal 
antibodies against a low and intermediate NadA expresser. We also observed that 
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GMMA from mutant strains with NadA KO and NadA + NadR KO also induced 
measurable bactericidal titres, which were directed against other OMPs than NadA, 
fHbp and PorA. The results from the typing and immunogenicity studies highlight the 
advantage of using fHbp and NadA in GMMA as a vaccine strategy. The data indicate 
that antibodies to other but shared OM antigens along with antibodies to the main 
target antigens may provide broad cross-protection (4). With GMMAs, dependency 
on a single antigen or antigen type is avoided. Moreover, antibodies induced by a 
control recombinant fHbp v.1 vaccine group only induced a low but detectable SBA 
response suggesting that fHbp expressed in the native membrane environment induces 
antibodies with greater functional activity. On the contrary, rHis-NadA elicited 
bactericidal titres comparable to those induced by GMMA indicating that 
immunogenicity is less dependent on the three-dimensional conformation of the 
protein than fHbp. One possibility for this difference could be that rHis-fHbp induces 
antibodies against “non-functional” epitopes on parts of the protein that are not 
naturally surface exposed, which may not be the case for NadA that is more exposed. 
While the GMMA may allow more antibodies to be induced against conformational 
parts of the protein that are also surface exposed, thus there may be a greater 
proportion of “functional” anti-fHbp antibodies. This also highlights the advantage of 
using GMMA as a vaccine strategy. 
 
From the results of the immunogenicity studies, we wanted to further understand the 
immune responses towards GMMA by generating mAbs against GMMA antigens, in 
particular focusing on NadA and fHbp as targets. We performed three fusions, 
whereby the first two fusions were performed using mice immunised with GMMA 
from a serogroup A recombinant strain with deleted nadR and capsule (generated in 
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Chapter 3) absorbed to Alum and without. The third fusion was recently performed 
using a mouse immunised with GMMA from a mutant serogroup W strain engineered 
to over-express fHbp v.1 absorbed to Alum, which is currently in progress. In total, 
25 mAbs were generated from the first two fusions. The anti-NadA mAbs were only 
bactericidal against the vaccine strain, while 5 mAbs targeting unknown antigens 
were also bactericidal against a second A strain. Seven mAbs of subclass IgG2a were 
produced in the NadA GMMA alone group and two mAbs of subclass IgG2a against 
GMMA with over-expressed fHbp formulated on Alum. The results suggest that 
GMMA alone induced IgG subtypes with a Th1 type response generating antibodies 
of subclass IgG2a, while the use of Alum favours a Th2 type immune response (5).  
The results also indicate that there could be more genetic diversity in NadA than 
would be indicated by the serotypes (i.e. microheterogeneity within the subtypes). 
mAbs may bind to such “private” epitopes, or epitopes shared by all members of a 
subtype and potentiall also across several subtypes.  
 
5.1.2 Implications for vaccine design against the meningococcus 
An effective vaccine needs to fullfill a number of criteria. Firstly, since there is a high 
disease burden in the meningitis belt, especially in young children, a vaccine against 
meningoccus needs to be immunogenic in all age groups and be affordable by these 
countries. Secondly, a vaccine that induces long-term protection is important, which 
is maintained by three mechanisms: antibody persitence, B cell memory and herd 
immunity (6–9).  
 
The results from our study point towards the investigation of a future GMMA vaccine 
over-expressing fHbp and NadA for the use in Africa, as these antigens appear to be 
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relatively conserved among African meningococci. Moreover, when natively 
expressed in GMMA, the antigens elicit broadly protective antibody responses, and 
the vaccine is cheap to manufacture. In principle, fHbp is a good vaccine candidate 
since it is found in more than >99% of both invasive and carriage genomes sequenced 
to date, and has been shown to be important for survival of N. meningitidis in ex vivo 
models (10). Therefore, a vaccine with fHbp may have an impact on carriage, interupt 
transmission and promote herd immunity. A recent evidence for this was seen by 
Read et al. (2014) where the 4CMenB vaccine, which contains recombinant fHbp, 
was able to reduce meningococcal carriage rates during 12 months after vaccination 
(11). Antibodies towards fHbp can both activate the classical and alternative 
complement pathaway and block fH binding (12). However, the results from this and 
other studies show that induction of bactericidal antibodies is dependent on several 
factors. Primarily the expression level of the antigen is important as it is sparsley 
distributed on the surface of meningococci. A vaccine based only on fHbp may thus 
decrease survival of the meningococci but not exclude the possibility of escape 
mutants expressing low levels of fHbp. Moreover, the three-dimensional structure of 
the fHbp protein and the epitope surface exposed on GMMA to the immune system 
are two other factors affecting the induction of “functional” bactericidal anti-fHbp 
antibodies (2,13–15). There is cross-reactivity between variant 2 and 3 but not 
between variant 1 and 2/3. For future vaccine design against the meningococcus, the 
solution could be to include a second fHbp variant or to engineer the recombinant 
strain to include another OMP.    
 
Looking at NadA as a vaccine candidate, results from the immunogenicity study 
suggest that antibodies towards NadA are less dependent on the three-dimensional 
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structure of the protein. Similarly to fHbp, bactericidal activity is dependent on NadA 
expression level, which in turn is phase variable. Highest expression of NadA is 
resported to be during adhesion/invasion of the nasopharynx. We also observed that 
the gene in several sergroup W isolates was interupted by IS1301, which could have 
implications for vaccine coverage. Although, all isolates in this study had the nadA 
gene, several other studies have shown that the gene is less present in carriage isolates 
(16–18).  
 
It is important to determine the host immune response towards a vaccine and the 
effect of adjuvant used to boost cellular and humoral immune responses to promote 
future vaccine design. Adjuvants may induce T-cell response that favours Th1 or Th2 
responses, which may have profound influence on the outcome of a vaccination. In 
this study, we present a novel approach whereby mAbs were generated against 
various natively surface exposed antigens on GMMA, as opposed to processed 
recombinant proteins. We used these mAbs to investigate the immune responses 
generated by GMMA alone, formulated on Alum and by the individual antigens 
themselves to better understand the immune responses against GMMA. One of the 
observations made was that the use of Alum in the vaccine formulations elicited an 
immune response that favoured a Th2 response, which is also widely known in the 
literature (19–21). MAbs generated from mice immunised with GMMA alone showed 
increased bactericidal activity and a Th1 response. It is known for polysaccharide 
conjugate vaccines that protection against N. meningitidis needs to involve 
presentation of the vaccine antigen through MHCII on B cells to Th1 in combination 
with co-stimulatory molecules CD40-CD40L and CD80-CD28. This interaction 
generates plasma cells that produce and secrete antibodies of subclass IgG1 and IgG3 
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in humans and IgG2a in mice. These IgG subclasses are the most effective at fixing 
complement necessary for clearance of the meningococcus through classical and 
alternative complement pathways (19). Therefore, the desirable immune response 
against the meningococcus appears to be a Th1-polarised response. GMMA itself 
contains LOS and is a TLR2 and TLR4 agonist and autoadjuvant that favours the 
adjuvant action of CD4+ T Th1 lymphocytes (22). As GMMA has been proven safe 
for use in mice due to the deletion of capsule biosynthesis genes and lpxL1 that 
reduces endotoxicity, Alum may not be necessary for future use in humans for the 
induction of appropriate immune response for the development of protective 
immunity. Alum is used in many vaccine formulations to reduce reactogenicity in 
man, occasionally associated with tissue reactions such as erythema (20). Future 
investigations into the Th type responses by GMMA alone and GMMA formulated on 
Alum would help improve the understanding of these results. Cytokine release in 
response to GMMA alone and GMMA+Alum immunisation would give additional 
indications as to whether a Th1 or Th2 response is induced. Th1 cells are 
characterised by their secretion of interleukin-2 (IL-2) and gamma interferon (IFN-γ), 
whereas Th2 cells produce IL-4, IL-5 and IL-10 (20,21,23–26).  
 
Moreover, with the novel mAb approach used here we generated mAbs against 
natively presented antigens on GMMA. The anti-NadA mAbs showed limited cross-
protective bactericidal responses to other serogroups than the serogroup A vaccine 
strain N2602. For future vaccine design, the novelty of this approach allows for 
mapping of the epitopes on the NadA protein in GMMA that induce production of 
bactericidal antibodies and the epitopes that can induce cross-protection across 
serogroups. Compared to mapping of epitopes using mAbs generated from mice 
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immunised with recombinant NadA, mapping using mAbs against NadA on GMMA 
could give an added comprehensive picture of the actual immune responses to NadA 
during invasive meningococcal disease. From fusion 1 and 2, most of the mAbs 
produced were directed against unknown antigens. Several of these mAbs were of 
IgG2a subclass, and for some of these mAbs cross-protection was observed against a 
second serogroup A isolate when human complement was used as complement 
source. Elucidating their identity could have an impact on future vaccine design as 
some of these antigens may be novel and could potentially be used in a future GMMA 
vaccine. Previous methods for identifying novel immunogenic antigens in N. 
meningitidis was by reverse vaccinology. We show that generation of mAbs against 
surface proteins on GMMA can be used to mine for new immunogenic antigens.  
 
5.1.2 Future directions 
Following on from the thesis, there are several potential future projects that could be 
undertaken to understand immune responses to GMMA better. Firstly, identification 
of the unknown antigens that the mAbs from fusion 1 and 2 bind would help to get a 
better overview of the immune responses induced by GMMA. Such a path was 
started, but halted due to time limitations. The experiments would immunopresipitate 
the soluble antigens using the mAbs generated and mass spectrometry to identify the 
extracted antigens. Whole cell lysates are prepared with a lysis buffer and the lysate is 
incubated with a mAb bound to protein G. The antigen-antibody complex is purified 
through washes with lysis buffer, and the immunopresipitate run on SDS-PAGE gel. 




A second project would involve characterising the anti-fHbp mAbs generated from 
fusion 3. This would follow the same direction and experiments as for fusion 1 and 2 
(Western blotting, IFA, flow cytometry, SBA). Alternatively, another fusion with 
GMMA over-expressing fHbp can be made in order to try and expand the anti-fHbp 
antibody repertoire. Further experiments to characterise these anti-fHbp mAbs could 
be undertaken by comparing the results generated with those from previous studies 
using recombinant fHbp mAbs. Such experiments could include mapping of the 
GMMA-fHbp or GMMA-NadA epitopes important for generating bactericidal anti-
fHbp antibodies by hydrogen/deuterium exchange mass spectrometry and using yeast 
display (27–29). Further studies could also investigate mAb functions such as avidity, 
affinity, ability to deposit C3b/C4b and block fH binding (30,28,31,32). Comparing 
the results obtained from previous studies using recombinat fHbp mAbs would give a 
better understanding of the advantageous immunogenicity induced by GMMA. The 
study can be further extended by investigating the cooperative bactericidal activities 
of the GMMA anti-fHbp mAbs with the anti-NadA mAbs generated here, as the 
bactericidal activity of anti-fHbp mAbs are known to depend on the density of fHbp 
on the bacterial surface. This could help determine whether expressing both fHbp and 
NadA in GMMA increases bactericidal responses.   
 
The anti-NadA mAbs generated here can also be used for determining the minimum 
level of NadA expression on the meningococcal surface that is required to cross-link 
two IgG anti-NadA antibodies to correctly spaced epitopes. Such experiments could 
involve generating isogenic mutant strains of different NadA expression. The ability 
of a bactericidal anti-NadA mAb to kill these strains can be assessed by SBA. 
Another potential project could involve over-expression of fHbp and NadA in the 
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same GMMA, or other immunogenic antigens identified from the mass spectrometry 
analysis. Similarly to the study undertaken in Chapter 3, the multi-antigen GMMA 
could be assessed if this genetic approach broadens protection.  
 
5.2 Conclusion 
To conclude, the findings of our study provide support for a GMMA-based vaccine 
approach as an affordable and broadly-protective vaccine strategy. The results also 
highlight the fact that inclusion of more vaccine antigens could impove breadth of 
coverage. Generation of mAbs against the antigens on GMMA indicate that there are 
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